


EXHIBIT 3

Electronically Filed
9/12/2019 9:42 AM
Steven D. Grierson
CLERK OF THE COURT


ACOM

STEVEN B. WOLFSON, ESQ.

Nevada Bar No. 1565

District Attorney

200 E. Lewis Ave

Las Vegas, NV 89101

Tel.: 702-671-2700

Email: steven.wolfson@clarkcountynvda.com

ROBERT T. EGLET, ESQ.

Nevada Bar No. 3402

ROBERT M. ADAMS, ESQ.

Nevada Bar No. 6551

RICHARD K. HY, ESQ.

Nevada Bar No. 12406

EGLET ADAMS

400 S. 7th Street, 4th Floor

Las Vegas, NV 89101

Tel.: (702) 450-5400

Fax: (702) 450-5451

E-Mail eservice@egletlaw.com*Attorneys for Plaintiff, Clark County***DISTRICT COURT****CLARK COUNTY, NEVADA**

CLARK COUNTY,

Plaintiff,

v.

PURDUE PHARMA, L.P.; PURDUE
PHARMA, INC.; THE PURDUE
FREDERICK COMPANY, INC. d/b/a THE
PURDUE FREDERICK COMPANY, INC.;
PURDUE PHARMACEUTICALS, L.P.;
RICHARD S. SACKLER; JONATHAN D.
SACKLER; MORTIMER D.A. SACKLER;
KATHE A. SACKLER; ILENE SACKLER
LEFCOURT; DAVID A. SACKLER;
BEVERLY SACKLER; THERESA
SACKLER; PLP ASSOCIATES HOLDINGS
L.P.; ROSEBAY MEDICAL COMPANY

) Case No.: A-17-765828-C

) Dept No.: Department 16

THIRD AMENDED COMPLAINT
AND DEMAND FOR JURY TRIAL

1 L.P.; BEACON COMPANY; TEVA)
 PHARMACEUTICALS USA, INC.;)
 2 CEPHALON, INC.; ENDO HEALTH)
 SOLUTIONS INC.; ENDO)
 3 PHARMACEUTICALS, INC.; PAR)
 PHARMACEUTICAL, INC.; PAR)
 4 PHARMACEUTICAL COMPANIES, INC.;)
 5 ALLERGAN INC.; ALLERGAN USA INC.;)
 ACTAVIS, INC. f/k/a WATSON)
 6 PHARMACEUTICALS, INC.; WATSON)
 LABORATORIES, INC.; INSYS)
 7 THERAPEUTICS, INC.; JOHN KAPOOR;)
 RICHARD M. SIMON; SUNRISE LEE;)
 8 JOSEPH A. ROWAN; MICHAEL J. GURRY;)
 9 MICHAEL BABICH; ALEC BURLAKOFF;)
 MALLINCKRODT LLC; SPECGX LLC;)
 10 ACTAVIS LLC; AND ACTAVIS PHARMA,)
 INC. f/k/a WATSON PHARMA, INC.;)
 11 AMERISOURCEBERGEN DRUG)
 CORPORATION; CARDINAL HEALTH,)
 12 INC.; CARDINAL HEALTH 6 INC.;)
 CARDINAL HEALTH TECHNOLOGIES)
 13 LLC; CARDINAL HEALTH 414 LLC;)
 CARDINAL HEALTH 200 LLC;)
 14 MCKESSON CORPORATION;)
 15 WALGREENS BOOTS ALLIANCE, INC.;)
 16 WALGREEN CO.; WALGREEN EASTERN)
 CO., INC.; WALMART INC.; CVS HEALTH)
 17 CORPORATION; CVS PHARMACY, INC.;)
 18 CVS INDIANA L.L.C.; CVS RX SERVICES,)
 INC.; CVS TENNESSEE DISTRIBUTION,)
 19 L.L.C.; MASTERS PHARMACEUTICAL,)
 20 LLC f/k/a MASTERS PHARMACEUTICAL,)
 INC.; C & R PHARMACY d/b/a KEN'S)
 21 PHARMACY f/k/a LAM'S PHARMACY,)
 INC.; EXPRESS SCRIPTS HOLDING)
 22 COMPANY; EXPRESS SCRIPTS, INC.;)
 23 AIDA B MAXSAM; STEVEN A HOLPER)
 MD; STEVEN A. HOLPER, M.D.,)
 24 PROFESSIONAL CORPORATION;)
 25 HOLPER OUT-PATIENTS MEDICAL)
 CENTER, LTD.; DOES 1 through 100; ROE)
 26 CORPORATIONS 1 through 100 and ZOE)
 27 PHARMACIES 1 through 100, inclusive,)
)
 28 Defendants.)

1 Plaintiff Clark County, by and through the undersigned attorneys, files this Second
2 Amended Complaint against the named Defendants seeking to recover its damages as a result
3 of the opioid epidemic Defendants caused, and alleges as follows:

4 **INTRODUCTION**

5 1. Opioid addiction and overdose in the United States as a result of prescription
6 opioid use has reached epidemic levels over the past decade.

7 2. While Americans represent only 4.6% of the world's population, they consume
8 over 80% of the world's opioids.

9 3. Since 1999, the amount of prescription opioids sold in the U.S. has nearly
10 quadrupled. In 2010, 254 million prescriptions were filled in the U.S. – enough to medicate
11 every adult in America around the clock for a month. In that year, 20% of all doctors' visits
12 resulted in the prescription of an opioid (nearly double the rate in 2000).

13 4. By 2014, nearly two million Americans either abused or were dependent upon
14 opioids.

15 5. On March 22, 2016, the Food and Drug Administration (FDA) recognized opioid
16 abuse as a "public health crisis" that has a "profound impact on individuals, families and
17 communities across our country."

18 6. The Centers for Disease Control (CDC) reports that overdoses from prescription
19 opioids are a driving factor in the 15-year increase in opioid overdose deaths.

20 7. From 2000 to 2015, more than half a million people died from drug overdoses
21 (including prescription opioids and heroin). The most recent figures from the CDC suggest that
22 175 Americans die everyday from an opioid overdose (prescription and heroin).

23 8. Many addicts, finding painkillers too expensive or too difficult to obtain, have
24 turned to heroin. According to the American Society of Addiction Medicine, four out of five
25 people who try heroin today started with prescription painkillers.

26 9. County and city governments and the services they provide their citizens have
27 been strained to the breaking point by this public health crisis.

28 10. The dramatic increase in prescription opioid use over the last two decades, and
the resultant public-health crisis, is no accident.

1 11. The crisis was precipitated by Defendants, who, through deceptive means, and
2 using one of the biggest pharmaceutical marketing campaigns in history, carefully engineered
3 and continue to support a dramatic shift in the culture of prescribing opioids by falsely
4 portraying both the risks of addiction and abuse and the safety and benefits of long-term use.

5 12. Defendant drug companies named herein, manufacture, market, and sell
6 prescription opioids (hereinafter "opioids"), including brand-name drugs like Oxycontin,
7 Vicodin and Percocet, as well as generics like oxycodone and hydrocodone, which are powerful
8 narcotic painkillers.

9 13. Historically, because they were considered too addictive and debilitating for the
10 treatment of chronic pain (like back pain, migraines and arthritis),¹ opioids were used only to
11 treat short-term acute pain or for palliative (end-of-life) care.

12 14. Defendants' goal was simple: to dramatically increase sales by convincing
13 doctors that it was safe and efficacious to prescribe opioids to treat not only the kind of severe
14 and short-term pain associated with surgery or cancer, but also for a seemingly unlimited array
15 of less severe, longer-term pain, such as back pain, headaches and arthritis.

16 15. Defendants knew that their opioid products were addictive, subject to abuse, and
17 not safe or efficacious for long-term use.

18 16. Defendants' nefarious plan worked and they dramatically increased their sales
19 and reaped billions upon billions of dollars of profit at the expense of millions of people who
20 are now addicted and the thousands who have died as a result.

21 17. Defendant drug companies should never place their desire for profits above the
22 health and well being of their customers or the communities where those customers live,
23 because they know prescribing doctors and other health-care providers rely on their statements
24 in making treatment decisions, and drug companies must tell the truth when marketing their
25 drugs and ensure that their marketing claims are supported by science and medical evidence.

26 18. Defendants broke these simple rules and helped unleash a healthcare crisis that
27 has had far-reaching financial, social, and deadly consequences in Clark County and throughout
28 Nevada.

1 19. Defendants falsely touted the benefits of long-term opioid use, including the
2 supposed ability of opioids to improve function and quality of life, even though there was no
3 “good evidence” to support their claims.

4 20. Defendants disseminated these common messages to reverse the popular and
5 medical understanding of opioids.


6 21. As a result of the drug companies’ marketing campaign, opioids are now the
7 most prescribed class of drugs generating over \$11 billion in revenue for drug companies in
8 2014 alone.

9 22. As a result of the drug companies’ marketing campaign, the fatalities continued
10 to mount while the living continue to suffer.

11 23. In 2015, over 33,000 Americans died of a drug overdose involving opioids with
12 studies suggesting that these fatalities are statistically underreported. In 2015, the estimated
13 economic impact of the opioid crisis was \$504.0 billion, or 2.8 % of our U.S.’s gross domestic
14 product that same year. Previous estimates of the economic cost of the opioid crisis greatly
15 understate it by undervaluing the most important component of the loss—fatalities resulting
16 from overdoses.

17 24. Most opioid related deaths occur among those between the ages of
18 approximately 25 and 55 years old. Studies have shown that the overall fatality rate was 10.3
19 deaths per 100,000 population, and in the 25 to 55 year old age group, fatality rates were much
20 higher, ranging from 16.1 to 22.0 deaths per 100,000 population.

Figure 2. Opioid-involved Overdose Deaths by Age in 2015
(Number of deaths)




Source: CDC Wonder database, multiple cause of death files

25. In addition to the cost of fatalities each year, opioid misuse among the living imposes important costs as well. It is estimated that prescription opioid misuse increases healthcare and substance abuse treatment costs in the United States by \$29.4 billion, increases criminal justice costs by \$7.8 billion, and reduces productivity among those who do not die of overdose by \$20.8 billion (in 2015 \$). The total nonfatal cost of \$58.0 billion divided by the 1.9 million individuals with a prescription opioid disorder in 2013 results in an average cost of approximately \$30,000.¹ And when patients can no longer afford or legitimately obtain opioids, they often turn to the street to buy prescription opioids or even heroin, fueling the secondary drug market.

26. Further compounding issues is that this problem is worsening at an alarming rate. According to a report published by the White House Council of Economic Advisors (CEA), opioid-involved overdose deaths have doubled in the past ten years and quadrupled in the past sixteen.

¹ Florence, C., Zhou, C., Luo, F. and Xu, L. 2016. "The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013." *Medical Care*, 54(10): 901-906.

Figure 1. Opioid-involved Overdose Deaths, 1999–2015
(Thousands of Deaths)



Source: CDC Wonder database, multiple cause of death files

27. The crisis that Defendants caused has directly impacted Clark County as it bears the financial brunt of this epidemic as it unfolds in our community.

28. Apart from the toll on human life, the crisis has financially strained the services Clark County provides its residents and employees. Human services, social services, court services, law enforcement services, the office of the coroner/medical examiner and health services, including hospital, emergency and ambulatory services, have all been severely impacted by the crisis. For example, as a direct and foreseeable consequence of Defendants' egregious conduct, Clark County paid, and continues to pay, a significant amount for health care costs that stem from prescription opioid dependency. These costs include unnecessary and excessive opioid prescriptions, substance abuse treatment services, ambulatory services, emergency department services, and inpatient hospital services, among others. Defendants' conduct also caused Clark County to incur substantial economic, administrative and social costs relating to opioid addiction and abuse, including criminal justice costs, victimization costs, child

1 protective services costs, lost productivity costs, and education and prevention program costs
2 among others.

3 29. After creating a public health crisis, Defendants have not pulled their opioid
4 products from the market, acknowledged the very real dangers of addiction and abuse even if
5 the opioids are taken as prescribed, or acknowledged that opioids are inappropriate for long-
6 term pain management. Instead, Defendants have taken the position that their opioid products
7 are not dangerous and continue to sell these dangerous and addictive drugs, thereby continuing
8 to fuel the crisis.

9 30. As a result, physicians, pharmacists and patients are not able to appropriately
10 and adequately evaluate the relevant risks associated with opioids use, particularly the risks to
11 patients who have been and are being exposed to, unnecessarily, including but not limited to the
12 risk of severe and disabling addiction, actual addiction, the consequences of addiction, and other
13 adverse medical conditions. Additionally, the rising numbers of persons addicted to opioids
14 have led to a dramatic increase of social problems, including drug abuse and diversion and the
15 commission of criminal acts to obtain opioids. Consequently, public health and safety have been
16 significantly and negatively impacted due to the misrepresentations and omissions by
17 Defendants regarding the appropriate uses and risks of opioids, ultimately leading to widespread
18 inappropriate use of the drug.

19 31. As a result of Defendants' misconduct, physicians, pharmacists and patients
20 have not been provided with accurate information about the appropriate uses, risks and safety
21 of these drugs, thus causing the crisis before us as well as giving rise to this lawsuit.

22 32. Plaintiff files this Complaint naming the drug companies herein as Defendants
23 and placing the industry on notice that Clark County is taking action to abate the public nuisance
24 that plagues our community.

25 33. By its Complaint, Clark County seeks to recover from Defendants its damages
26 as a result of the opioid public-health crisis Defendants caused. Namely, this action is brought
27 by this Plaintiff pursuant to constitutional, statutory, common law and/or equitable authority for
28 purposes of, *inter alia*:

- 1 a. recovering restitution and reimbursement for all the costs Clark County
- 2 has incurred in paying excessive and unnecessary prescription costs
- 3 related to opioids;
- 4 b. recovering restitution and reimbursement for all the costs expended by
- 5 Clark County for health care services and programs associated with the
- 6 diagnosis and treatment of adverse health consequences of opioids use,
- 7 including but not limited to, addiction;
- 8 c. recovering restitution and reimbursement for all the costs consumers
- 9 have incurred in excessive and unnecessary prescription costs related to
- 10 opioids;
- 11 d. disgorgement;
- 12 e. recovering damages for all costs incurred and likely to be incurred in an
- 13 effort to combat the abuse and diversion of opioids in Clark County;
- 14 f. recovering damages incurred as costs associated with the harm done to
- 15 the public health and safety.

16 34. However, Plaintiff does not bring claims, as part of this action, for products
17 liability nor does the County seek compensatory damages for death, physical injury to person,
18 emotional distress, or physical damage to property.

19 **PARTIES AND JURISDICTION**

20 **A. Plaintiff, Clark County.**

21 35. Plaintiff, Clark County ("CLARK COUNTY" or "Plaintiff"), is an
22 unincorporated county organized under the laws of the State of Nevada.

23 36. Plaintiff provides a wide range of services on behalf of its residents, including
24 services for families and children, public health, public assistance, law enforcement, and
25 emergency care.

26 37. Plaintiff has all the powers possible for a county to have under the constitution
27 of the State of Nevada, and the laws of the State of Nevada.

28

1 38. Plaintiff has standing to bring this litigation to provide for the orderly
2 government of Clark County and to address matters of local concern including the public health,
3 safety, prosperity, security, comfort, convenience and general welfare of its citizens.

4 39. Clark County declares that the unlawful distribution of prescription opiates, by
5 the Defendants named herein, has created a serious public health crisis of opioid abuse,
6 addiction, morbidity and mortality and is a public nuisance.

7 40. Plaintiff is authorized by law to abate any nuisance and prosecute in any court
8 of competent jurisdiction, any person who creates, continues, contributes to, or suffers such
9 nuisance to exist and prevent injury and annoyance from such nuisance.

10 **B. Defendants, Drug Manufacturers.**

11 41. Defendant PURDUE PHARMA L.P. is a limited partnership organized under
12 the laws of Delaware, and registered and authorized to do business in the State of Nevada, under
13 the laws thereof. At all times relevant herein, PURDUE PHARMA L.P. takes and took
14 advantage of the legislative, regulatory and tax schemes of the State of Nevada to own, maintain
15 and defend drug patents. PURDUE PHARMA INC. is a corporation organized under the laws
16 of both Delaware and New York, with its principal place of business in Stamford, Connecticut,
17 and THE PURDUE FREDERICK COMPANY, INC. is a Delaware corporation with its
18 principal place of business in Stamford, Connecticut. Defendant PURDUE
19 PHARMACEUTICALS, L.P., (“Purdue Pharmaceuticals”) is and was a limited partnership
20 organized under the laws of the State of Delaware. At all times relevant hereto, the foregoing,
21 (collectively, “PURDUE”) are and were in the business of designing, testing, manufacturing,
22 labeling, advertising, promoting, marketing, selling and/or distributing OxyContin and have
23 done so to and within the State of Nevada. At all times relevant herein, PURDUE hired
24 “Detailers” in Clark County, Nevada, to make personal contact with physicians and clinics to
25 advocate for the purchase and use of opioid medications which were contrary to known safety
26 concerns and sound medical advice.

27 42. In 2007, Purdue settled criminal and civil charges against it for misbranding
28 OxyContin and agreed to pay a \$635 million fine – at the time, one of the largest settlements
with a drug company for marketing misconduct. None of this stopped Purdue. In fact, Purdue

1 continued to create the false perception that opioids were safe and effective for long-term use,
2 even after being caught, by using unbranded marketing methods to circumvent the system. On
3 May 8, 2007, as part of these settlements, Purdue entered into a consent judgment with the State
4 of Nevada, in which it agreed to a number of terms intended to prevent any further misleading
5 marketing in the State of Nevada. In short, Purdue paid the fine when caught and then continued
6 business as usual, deceptively marketing and selling billions of dollars of opioids each year.

7 43. At all relevant times, Purdue, which is a collection of private companies, has
8 been controlled by members of the extended Sackler family, who are the ultimate intended
9 beneficiaries of virtually all of Purdue's profit distributions. The individual Defendants named
10 in this action are the remaining living Sackler family members who served on the board of
11 Purdue Pharma, Inc. (the "Purdue board"), which functioned as the nexus of decision-making
12 for all of Purdue.

13 44. Defendant RICHARD S. SACKLER became a member of the Purdue board in
14 1990 and became its co-chair in 2003, which he remained until he left the board in 2018. He was
15 also Purdue's head of research and development from at least 1990 through 1999, and its
16 president from 1999 through 2003. He resides in New York, Florida, and Texas. He currently
17 holds an active license to practice medicine issued by the New York State Education
18 Department. He is a trustee of the Sackler School of Medicine, a director and the vice president
19 of the Raymond and Beverly Sackler Foundation, and a director and the president and treasurer
20 of the Richard and Beth Sackler Foundation, Inc., all three of which are New York Not-for-
21 Profit Corporations.

22 45. Defendant JONATHAN D. SACKLER was a member of Purdue's board from
23 1990 through 2018. He resides in Connecticut. He is a trustee of the Sackler School of Medicine,
24 the president and CEO of the Raymond and Beverly Sackler Foundation, and the vice president
25 of the Richard and Beth Sackler Foundation Inc., all three of which are New York Not-for-Profit
26 Corporations.

27 46. Defendant MORTIMER D.A. SACKLER has been a member of Purdue's
28 Board since 1993. He resides in New York. Mortimer is a director and the president of the

1 Mortimer and Jacqueline Sackler Foundation, and a director and the vice president and treasurer
2 of the Mortimer D. Sackler Foundation, Inc., both of which are New York Not-for-Profit
3 Corporations.

4 47. Defendant KATHE A. SACKLER was a member of Purdue's board from 1990
5 through 2018. She resides in New York and Connecticut. Kathe is a director and president of
6 the Shack Sackler Foundation, a director and vice president and secretary of the Mortimer D.
7 Sackler Foundation Inc. and is a governor of the New York Academy of Sciences, all three of
8 which are New York Not-for-Profit Corporations.

9 48. Defendant ILENE SACKLER LEFCOURT was a member of Purdue's board
10 between 1990 and 2018. She resides in New York. She is a director of Columbia University and
11 is the president of the Sackler Lefcourt Center for Child Development Inc., both of which are
12 New York Not-for-Profit Corporations.

13 49. Defendant DAVID A. SACKLER was a member of Purdue's board from 2012
14 through 2018. He resides in New York.

15 50. Defendant BEVERLY SACKLER was a member of Purdue's board from 1993
16 through 2017. She resides in Connecticut. Beverly Sackler serves as a Director and the Secretary
17 and Treasurer of the Raymond and Beverly Sackler Foundation, a New York Not-for-Profit
18 Corporation.

19 51. Defendant THERESA SACKLER was a member of Purdue's board from 1993
20 through 2018. She resides in New York and the United Kingdom.

21 52. These individual Defendants used a number of known and unknown entities,
22 named as Defendants herein as vehicles to transfer funds from Purdue directly or indirectly to
23 themselves. These include the following:

24 53. Defendant PLP ASSOCIATES HOLDINGS L.P., which is a Delaware limited
25 partnership and a limited partner of Purdue Holdings L.P. Its partners are PLP Associates
26 Holdings Inc. and BR Holdings Associates L.P.

27 54. Defendant ROSEBAY MEDICAL COMPANY L.P., which is a Delaware
28 limited partnership ultimately owned by trusts for the benefit of one or more of the individual

1 Defendants. Its general partner is Rosebay Medical Company, Inc., a citizen of Delaware and
2 Connecticut. The Board of Directors of Rosebay medical Company, Inc. includes board
3 members Richard S. Sackler and Jonathan D. Sackler.

4 55. Defendant BEACON COMPANY, which is a Delaware general partnership
5 ultimately owned by trusts for the benefit of members of one or more of the individual
6 Defendants.

7 56. The foregoing individual Defendants are referred to collectively as “the
8 Sacklers.” The foregoing entities they used as vehicles to transfer funds from Purdue directly
9 or indirectly to themselves are referred to as “the Sackler Entities.” Together, the Sacklers and
10 the Sackler Entities are referred to collectively as “the Sackler Defendants.”

11 57. Defendant TEVA PHARMACEUTICALS USA, INC., is a Delaware
12 corporation with its principal place of business located in North Wales, Pennsylvania. Teva
13 USA is a wholly owned subsidiary of TEVA PHARMACEUTICALS INDUSTRIES LTD., an
14 Israeli Corporation. TEVA develops, makes, manufactures, and distributes generic opioid
15 medications worldwide, including within Clark County, Nevada.

16 58. Defendant CEPHALON, INC., is Delaware corporation with its principal place
17 of business located in Frazer, Pennsylvania. In 2011, Teva Ltd. acquired CEPHALON, INC.

18 59. Defendant ENDO HEALTH SOLUTIONS INC., is a Delaware corporation with
19 its principal place of business located in Malvern, Pennsylvania. ENDO
20 PHARMACEUTICALS, INC., is a wholly-owned subsidiary of Endo Health Solutions Inc.,
21 and is a Delaware corporation with its principal place of business in Malvern, Pennsylvania.

22 60. Defendant PAR PHARMACEUTICAL, INC. is a Delaware corporation with its
23 principal place of business located in Chestnut Ridge, New York. Par Pharmaceutical, Inc. is a
24 wholly- owned subsidiary of Par Pharmaceutical Companies, Inc. f/k/a Par Pharmaceutical
25 Holdings, Inc. Defendant PAR PHARMACEUTICAL COMPANIES, INC. is a Delaware
26 corporation with its principal place of business located in Chestnut Ridge, New York. Par
27 Pharmaceutical Companies, Inc. (and by extension its subsidiary, Par Pharmaceutical, Inc.,)
28 (collectively, “Par Pharmaceutical”) was acquired by Endo International plc in September 2015
and is currently an operating company of Endo International plc. Endo Health Solutions Inc.,

1 Endo Pharmaceuticals, Inc., Par Pharmaceutical, and their DEA registrant subsidiaries and
2 affiliates, (collectively, “Endo”), manufacture opioids sold nationally, and in Clark County,
3 Nevada.

4 61. Defendants ALLERGAN INC. and ALLERGAN USA INC. are Delaware
5 corporations with headquarters in Madison, New Jersey. ALLERGAN INC. and ALLERGAN
6 USA INC. (ALLERGAN INC. and ALLERGAN USA INC., collectively are referred to herein
7 as “Allergan.”) Prior to that, WATSON PHARMACEUTICALS, INC., acquired ACTAVIS,
8 INC. in October 2012; the combined company changed its name to ACTAVIS, INC.
9 SUBSEQUENTLY, ACTAVIS, INC. acquired ALLERGAN and changed the parent company
10 to ALLERGAN.

11 62. Defendant WATSON LABORATORIES, INC. is, and was at all times relevant
12 herein, a Nevada corporation with its principal place of business in Corona, California, and is a
13 wholly owned subsidiary of Allergan PLC, the parent company of Defendants ALLERGAN
14 INC. and ALLERGAN USA INC., (f/k/a ACTAVIS, INC., f/k/a WATSON
15 PHARMACEUTICALS, INC.). At all times relevant herein, Watson Laboratories, Inc. takes
16 and took advantage of the legislative, regulatory and tax schemes of the State of Nevada to own,
17 maintain and defend drug patents. ACTAVIS PHARMA, INC. (f/k/a ACTAVIS, INC.), is a
18 Delaware corporation with its principal place of business in New Jersey, and was formerly
19 known as WATSON PHARMA, INC. ACTAVIS LLC is a Delaware limited liability company
20 with its principal place of business in Parsippany, New Jersey.

21 63. Defendant INSYS THERAPEUTICS, INC.², is, and was at all times relevant
22 herein, a Delaware corporation with its principal place of business located in Chandler, Arizona.
23 At all times relevant herein, Defendant INSYS THERAPEUTICS, INC. was in the business of
24 designing, testing, manufacturing, labeling, advertising, promoting, marketing, selling and/or
25 distributing Subsys, a transmucosal immediate-release formulation of fentanyl, packed in a
26 single-dose spray device intended for oral sublingual administration, and has done so to and
27 within in the State of Nevada. At all times relevant herein, INSYS THERAPEUTICS, INC.

28

² Defendant Insys Therapeutics, Inc. recently filed for Chapter 11 Bankruptcy and, thus, in accordance with the automatic stay, has not been served with these papers.

1 hired “Detailers” in Clark County, Nevada to make personal contact with physicians and clinics
2 to advocate for the purchase and use of opioid medications which were contrary to known safety
3 concerns and sound medical advice. At all times relevant herein, INSYS THERAPEUTICS,
4 INC., used deceptive tactics to gain authorization for Subsys prescriptions from health insurance
5 providers for off-label, high dosage uses.

6 64. Defendant JOHN KAPOOR, the founder of Insys Therapeutics, Inc. and former
7 Executive Chairman, was a member of Insys’s board between 1990 and 2017. He resides in
8 Phoenix, Arizona.

9 65. Defendant RICHARD M. SIMON was a former National Director of Sales for
10 Insys during the time relevant to the allegations of this action. He resides in Seal Beach,
11 California.
12

13 66. Defendant SUNRISE LEE was a former Regional Sales Director of Insys. He
14 resides in Bryant City, Michigan.

15 67. Defendant JOSEPH A. ROWAN was a former Regional Sales Director of Insys
16 during the time relevant to the allegations of this action. He resides in Panama City, Florida.
17

18 68. Defendant MICHAEL J. GURRY was a former Vice President of Managed
19 Markets for Insys during the time relevant to the allegations of this action. He resides in
20 Scottsdale, Arizona.

21 69. Defendant MICHAEL BABICH was the former president and CEO of Insys
22 during the time relevant to the allegations of this action. He resides in Scottsdale, Arizona.
23

24 70. Defendant ALEC BURLAKOFF was the former vice president of sales for
25 Insys during the time relevant to the allegations of this action. He resides in Charlotte, North
26 Carolina.

27 71. The foregoing individual Defendants associated with Insys are referred to
28 collectively as “the Insys Executives.”

1 72. Insys's founder and owner, John Kapoor, was recently convicted of criminal
2 racketeering in a case brought by the Massachusetts Department of Justice. Insys executives,
3 Richard M. Simon, Sunrise Lee, Joseph A. Rowan, and Michael J. Gurry, were all convicted in
4 the same case. Michael L. Babich, former Insys chief executive, pleaded guilty to conspiracy
5 and mail fraud charges. Alec Burlakoff pled guilty to one count of racketeering conspiracy.
6

7 73. MALLINCKRODT LLC is a Delaware corporation with its principal place of
8 business in Hazelwood, Missouri. MALLINCKRODT operates in the United States under the
9 name Mallinckrodt Pharmaceuticals, with its United States headquarters are located in
10 Hazelwood, Missouri. At all times relevant herein, Defendant MALLINCKRODT was in the
11 business of designing, testing, manufacturing, labeling, advertising, promoting, marketing,
12 selling, and/or distributing opioid products known as Exalgo, Roxicodone, and Xartemis XR,
13 and has done so to and within the State of Nevada.

14 74. Defendant SPECGX LLC is a Delaware limited liability company with its
15 headquarters in Clayton, Missouri, and is registered with the Nevada Secretary of State to do
16 business in Nevada. SpecGx LLC is a subsidiary of Mallinckrodt plc that operates its specialty
17 generics business. Defendants Mallinckrodt LLC and SpecGx LLC, together with their DEA
18 and Nevada registrant and licensee subsidiaries and affiliates (collectively, "Mallinckrodt"),
19 manufacture, market, sell, and distribute pharmaceutical drugs throughout the United States,
20 and in Clark County, Nevada.

21 75. That at all times relevant herein, PURDUE PHARMA, L.P.; PURDUE
22 PHARMA, INC.; THE PURDUE FREDERICK COMPANY, INC. dba THE PURDUE
23 FREDERICK COMPANY, INC.; PURDUE PHARMACEUTICALS, L.P.; RICHARD S.
24 SACKLER; JONATHAN D. SACKLER, MORTIMER D.A. SACKLER; KATHE A.
25 SACKLER; ILENE SACKLER LEFCOURT; DAVID A. SACKLER; BEVERLY SACKLER;
26 THERESA SACKLER; PLP ASSOCIATES HOLDINGS L.P.; ROSEBAY MEDICAL
27 COMPANY L.P.; BEACON COMPANY; TEVA PHARMACEUTICALS USA, INC.; TEVA
28 PHARMACEUTICALS INDUSTRIES LTD; CEPHALON, INC.; ENDO HEALTH
SOLUTIONS INC.; ENDO PHARMACEUTICALS, INC.; PAR PHARMACEUTICAL, INC.;

1 PAR PHARMACEUTICAL COMPANIES, INC.; ALLERGAN INC.; ALLERGAN USA
 2 INC.; ACTAVIS, INC. f/k/a WATSON PHARMACEUTICALS, INC.; WATSON
 3 LABORATORIES, INC.; ACTAVIS LLC; ACTAVIS PHARMA, INC. f/k/a WATSON
 4 PHARMA, INC., INSYS THERAPEUTICS, INC.; JOHN KAPOOR; RICHARD M. SIMON,
 5 SUNRISE LEE, JOSEPH A. ROWAN; MICHAEL J. GURRY; MICHAEL BABICH; ALEC
 6 BURLAKOFF; MALLINCKRODT, LLC and SPECGX LLC, (collectively "Defendant
 7 Manufacturers" or "Defendants") were, and currently are, regularly engaged in business in
 8 Clark County. More specifically, Defendants were, and currently are, in the business of
 9 designing, testing, manufacturing, labeling, advertising, promoting, marketing, and/or selling
 10 opioids throughout Clark County.

11 **C. Defendants, Wholesale Distributors.**

12 76. Defendant, AMERISOURCEBERGEN DRUG CORPORATION, is, and at all
 13 times pertinent hereto, was, a foreign corporation authorized to do business in the County of
 14 Clark, State of Nevada. Upon information and belief, and at all times relevant hereto,
 15 AMERISOURCEBERGEN DRUG CORPORATION's principal place of business is located in
 16 Chesterbrook, Pennsylvania, operating distribution centers in Ohio.

17 77. Defendant, CARDINAL HEALTH, INC. is, and at all times pertinent hereto,
 18 was, a foreign corporation with multiple wholly-owned subsidiaries incorporated under the laws
 19 of the State of Nevada and/or authorized to do business in said state, and conducting business
 20 in the County of Clark, State of Nevada.

21 78. Upon information and belief, and at all times relevant hereto, CARDINAL
 22 HEALTH, INC.'s principal office is located in Dublin, Ohio, operating, distribution centers in
 23 Ohio. CARDINAL HEALTH 6 INC. is a Nevada Domestic Corporation. CARDINAL
 24 HEALTH TECHNOLOGIES LLC is a Nevada Domestic LLC. At all times relevant herein,
 25 CARDINAL HEALTH TECHNOLOGIES LLC takes and took advantage of the legislative,
 26 regulatory and tax schemes of the State of Nevada to own, maintain and defend patents,
 27 including those relating to drug labeling, coding and distribution.

28 79. CARDINAL HEALTH 414 LLC is an LLC incorporated under the laws of the
 state of Delaware and headquartered in Dublin, Ohio, and registered and authorized to conduct

1 business within the State of Nevada. At all times relevant herein, CARDINAL HEALTH 414
2 LLC takes and took advantage of the legislative, regulatory and tax schemes of the State of
3 Nevada to own, maintain and defend medical patents. Further, CARDINAL HEALTH 414
4 LLC operates a pharmacy within the physical confines of the County of Clark. CARDINAL
5 HEALTH 200 LLC is an LLC incorporated under the laws of the state of Delaware and
6 headquartered in Dublin, Ohio, and registered and authorized to conduct business within the
7 State of Nevada. To Wit, CARDINAL HEALTH 200 LLC has obtained a business license in
8 the County of Clark to register as a "Procurement Vendor," which is a company registered to
9 submit bids to sell products to Nevada and Clark County government entities, such as to sell
10 medical goods or drugs to the County-operated hospital.
11

12
13 80. Defendant, McKESSON CORPORATION, is, and at all times pertinent hereto,
14 was, foreign corporation authorized to do business in the County of Clark, State of Nevada.
15 Upon information and belief, and at all times relevant hereto, McKESSON CORPORATION's
16 principal place of business is located in San Francisco, California, operating distribution centers
17 in Ohio. At all times relevant herein, McKESSON CORPORATION takes and took advantage
18 of the legislative, regulatory and tax schemes of the State of Nevada to own, maintain and
19 defend patents, including those relating to drug labeling, coding and distribution.
20

21 81. Defendant WALGREENS BOOTS ALLIANCE, INC. is a Delaware
22 corporation with its principal place of business in Illinois.
23

24 82. Defendant WALGREEN CO. is and was registered to do business with the
25 Nevada Secretary of State as an Illinois corporation with its principal place of business in
26 Deerfield, Illinois. Walgreen Co. is a subsidiary of Walgreens Boots Alliance, Inc. and does
27 business under the trade name Walgreens.
28

83. Defendant WALGREEN EASTERN CO., INC. is a New York corporation with

1 its principal place of business in Deerfield, Illinois.

2 84. Defendants Walgreens Boots Alliance, Inc., Walgreen Eastern Co., and
3 Walgreen Co. are collectively referred to as “Walgreens”. Walgreens, through its various DEA
4 registered subsidiaries and affiliated entities, conducts business as a licensed wholesale
5 distributor. At all times relevant to this Complaint, Walgreens distributed prescription opioids
6 throughout the United States, including in Clark County, Nevada. At all relevant times, this
7 Defendant operated as a licensed pharmacy wholesaler in the State of Nevada, and in Clark
8 County, Nevada.
9

10 85. Defendant WALMART INC., (“Walmart”) formerly known as Wal-Mart
11 Stores, Inc., is and was registered to do business with the Nevada Secretary of State as a
12 Delaware corporation with its principal place of business in Arkansas. Walmart, through its
13 various DEA registered subsidiaries and affiliated entities, conducts business as a licensed
14 wholesale distributor under named business entities including Wal-Mart Warehouse #6045 a/k/a
15 Wal-Mart Warehouse #45. At all times relevant to this Complaint, Walmart distributed
16 prescription opioids throughout the United States, including in Clark County, Nevada. At all
17 relevant times, this Defendant operated as a licensed pharmacy wholesaler in the State of
18 Nevada, and in Clark County, Nevada.
19

20 86. Defendant CVS HEALTH CORPORATION (“CVS HC”) is a Delaware
21 corporation with its principal place of business in Woonsocket, Rhode Island. CVS HC conducts
22 business as a licensed wholesale distributor under the following named business entities, among
23 others: CVS Orlando FL Distribution L.L.C. and CVS Pharmacy, Inc. (collectively “CVS”). At
24 all times relevant to this Complaint, CVS distributed prescription opioids throughout the United
25 States, including in Clark County, Nevada.
26
27

28 87. Defendant CVS PHARMACY, INC. (“CVS Pharmacy”) is a Rhode Island

1 corporation with its principal place of business in Woonsocket, Rhode Island. CVS Pharmacy is
2 a subsidiary of CVS HC. At all times relevant to this Complaint, CVS Pharmacy operated as a
3 licensed pharmacy wholesaler, distributor and controlled substance facility in Clark County,
4 Nevada.

5
6 88. Defendant CVS Pharmacy, Inc. distributed prescription opioids to Plaintiffs'
7 Community through the following wholly owned subsidiaries that are alter-egos of CVS
8 Pharmacy, Inc.:

9 a. Defendant CVS INDIANA L.L.C., an Indiana limited liability company with its
10 principal place of business in Indianapolis, Indiana;

11 b. Defendant CVS RX SERVICES, INC. d/b/a CVS Pharmacy Distribution
12 Center, a New York corporation with its principal place of business in Woonsocket,
13 RI; and
14

15 c. Defendant CVS TENNESSEE DISTRIBUTION, L.L.C. a Tennessee corporation
16 with its principal place of business in Woonsocket, Rhode Island.
17

18 89. Defendant CVS Pharmacy, Inc. instituted set-up, ran, directed, and staffed with
19 its own employees, the majority of the Suspicious Order Monitoring and diversion control
20 functions for CVS Indiana, LLC, CVS Rx Services, Inc., and CVS TN Distribution LLC.

21 90. Collectively, CVS Health Corporation, CVS Pharmacy, Inc., CVS Indiana, LLC,
22 CVS Rx Services, Inc., and CVS TN Distribution, LLC are referred to as "CVS." CVS conducts
23 business as a licensed wholesale distributor. At all times relevant to this Complaint, CVS
24 distributed prescription opioids throughout the United States, including in Clark County,
25 Nevada; CVS pharmacies located in Clark County supplemented their supply of Schedule 3
26 controlled substances including prescription opioids through purchases made by CVS from
27 outside vendors; and CVS pharmacies located in Clark County were supplied with Schedule 2
28

1 controlled substances including prescription opioids through purchases made by CVS from
2 outside vendors.

3 91. Defendant, MASTERS PHARMACEUTICAL, LLC f/k/a MASTERS
4 PHARMACEUTICAL, INC., is, and at all times pertinent hereto, was, foreign corporation
5 authorized to do business in the County of Clark, State of Nevada. Upon information and belief,
6 and at all times relevant hereto, MASTERS PHARMACEUTICAL, LLC f/k/a MASTERS
7 PHARMACEUTICAL, INC.'s, operates distribution centers in Ohio.

8 92. AMERISOURCEBERGEN DRUG CORPORATION; CARDINAL HEALTH,
9 INC.; CARDINAL HEALTH 6 INC.; CARDINAL HEALTH TECHNOLOGIES LLC;
10 CARDINAL HEALTH 414 LLC; CARDINAL HEALTH 200 LLC; McKESSON
11 CORPORATION; WALGREENS BOOTS ALLIANCE, INC.; WALGREEN CO.;
12 WALGREEN EASTERN CO., INC.; WALMART INC.; CVS HEALTH CORPORATION;
13 CVS PHARMACY, INC.; CVS INDIANA, LLC; CVS RX SERVICES, INC.; CVS TN
14 DISTRIBUTION, LLC; and MASTERS PHARMACEUTICAL, LLC f/k/a MASTERS
15 PHARMACEUTICAL, INC.; (collectively "Defendant Distributors" or "Defendants")
16 distributed opioids or facilitated the distribution of opioids into Clark County. The United
17 States Drug Enforcement Administration has found it necessary to levy disciplinary action
18 against these and each of these including large fines and suspension or permanent cancellation
19 of their licenses for distribution of controlled substances, based on dangerous and abusive
20 distribution practices as detailed herein and below.

21 93. Defendant Distributors purchased opioids from manufacturers, including the
22 named Defendants herein, and distributed them to pharmacies throughout Clark County, and
23 the State of Nevada.

24 94. Defendant Distributors played an integral role in the chain of opioids being
25 distributed throughout Clark County, and the State of Nevada.

26 **D. Defendants, Detailers.**
27
28

1 95. Defendant AIDA B MAXSAM (hereinafter “DETAILER”) is a natural person
2 who is, and at all relevant times herein was, a resident of Clark County, Nevada, who is or was
3 engaged in specialty drug sales on behalf of Defendant Manufacturer and Distributor PURDUE.

4 96. Defendant DETAILER was trained to, and did in fact, make personal contact
5 with physicians and clinics within Clark County, Nevada for the purpose, and with the result,
6 of encouraging them to prescribe opioid medications in a manner inconsistent with known
7 safety concerns and contrary to sound medical practice.

8 **E. Defendants, Pharmacies, and Pharmacy Benefit Managers.**

9 97. Defendant C & R PHARMACY d/b/a KEN’S PHARMACY f/k/a LAM’S
10 PHARMACY, INC. (“LAM’S PHARMACY”) is and was at all times pertinent hereto a
11 domestic corporation authorized to do business in the County of Clark, State of Nevada. Upon
12 information and belief, and at all times relevant hereto, KEN’S PHARMACY f/k/a LAM’S
13 PHARMACY, INC.’s principal place of business was and is in Las Vegas, Nevada. Plaintiff is
14 informed, believes, and alleges that C & R PHARMACY d/b/a KEN’S PHARMACY purchased
15 and is the possessor and controller of all of the assets of the former LAM’S PHARMACY
16 including drugs, premises, prescription records, customer lists, telephone numbers, goodwill,
17 and all other business assets.

18 98. Defendant LAM’S PHARMACY and other pharmacies (collectively
19 “Defendant Pharmacies” or “Defendants”) sold opioids to residents of Clark County giving rise
20 to the opioid crisis.

21 99. Pharmacy Benefit Managers (“PBMs”) administer benefit contracts and riders
22 that determine coverage for some or all of the costs of pharmaceutical products and/or provide
23 access to such products, sometimes through the PBM’s own mail-order pharmacy. PBMs
24 establish formularies which govern which drugs are reimbursed and how. PBMs also determine
25 pre-authorization requirements and negotiate with drug manufacturers to offer preferred drug
26 formulary placement for drugs. Additionally, PBMs establish reimbursement rates for drugs
27 dispensed and can earn revenue from fees from health plans and insurers, rebates and other
28 incentives from drug manufacturers, including administrative fees and volume bonuses, and

1 fees from maintaining pharmacy networks. Given their “gatekeeper” role, PBMs exercise
2 significant power over the quantity of prescription opioids that enter the market.

3 100. PBMs also have massive quantities of data regarding the opioid prescribing and
4 usage of the doctors and patients who participate in their plans. As a result, PBMs can
5 identify: (a) patients who receive, and doctors who prescribe opioids in excessive volumes,
6 frequency, or dosage; (b) patients who receive, and doctors who prescribe opioids in
7 combination with other drugs indicative of diversion; (c) patients who receive opioids after
8 having been treated or while being treated for opioid overdoses and addition; and (d) patients
9 who receive opioids who are at higher risk for overdose, for example, because they also receive
10 benzodiazepines. This information, and their representations about their efforts to manage and
11 improve patients’ health, created an obligation for PBMs to identify, report, and otherwise
12 address potential diversion or other dangerous instances of opioid use and prescribing.

13 101. In addition, PBMs distribute opioids directly through their mail order
14 pharmacies, and, like other pharmacies, are DEA and state registrants. In distributing opioids,
15 PBMs are obligated to prevent diversion and to identify, report, and not ship suspicious orders
16 of opioids. Upon information and belief, to be confirmed by transaction data in the exclusive
17 possession of the PBMs, PBMs failed to carry out these duties.

18 102. Defendant EXPRESS SCRIPTS HOLDING COMPANY (“ESHC”) is a
19 Delaware corporation with its principal place of business in St. Louis, Missouri. Defendant
20 EXPRESS SCRIPTS, INC. (“ESI”) is a wholly-owned subsidiary of ESHC and is incorporated
21 in the State of Delaware with its principal place of business located in St. Louis, Missouri. In
22 2012, ESI acquired its rival, Medco Health Solutions Inc., otherwise known as Merck Medco,
23 in a \$29.1 billion deal. As a result of the merger, ESHC was formed and became the largest
24 PBM in the nation, filing a combined 1.4 billion prescriptions for employers and
25 insurers. ESHC and ESI are collectively referred to as “Express Scripts.”

26 103. Upon information and belief, Express Scripts derived and continues to derive
27 substantial revenue as a result of managing pharmacy benefits throughout Nevada, including
28 within Clark County.

1 104. Defendant Pharmacies and PBMs played an integral role in the chain of opioids
2 being sold throughout Clark County.

3 **F. Defendants, Health Care Providers**

4 105. Defendant STEVEN A HOLPER MD is, and was at all times relevant herein, a
5 resident of Clark County, Nevada and was a licensed medical doctor in the State of Nevada.
6 Upon information and belief, and at all times relevant hereto, Defendant STEVEN A HOLPER
7 MD, conducted business and provided medical services as STEVEN A. HOLPER, M.D., PC, a
8 Nevada Domestic Professional Corporation in Clark County, Nevada. Defendant HOLPER
9 OUT-PATIENTS MEDICAL CENTER, LTD. (collectively, with STEVEN A HOLPER MD
10 and STEVEN A. HOLPER M.D., PC, "Defendant Providers" or "HOLPER"), is, and was at all
11 times relevant herein, a Nevada Domestic Corporation with its principal place of business in
12 Clark County, Nevada, and served as the location from which Defendant STEVEN A HOLPER
13 MD provided his medical services.

14 106. HOLPER habitually prescribed and delivered highly addictive and potentially
15 lethal opioid medications, including, but not limited to, Subsys, to patients in Clark County,
16 Nevada who did not meet the qualifications for such medication, specifically, were not cancer
17 patients experiencing break-through cancer pain.

18 107. HOLPER participated in a deceptive scheme to obtain authorization for such
19 prescriptions from health insurance providers.

20 **G. Defendants, Does, Roes and Zoes.**

21 108. That the true names and the capacities, whether individual, agency, corporate,
22 associate or otherwise, of Defendant DOES 1 through 100, inclusive, are unknown to Plaintiff.
23 Plaintiff will ask leave of the Court to amend this Complaint to show the true names and
24 capacities of these Defendants, when they become known to Plaintiff. Plaintiff believes each
25 Defendant named as DOE was responsible for the misconduct alleged herein.

26 109. That the true names and the capacities, whether individual, agency, corporate,
27 associate or otherwise, of Defendant ROE CORPORATIONS I through 100, are unknown to
28 Plaintiff. These Defendants include the manufacturer(s), distributor(s) and any third party that

1 may have developed, manufactured, produced, sold, altered or otherwise distributed the subject
 2 drug, which caused Plaintiff's injuries as complained herein. Plaintiff will ask to leave of the
 3 Court to amend this Complaint to show the true names and capacities of these Defendants, when
 4 they become known to Plaintiff. Plaintiff believes each Defendant named as ROE
 5 CORPORATION was responsible for contributing to the misconduct alleged herein.

6 110. That the true names and the capacities, whether individual, agency, corporate,
 7 associate or otherwise, of Defendant ZOE PHARMACIES I through 100, are unknown to
 8 Plaintiff. These Defendants include the pharmacies or similarly situated retailers that may have
 9 developed, manufactured, produced, sold, altered or otherwise distributed opioids which caused
 10 Plaintiff's injuries as complained herein. Plaintiff will ask to leave of the Court to amend this
 11 Complaint to show the true names and capacities of these Defendants, when they become known
 12 to Plaintiff. Plaintiff believes each Defendant named as ZOE PHARMACY was responsible for
 13 contributing to the misconduct alleged herein.

14 111. That Plaintiff is informed and believes, and based upon such information and
 15 belief, alleges that each of the Defendants herein designated as DOES, ROES and/or ZOES are
 16 in some manner responsible for the misconduct alleged herein.

17 112. Plaintiff is informed and believes and thereon alleges that at all relevant times
 18 herein mentioned Defendants, and each of them, were the agents and/or servants and/or partners
 19 and/or joint venture partners and/or employers and/or employees and/or contractors of the
 20 remaining Defendants and were acting within the course and scope of such agency,
 21 employment, partnership, contract or joint venture and with the knowledge and consent of the
 22 remaining Defendants at the time of the event leading to the misconduct alleged herein.

23 **H. Jurisdiction & Venue.**

24 113. That exercise of the jurisdiction by this Court over each and every Defendant in
 25 this action is appropriate because each and every Defendant has done, and continues to do,
 26 business in the State of Nevada, and committed a tort in the State of Nevada. Additionally, this
 27 Court has jurisdiction over the claims alleged herein as they arise under Nevada statutes and
 28 Nevada common law.

114. Venue is proper in the District Court of Clark County, Nevada where part of the claims alleged herein occurred.

GENERAL FACTUAL ALLEGATIONS

A. Opioids Generally

115. Defendants design, manufacture, distribute, sell, market, and advertise prescription opioids, including brand-name drugs like Oxycontin and Subsys, and generics like oxycodone, which are powerful narcotic painkillers. Historically, because they were considered too addictive and debilitating for the treatment of chronic pain (like back pain, migraines and arthritis), opioids were used only to treat short-term acute pain cancer patients or for palliative (end-of-life) care.

116. Due to the lack of evidence that opioids improved patients' ability to overcome pain and function, coupled with evidence of greater pain complaints as patients developed tolerance to opioids over time and the serious risk of addiction and other side effects, the use of opioids for chronic pain was discouraged or prohibited. As a result, doctors generally did not prescribe opioids for chronic pain.

117. In the 1970s and 1980s, studies were conducted that made clear the reasons to avoid opioids. By way of example, the World Health Organization ("WHO") in 1986 published an "analgesic ladder" for the treatment of cancer pain. The WHO recommended treatment with over-the-counter or prescription acetaminophen or non-steroidal anti-inflammatory drugs ("NSAIDs") first, then use of unscheduled or combination opioids, and then stronger (Schedule II or III) opioids if pain persisted. The WHO ladder pertained only to the treatment of cancer pain, and did not contemplate the use of narcotic opioids for chronic pain - because the use of opioids for chronic pain was not considered appropriate medical practice at the time.

118. Due to concerns about their addictive qualities, opioids have been regulated as controlled substances by the U.S. Drug Enforcement Administration ("DEA") since 1970. The labels for scheduled opioid drugs carry black box warnings of potential addiction and "[s]erious, life-threatening, or fatal respiratory depression," as a result of an excessive dose.

B. Defendants' Fraudulent Marketing

1 119. To take advantage of the lucrative market for chronic pain patients, Defendants
2 developed a well-funded marketing scheme based on deception. Defendants used both direct
3 marketing and unbranded advertising disseminated by purported independent third parties to
4 spread false and deceptive statements about the risks and benefits of long-term opioid use.

5 120. Yet these statements were not only unsupported by or contrary to the scientific
6 evidence, they were also contrary to pronouncements by and guidance from federal agencies
7 such as the Food and Drug Administration (“FDA”) and Centers for Disease Control and
8 Prevention (“CDC”) based on that evidence. They also targeted susceptible prescribers and
9 vulnerable patient populations, including the elderly and veterans.

10 121. Defendants also used kickback systems, prior authorization systems, and
11 incentives to encourage health care providers to prescribe the opioid medications.

12 **Direct Marketing Efforts**

13 122. Defendants’ direct marketing of opioids generally proceeded on two tracks.
14 First, Defendants conducted, and continue to conduct, promotional campaigns extolling the
15 purported benefits of their branded drugs. Advertisements were branded to deceptively portray
16 the benefits of opioids for chronic pain. For instance, Defendant Purdue commissioned series
17 of ads in medical journals, called “Pain vignettes,” for Oxycontin in 2012. These ads featured
18 chronic pain patients and recommended opioids for each. One ad described a “54-year-old
19 writer with osteoarthritis of the hands” and implied that Oxycontin would help the writer work
20 more effectively. Purdue agreed in late 2015 and 2016 to halt these misleading representations
21 in New York, but no similar order has been issued in Nevada. Defendant Mallinckrodt marketed
22 its products, Exalgo and Xartemis as specially formulated to reduce abuse and published
23 information on its website minimizing addition risk as well as advocating access to opioids.
24 Defendant Insys provided health care providers with false and misleading information in order
25 to deceive such providers into believing the FDA had approved Subsys for more uses than the
26 FDA had actually approved.

27 123. Second, Defendants promoted, and continue to promote, the use of opioids for
28 chronic pain through “detailers” – sales representatives who visited individual doctors and
medical staff in their offices – and small-group speaker programs. Defendants’ detailing to

1 doctors is effective. By establishing close relationships with prescribing physicians,
2 Defendants' sales representatives are able to disseminate their misrepresentations in targeted,
3 one-on-one settings that allowed them to differentiate their opioids and to address individual
4 prescribers' concerns about prescribing opioids for chronic pain.

5 124. These direct techniques were also accompanied by kickbacks, prior
6 authorization systems, and the use of other incentives to encourage health care providers, to
7 prescribe the opioid medication for chronic pain.

8 125. Numerous studies indicate that marketing impacts prescribing habits, with face-
9 to-face detailing having the greatest influence. Defendants devoted, and continues to devote,
10 massive resources to direct sales contacts with doctors.

11 126. Defendants paid sham "speaker fees" to doctors to run educational events to
12 discuss the use of their products, but the fees were actually intended to reward those doctors for
13 prescribing Defendants' product and incentivize them to prescribe more of those products to
14 patients. In fact, often times the speakers spoke at events with minimal to no attendance simply
15 to collect the fee. These kickbacks increased as the number of prescriptions written by the
16 speakers increased.

17 127. Upon information and belief and at all times relevant herein, Defendants
18 ensured, and continue to ensure, marketing consistency nationwide through national and
19 regional sales representative training; national training of local medical liaisons, the company
20 employees who respond to physician inquiries; centralized speaker training; single sets of visual
21 aids, speaker slide decks, and sales training materials; and nationally coordinated advertising.
22 Upon information and belief, Defendants' sales representatives and physician speakers were
23 required to adhere to prescribed talking points, sales messages, and slide decks, and supervisors
24 rode along with them periodically to both check on their performance and compliance.

25 128. Upon information and belief and at all times relevant herein, Defendants
26 employed, and continue to employ, the same marketing plans and strategies and deployed the
27 same messages in Nevada as they did nationwide.

28 129. As the opioid epidemic spread, many health care providers recognized the
dangers of opioid medication, including health risks and the risk of addiction. Others, however,

1 continued to prescribe such medication for off-label purposes without adequately warning
2 patients of the dangers associated with opioids.

3 130. Upon information and belief, Defendant Providers received financial incentives
4 to continue writing prescriptions for such opioid medication despite the dangers associated with
5 same.

6 131. Across the pharmaceutical industry, “core message” development is funded and
7 overseen on a national basis by corporate headquarters. This comprehensive approach ensures
8 that Defendants’ messages are accurately and consistently delivered across marketing channels
9 – including detailing visits, speaker events, and advertising – and in each sales territory.
10 Defendants consider this high level of coordination and uniformity crucial to successfully
11 marketing their drugs.

12 **Unbranded/Third-Party Marketing by Defendants**

13 132. In addition to direct communications, Defendants utilized third-party marketing
14 to promote their line of prescription opiates. This “unbranded” marketing refers not to a specific
15 drug, but more generally to a disease state or treatment. For instance, these marketing materials
16 generally promoted opioid use but did not name a specific opioid. Through these unbranded
17 materials, Defendants presented information and instructions concerning opioids that were
18 generally contrary to, or at best, inconsistent with, information and instructions listed on
19 Defendants’ branded marketing materials and drug labels and with Defendants’ own knowledge
20 of the risks, benefits and advantages of opioids. An example of such unbranded marketing
21 techniques is Defendant Mallinckrodt’s Collaborating and Acting Responsible to Ensure Safety
22 (C.A.R.E.S.) Alliance, which promoted a book “Defeat Chronic Pain Now!” minimizing the
23 risk of opioid addiction and emphasizing opioid therapy for regular use for moderate chronic
24 pain.

25 133. Using “Key Opinion Leaders” (KOLs) and “Front Groups,” Defendants
26 disseminated their false and misleading statements regarding the efficacy of opioids. These
27 KOLs and Front Groups were important elements of Defendants’ marketing plans, because they
28 appeared independent and therefore outside of FDA oversight. However, Defendants did so
knowing that unbranded materials typically were not submitted or reviewed by the FDA. By

1 acting through third parties, Defendants was able both to avoid FDA scrutiny and to give the
2 false appearance that these messages reflected the views of independent third parties.
3 Afterwards, Defendants would cite to these sources as corroboration of their own statements.

4 134. Defendants worked, and continue to work, in concert with the Front Groups and
5 KOLs which they funded and directed to carry out a common scheme to deceptively market the
6 risks, benefits, and superiority of opioids to treat chronic pain. Although participants knew this
7 information was false and misleading, these misstatements were nevertheless disseminated to
8 Nevada prescribers and patients.

9 **Key Opinion Leaders (KOLs)**

10 135. Upon information and belief and at all times relevant herein, Defendants
11 recruited, as part of its unbranded marketing efforts, a cadre of doctors who were financially
12 sponsored because of their preference to aggressively treat chronic pain with opioids. KOLs
13 were retained by Defendants to influence their peers' medical practice, including but not limited
14 to their prescribing behavior. KOLs gave lectures, conducted clinical trials and occasionally
15 made presentations at regulatory meetings or hearings. KOLs were carefully vetted to ensure
16 that they were likely to remain on message and supportive of Defendant' agenda.

17 136. Defendants' financial support helped these doctors become respected industry
18 experts. Upon information and belief, these doctors repaid Defendants by extolling the benefits
19 of opioids to treat chronic pain as quid pro quo. Defendants would cite to these sources later
20 on as corroboration of their own false and misleading statements regarding opioids.

21 **Front Groups**

22 137. Defendants also entered into arrangements with seemingly unbiased and
23 independent patient and professional organizations to promote opioids for the treatment of
24 chronic pain. Under their direction and control, these "Front Groups" generated treatment
25 guidelines, unbranded materials, and programs that favored chronic opioid therapy. They also
26 assisted Defendants by refuting negative articles, by advocating against regulatory changes that
27 would limit opioid prescribing in accordance with the scientific evidence, and by conducting
28 outreach to vulnerable patient populations targeted by Defendants.

1 138. These Front Groups depended on Defendants for funding and, in some cases, for
 2 survival. Defendants exercised significant control over programs and materials created by these
 3 groups by collaborating on, editing, and approving their content, and by funding their
 4 dissemination. In so doing, Defendants made sure that these Front Groups would generate only
 5 favorable messages. Despite this, the Front Groups held themselves out as independent and
 6 serving the needs of their members – whether patients suffering from pain or doctors treating
 7 those patients.

8 139. While Defendants utilized many Front Groups, one of the most prominent of was
 9 the American Pain Foundation (“APF”). APF received more than \$10 million in funding from
 10 opioid manufacturers from 2007 until it closed its doors in May 2012. Upon information and
 11 belief, Defendant Purdue was one of its primary financial backers.

12 140. APF issued education guides for patients, reporters, and policymakers that touted
 13 the benefits of opioids for chronic pain and trivialized their risks, particularly the risk of
 14 addiction. APF also launched a campaign to promote opioids for returning veterans, which has
 15 contributed to high rates of addiction and other adverse outcomes – including death – among
 16 returning soldiers. APF also engaged in a significant multimedia campaign – through radio,
 17 television and the internet – to educate patients about their “right” to pain treatment, namely
 18 opioids. All of the programs and materials were available nationally and were intended to reach
 19 Nevadans.

20 141. In or about May 2012, the U.S. Senate Finance Committee began investigating
 21 APF to determine the relationship, financial and otherwise, between the organization and the
 22 manufacturers of opioid analgesics. The investigation caused considerable damage to APF’s
 23 credibility as an objective and neutral third party, and Purdue, upon information and belief,
 24 stopped financially supporting the organization.

25 142. Within days of being targeted by Senate investigation, APF’s board voted to
 26 dissolve the organization “due to irreparable economic circumstances.” APF “cease[d] to exist,
 27 effective immediately.”

28 **Continuing Medical Education (CMEs)**

143. CMEs are ongoing professional education programs required for physicians. Physicians must attend a certain number and, often, type of CME programs each year as a condition of their licensure. These programs are delivered in person, often in connection with professional organizations' conferences, and online, or through written publications. Doctors rely on CMEs not only to satisfy licensing requirements, but to get information on new developments in medicine or to deepen their knowledge in specific areas of practice. Because CMEs are typically delivered by KOLs who are highly-respected in their fields and are thought to reflect their medical expertise, they can be especially influential with doctors.

144. By utilizing CMEs, Defendants sought to reach general practitioners, whose broad area of focus and lack of specialized training in pain management made them particularly dependent upon CMEs and, as a result, especially susceptible to Defendants' deceptions. Defendants sponsored CMEs promoted chronic opioid therapy.

145. These CMEs, while often generically titled to relate to the treatment of chronic pain, focused on opioids to the exclusion of alternative treatments, inflated the benefits of opioids, and frequently omitted or downplayed their risks and adverse effects.

146. Upon information and belief and at all times relevant herein, CMEs paid for or sponsored by Defendants were intended to reach prescribing physicians in Nevada.

Drug Manufacturer Defendants—Kickbacks to Encourage Prescriptions

147. Upon information and belief, Defendants utilized a system of kickbacks to encourage health care providers to write prescriptions for, and deliver, the opioid medications. Kickbacks took the form of "speaker fees" paid to health care providers that spoke at programs regarding the purported benefits and safety of using opioid medications to treat chronic pain. Such speakers were recruited by Defendants based upon the number of prescriptions the providers wrote for opioid medications. The more prescriptions written, the more times the speaker was asked to appear at a program, and the more "speaker fees" were paid to the provider. Defendants' employees were rewarded when their "speakers" increased the prescriptions they wrote. These speaking programs did not result in other health care providers writing a significant number of prescriptions for Defendants' products, but the "speakers" continued to be paid to speak so long as they increased their own prescriptions. Many of the speaker

1 programs had few or no attendees that would actually be able to write prescriptions for
 2 Defendants' products. Upon information and belief, Defendant Providers, benefitted from such
 3 programs.

4 **Prior Authorization Programs**

5 148. Upon information and belief, Defendants developed prior authorization
 6 programs in order to gain authorization and approval from insurance companies to cover the
 7 costly opioid products for off-label uses. These programs involved representatives from
 8 Defendants contacting insurance companies and representing that they are from a health care
 9 provider's office rather than from the Defendant manufacturer or distributor; providing
 10 inaccurate diagnosis information on the authorization requests; and drafting Letters of Medical
 11 Necessity for health care providers to sign-off on for purposes of receiving authorization from
 12 health insurance providers. Upon information and belief, Defendant Providers also participated
 13 in misleading the health insurance providers to authorize the numerous prescriptions written for
 14 opioid medications, including, but not limited to, Subsys.

15 **Medication Switch Programs**

16 149. Upon information and belief, Defendants encouraged and incentivized detailers
 17 and sales people to convince health care providers to substitute stronger, more expensive opioid
 18 medications for medications that patients were already prescribed. Detailers and sales people
 19 were informed that they would receive higher pay and/or bonuses by convincing health care
 20 providers to change prescriptions. These programs ignored any warnings that one opioid drug
 21 could not be substituted on a one-for-one basis with another opioid medication. Each opioid
 22 medication is unique in its dosing and has a different approved dosage level. Switch programs
 23 encouraged a one-for-one substitution despite the differences in the original and substitute
 24 medication.

25 **Drug Manufacturer Defendants—Marketing Targeting the Elderly and Veterans**

26 150. In its pursuit of profit, Defendants targeted vulnerable segments of the
 27 population suffering from chronic pain including veterans and the elderly.

28 151. Defendants' targeted marketing to the elderly and the absence of cautionary
 language in their promotional materials creates a heightened risk of serious injury. Studies have

1 shown that elderly patients who used opioids had a significantly higher rate of death, heart
2 attacks, and strokes than users of NSAIDs. Additionally, elderly patients taking opioids have
3 been found to suffer elevated fracture risks, greater risk for hospitalizations, and increased
4 vulnerability to adverse drug effects and interactions, such as respiratory depression.

5 152. Defendants' efforts were successful. Since 2007, opioid prescriptions for the
6 elderly have grown at twice the rate of prescriptions for adults between the ages of 40 and 59.
7 Based on anecdotal evidence, many of these elderly patients started on opioids for chronic back
8 pain or arthritis.

9 153. Veterans are also suffering greatly from the effects of Defendants' targeted
10 marketing. Opioids are particularly dangerous to veterans. According to a study published in
11 the 2013 Journal of American Medicine, veterans returning from Iraq and Afghanistan who
12 were prescribed opioids have a higher incidence of adverse clinical outcomes, like overdoses
13 and self-inflicted and accidental injuries, than the general U.S. population.

14 154. *Exit Wounds*, a 2009 publication sponsored by Defendant Purdue and distributed
15 by APF, written as a personal narrative of one veteran, describes opioids as "underused" and
16 the "gold standard of pain medications" and fails to disclose the risk of addiction, overdose, or
17 injury. It notes that opioid medications "increase a person's level of functioning" and that "[l]ong
18 experience with opioids shows that people who are not predisposed to addiction are unlikely to
19 become addicted to opioid pain medications."

20 155. *Exit Wounds* downplays and minimizes the risks from chronic opioid therapy
21 and does not disclose the risk that opioids may cause fatal interactions with benzodiazepines
22 taken by a significant number of veterans. It is not the unbiased narrative of a returning war
23 veteran. It is another form of marketing, sponsored by Defendant Purdue.

24 156. The deceptive nature of *Exit Wounds* is made obvious in comparing it to
25 guidance on opioids published by the U.S. Department of Veterans Affairs and the Department
26 of Defense in 2010 and 2011. The VA's Taking Opioids Responsibly describes opioids as
27 "dangerous." It cautions against taking extra doses and mentions the risk of overdose and the
28 dangers of interactions with alcohol.

C. Defendants' Misrepresentations

1 157. To convince prescribing physicians and prospective patients that opioids are
2 safe, Defendants deceptively concealed the risks of long-term opioid use, particularly the risk
3 of addiction, through a series of misrepresentations. Defendants manipulated their promotional
4 materials and the scientific literature to make it appear that these items were accurate, truthful,
5 and supported by objective evidence when they were not.

6 158. These misrepresentations regarding opioids include but are not limited to:

- 7 a. Starting patients on opioids was low-risk because most patients would not
8 become addicted, and because those who were at greatest risk of addiction could
9 be readily identified and managed;
- 10 b. Patients who displayed signs of addiction probably were not addicted and, in any
11 event, could easily be weaned from the drugs;
- 12 c. The use of higher opioid doses, which many patients need to sustain pain relief
13 as they develop tolerance to the drugs, do not pose special risks; and
- 14 d. Abuse-deterrent opioids both prevent abuse and overdose and are inherently less
15 addictive.

16 159. Upon information and belief, Defendants have not only failed to correct these
17 misrepresentations, they continue to make them today.

18 160. For example, Defendant Purdue misrepresented, and continues to misrepresent,
19 Oxycontin as providing 12 continuous hours of pain relief with one dose. However, studies
20 have shown, as well as Purdue's own internal research, that the effects of the drug wear off in
21 or about six (6) hours in one quarter of its patients and in or about ten (1) hours in one-half of
22 its patients.

23 161. Defendants also misrepresented the benefits of chronic opioid therapy. For
24 example, Defendant Purdue falsely claimed that long-term opioid use improved patients'
25 function and quality of life in advertisements for Oxycontin in medical journals entitled, "Pain
26 Vignettes" which were case studies featuring patients with pain conditions persisting over
27 several months and recommending Oxycontin for them. These advertisements implied that
28 Oxycontin improves patients' function.

1 162. However, these claims find no support in the scientific literature. In 2008, the
 2 FDA sent a warning letter to an opioid manufacturer, making it clear “that [the claim that]
 3 patients who are treated with the drug experience an improvement in their overall function,
 4 social function, and ability to perform daily activities . . . has not been demonstrated by
 5 substantial evidence or substantial clinical experience.” Most recently, the 2016 CDC
 6 Guideline approved by the FDA concluded that “there is no good evidence that opioids improve
 7 pain or function with long-term use, and . . . complete relief of pain is unlikely.”

8 163. Upon information and belief and at all times relative herein, Defendants made
 9 and/or disseminated deceptive statements related to opioids, including, but not limited to, in the
 10 following ways:

- 11 a. Creating, sponsoring, and assisting in the distribution of patient education
 12 materials distributed to Nevada consumers that contained deceptive statements;
- 13 b. Creating and disseminating advertisements that contained deceptive statements
 14 concerning the ability of opioids to improve function long-term and concerning
 15 the evidence supporting the efficacy of opioids long-term for the treatment of
 16 chronic non-cancer pain;
- 17 c. Assisting in the distribution of guidelines that contained deceptive statements
 18 concerning the use of opioids to treat chronic non-cancer pain and
 19 misrepresented the risks of opioid addiction;
- 20 d. Developing and disseminating scientific studies that misleadingly concluded
 21 opioids are safe and effective for the long-term treatment of chronic non-cancer
 22 pain and that opioids improve quality of life, while concealing contrary data;
- 23 e. Targeting the elderly and veterans by assisting in the distribution of guidelines
 24 that contained deceptive statements concerning the use of opioids to treat chronic
 25 non-cancer pain and misrepresented the risks of opioid addiction in this
 26 population;
- 27 f. Exclusively disseminating misleading statements in education materials to
 28 Nevada hospital doctors and staff while purportedly educating them on new pain
 standards; and

1 g. Making deceptive statements concerning the use of opioids to treat chronic non-
2 cancer pain to Nevada prescribers through in-person detailing.

3 **D. Duty of Drug Distributors and Pharmacies as Gate Keepers**

4 164. In Nevada, opioids are a controlled substance and are categorized as "dangerous
5 drugs." Therefore, Defendant Distributors have a duty to exercise reasonable care under the
6 circumstances.

7 165. This involves a duty not to create a foreseeable risk of harm to others.
8 Additionally, one who engages in affirmative conduct-and thereafter realizes or should realize
9 that such conduct has created an unreasonable risk of harm to another-is under a duty to exercise
10 reasonable care to prevent the threatened harm.

11 166. All opioid distributors are required and have a duty to maintain effective controls
12 against opioid diversion. They are also required and have a duty to create and use a system to
13 identify and report downstream suspicious orders of controlled substances to law enforcement.
14 Suspicious orders include orders of unusual size, orders deviating substantially from the normal
15 pattern, and orders of unusual frequency.

16 167. To comply with these requirements, distributors must know their customers,
17 report suspicious orders, conduct due diligence, and terminate orders if there are indications of
18 diversion.

19 168. Defendant Distributors each have an affirmative duty to act as a gatekeeper
20 guarding against the diversion of the highly addictive, dangerous opioid drugs.

21 169. Defendant Distributors each have a non-delegable duty to identify and track
22 suspicious orders of controlled substances.

23 170. In addition, Defendant Distributors must also stop shipment on any order which
24 is flagged as suspicious and only ship orders which were flagged as potentially suspicious if,
25 after conducting due diligence, the distributor can determine that the order is not likely to be
26 diverted into illegal channels.

27 171. Defendant Distributors have a duty to detect questionable and suspicious orders
28 to prevent the diversion of opioids into Clark County, which include orders of unusual size,
 orders deviating substantially from a normal pattern, and orders of an unusual frequency.

1 172. Defendant Distributors not only have a duty to detect and prevent diversion of
2 controlled prescription drugs, but undertake such efforts as responsible members of society.

3 173. In so doing, this is intended to reduce the widespread diversion of these drugs
4 out of legitimate channels into the illicit market, while at the same time providing the legitimate
5 drug industry with a unified approach to narcotic and dangerous drug control.

6 174. Notwithstanding this duty and obligation, the DEA has been required to take
7 administrative action against Defendant Distributors to force compliance. The United States
8 Department of Justice, Office of the Inspector General, Evaluation and Inspections Division,
9 reported that the DEA issued final decisions in 178 registrant actions between 2008 and 2012.
10 The Office of Administrative Law Judges issued a recommended decision in a total of 117
11 registrant actions before the DEA issued its final decision, including 76 actions involving orders
12 to show cause and 41 actions involving immediate suspension orders.³ Some of these actions
13 include the following:

14
15 (a) On April 24, 2007, the DEA issued an *Order to Show Cause and*
16 *Immediate Suspension Order* against the AmerisourceBergen Orlando, Florida
17 distribution center ("Orlando Facility") alleging failure to maintain effective controls
against diversion of controlled substances. On June 22, 2007, AmerisourceBergen
entered into a settlement which resulted in the suspension of its DEA registration;

18
19 (b) On November 28, 2007, the DEA issued an *Order to Show Cause and*
20 *Immediate Suspension Order* against the Cardinal Health Auburn, Washington
Distribution Center ("Auburn Facility") for failure to maintain effective controls against
diversion of hydrocodone;

21
22 (c) On December 5, 2007, the DEA issued an *Order to Show Cause and*
23 *Immediate Suspension Order* against the Cardinal Health Lakeland, Florida Distribution
Center ("Lakeland Facility") for failure to maintain effective controls against diversion
of hydrocodone;

24
25 (d) On December 7, 2007, the DEA issued an *Order to Show Cause and*
26 *Immediate Suspension Order* against the Cardinal Health Swedesboro, New Jersey
Distribution Center ("Swedesboro Facility") for failure to maintain effective controls
against diversion of hydrocodone;

27 (e) On January 30, 2008, the DEA issued an *Order to Show Cause and*
28

³ *The Drug Enforcement Administration's Adjudication of Registrant Actions*, United States Department of Justice, Office of the Inspector General, Evaluation and Inspections Divisions, 1-2014-003 (May 2014).

1 *Immediate Suspension Order* against the Cardinal Health Stafford, Texas Distribution
 2 Center ("Stafford Facility") for failure to maintain effective controls against diversion
 of hydrocodone;

3 (f) On May 2, 2008, McKesson Corporation entered into an *Administrative*
 4 *Memorandum of Agreement* ("2008 MOA") with the DEA which provided that
 5 McKesson would "maintain a compliance program designed to detect and prevent the
 6 diversion of controlled substances, inform DEA of suspicious orders required by 21
 CFR § 1301.74(b), and follow the procedures established by its Controlled Substance
 Monitoring Program;"

7 (g) On September 30, 2008, Cardinal Health entered into a *Settlement and*
 8 *Release Agreement and Administrative Memorandum of Agreement* with the DEA
 9 related to its Auburn Facility, Lakeland Facility, Swedesboro Facility and Stafford
 10 Facility. The document also referenced allegations by the DEA that Cardinal failed to
 11 maintain effective controls against the diversion of controlled substances at its
 distribution facilities located in McDonough, Georgia; Valencia, California; and
 Denver, Colorado;

12 (h) On February 2, 2012, the DEA issued an *Order to Show Cause and*
 13 *Immediate Suspension Order* against the Cardinal Health Lakeland, Florida Distribution
 14 Center for failure to maintain effective controls against diversion of oxycodone;

15 (i) On December 23, 2016, Cardinal Health agreed to pay a \$44 million fine
 16 to the DEA to resolve the civil penalty portion of the administrative action taken against
 its Lakeland, Florida Distribution Center;

17 (j) On January 5, 2017, McKesson Corporation entered into an
 18 *Administrative Memorandum Agreement* with the DEA wherein it agreed to pay a
 19 \$150,000,000 civil penalty for violation of the 2008 MOA as well as failure to identify
 20 and report suspicious orders at its facilities in Aurora CO, Aurora IL, Delran NJ,
 LaCrosse WI, Lakeland FL, Landover MD, La Vista NE, Livonia MI, Methuen MA,
 Santa Fe Springs CA, Washington Courthouse OH and West Sacramento CA; and

21 (k) On July 11, 2017, Mallinckrodt agreed to pay the DEA \$35 million to
 22 settle allegations for the company's failure to report suspicious orders of opioids and
 23 allegations of faulty record keeping. The investigation originally began in 2011 and
 24 federal investigators reportedly found 44,000 violations potentially exposing
 Mallinckrodt to \$2.3 billion in fines.

25 175. In another example, on August 9, 2013, the DEA issued an Order to Show Cause
 26 for Defendant MASTERS PHARMACEUTICALS, LLC to consider whether to revoke its
 27 distributor license for failing to monitor, report, and prevent the distribution of suspicious orders
 28 under federal law. *See, Masters Pharmaceuticals, Inc.; Decision and Order*, 80 FR 55418, 55419

1 (2015). The Order *inter alia* made allegations regarding Masters suspicious distributions of
2 oxycodone to various pharmacies across the country, including 1.7 million dosage units . . . to
3 a pharmacy located in Clark County from January 1, 2009 through November 30, 2010. *Id.*
4 The registration was ultimately revoked and Masters appealed.

5 176. On June 30, 2017, the Court of Appeals for the D.C. Circuit issued an order in
6 denying MASTERS PHARMACEUTICAL, INC.'s, Petition for Review seeking to overturn
7 the DEA's revocation of Masters' DEA registration finding that there was substantial evidence
8 which supported revocation because suspicious orders were not investigated. *See, Masters*
9 *Pharmaceutical, Inc. v. Drug Enforcement Administration* (No. 15-1335).

10 177. Because Defendant Distributors handle such large volumes of controlled
11 substances, and are the first major line of defense in the movement of legal pharmaceutical
12 controlled substances from legitimate channels into the illicit market, it is incumbent on these
13 distributors to maintain effective controls to prevent diversion of controlled substances. Should
14 a distributor deviate from these checks and balances, the closed system collapses.

15 178. The sheer volume of prescription opioids distributed to pharmacies in Clark
16 County is excessive for the medical need of the community and facially suspicious. Some red
17 flags are so obvious that no one who engages in the legitimate distribution of controlled
18 substances can reasonably claim ignorance of them.

19 179. Over the course of a decade, Defendant Distributors and Pharmacies failed to
20 detect suspicious orders of prescription opioids which Defendants knew or should have known
21 were likely to be delivered and/or diverted into Clark County.

22 180. Defendants ignored the law, paid the fines, and continued to unlawfully fill
23 suspicious orders of unusual size, orders deviating substantially from a normal pattern and/or
24 orders of unusual frequency in Clark County, and/or orders which Defendants knew or should
25 have known were likely to be delivered and/or diverted into Clark County.

26 181. Defendant Pharmacies must exercise reasonable care under the circumstances.
27 This involves a duty not to create a foreseeable risk of harm to others. Additionally, one who
28 engages in affirmative conduct, and thereafter realizes or should realize that such conduct has

1 created an unreasonable risk of harm to another, is under a duty to exercise reasonable care to
2 prevent the threatened harm.

3 182. Like Defendant Distributors, Defendant Pharmacies also serve as gatekeepers in
4 keeping drugs from entering the illicit market. As the “last line of defense,” they are meant to
5 be the drug experts in the healthcare delivery system and as such have considerable duties and
6 responsibility in the oversight of patient care. They cannot blindly fill prescriptions written by
7 a doctor if the prescription is not for a legitimate medical purpose.

8 183. Therefore, Defendant Pharmacies are required to ensure that prescriptions for
9 controlled substances are valid, and that they are issued for a legitimate medical purpose by
10 practitioners acting in their usual course. But by filling prescriptions of questionable or
11 suspicious origin the Defendant Pharmacies have subsequently breached that duty.

12 184. Upon information and belief and at all times relevant herein, questionable or
13 suspicious prescriptions issued by Defendant Pharmacies include: (1) prescriptions written by
14 a doctor who writes significantly more prescriptions (or in larger quantities) for controlled
15 substances compared to other practitioners in the area; (2) prescriptions which should last for a
16 month in legitimate use, but are being refilled on a shorter basis; (3) prescriptions for
17 antagonistic drugs, such as depressants and stimulants, at the same time; (4) prescriptions with
18 quantities or dosages that differ from usual medical usage; (5) prescriptions that do not comply
19 with standard abbreviations and/or contain no abbreviations; (6) photocopied prescriptions;
20 and/or (7) prescriptions containing different handwritings.

21 185. In addition to having common law duties, Defendant Pharmacies have a statutory
22 duty under state law to track and report certain information to the Nevada State Board of
23 Pharmacy. The Nevada State Board of Pharmacy has been licensing and regulating the practices
24 of pharmaceutical wholesalers in Nevada since 1967.

25 186. State law requires that statements of prior sales (“pedigrees”) must be in
26 “electronic form, if the transaction occurs on or after January 1, 2007 and also when one of two
27 things is true: (1) the selling wholesaler is not an authorized distributor for the manufacturer of
28 the drug, or (2) The selling wholesaler bought the drug from another wholesaler.

1 187. In addition, the mandatory data to be reported must include, but is not limited to
2 as follows: (a) name, address, telephone number, and Nevada license number of the wholesaler
3 making the pedigree; (b) name and title of person certifying the pedigree's accuracy;
4 (c) invoice number and date for the transaction of which the pedigree is part; (d) purchase
5 order number and date for the transaction of which the pedigree is part; (e) order number and
6 date (if one) for the transaction of which the pedigree is part; (f) the business name, address,
7 and telephone number of each preceding seller of the drug; (g) the business name, address, and
8 telephone number of the customer to whom the reporting wholesaler sold the drug; (h) the date
9 of each preceding or subsequent sale; (i) name of the drug; (j) strength of the drug; (k) size of
10 the container; and/or (l) number of containers.

11 188. Because Defendant Pharmacies handle such large volumes of controlled
12 substances, and are a last line of defense in the movement of legal pharmaceutical controlled
13 substances from legitimate channels into the illicit market, it is incumbent on these Defendants
14 to maintain effective controls to prevent diversion of controlled substances. Should Defendants
15 deviate from these checks and balances, the closed system collapses.

16 189. For instance, on August 9, 2013, the DEA issued an Order to Show Cause for
17 Defendant MASTERS PHARMACEUTICALS, LLC to consider whether to revoke its
18 distributor license for failing to monitor, report, and prevent the distribution of suspicious orders
19 under federal law. *See, Masters Pharmaceuticals, Inc.; Decision and Order*, 80 FR 55418, 55419
20 (2015). The Order *inter alia* made allegations regarding Masters suspicious distributions of
21 oxycodone to various pharmacies across the country, including 1.7 million dosage units . . . to
22 a pharmacy located in Clark County, LAM'S PHARMACY, from January 1, 2009 through
23 November 30, 2010. *Id.*

24 190. The sheer volume of prescription opioids distributed to pharmacies in Clark
25 County is excessive for the medical need of the community and facially suspicious. Some red
26 flags are so obvious that no one who engages in the legitimate distribution of controlled
27 substances can reasonably claim ignorance of them.

1 191. Over the course of a decade, Defendant Pharmacies failed to detect suspicious
2 orders of prescription opioids which Defendants knew or should have known were likely to be
3 delivered and/or diverted into Clark County.

4 192. Yet, Defendants ignored the law, paid the fines, and continued to unlawfully fill
5 suspicious orders of unusual size, orders deviating substantially from a normal pattern and/or
6 orders of unusual frequency in Clark County, and/or orders which Defendants knew or should
7 have known were likely to be delivered and/or diverted into Clark County.

8 193. Additionally, PMBs were gate keepers with the duty to prevent the flood of
9 opioids into the market. Instead of fulfilling their duties to Clark County residents, these
10 Defendants further exacerbated the flood of opioids into the market.

11 194. Pharmacy Benefit Managers (PBM) are companies that administer prescription
12 drug plans for entities that include insurers, self-insured employers, and state and federal
13 government agencies (collectively, these entities are referred to as “plan sponsors”). PBMs
14 review and pay claims; PBMs also review and decide the medications that are most effective
15 for any given therapeutic use. In effect, a PBM’s plan can determine what medications will (or
16 will not) be available, at what quantity, and how difficult it may be for a prescriber to receive
17 that medication (e.g., by requiring pre-authorization).

18 195. In essence, because PBMs choose which drugs appear on their formularies, they
19 wield significant influence over which drugs are disseminated throughout Plaintiffs’
20 communities and how those drugs are paid for.

21 196. Upon information and belief, PBM Defendants colluded with manufacturers
22 who offer financial incentives, such as rebates and administrative fees, in exchange for benefit
23 plan design, formulary placement, and drug utilization management that would result in more
24 opioids entering the marketplace. PBMs earnings were maximized when manufacturers charged
25 high list prices then paid large rebates and discounts to lower the actual price of the transaction.

26 197. In addition to rebates, PBMs negotiate the payment of administrative fees,
27 volume bonuses and other forms of consideration from manufacturers. The PBMs’ ability to
28 negotiate these incentives from drug manufacturers derives from their control of the factors
driving utilization, including formulary development and plan design.

1 198. PBMs require, and receive, incentives from Manufacturer Defendants to keep
2 certain drugs on and off formularies.

3 199. These incentives include the payment of rebates by Manufacturer Defendants to
4 PBMs based on utilization, bonuses for moving product and hitting volume targets, and the
5 payment of lucrative administrative fees to maximize PBM profits. Much of this activity is not
6 transparent to anyone, including those who in good faith hire PBMs to manage their benefits.

7 200. Upon information and belief, when PBMs were asked by their clients to
8 implement greater safeguards that limited access to opioids, PBMs refused. Instead, the PBMs
9 opted to receive lucrative rebates from drug manufacturers in exchange for making the
10 manufacturers' prescription opioids as available and accessible as possible.

11 201. By placing prescription opioids on their formularies and declining to impose
12 appropriate limits on approval for its use, the PBM Defendants facilitated the proliferation and
13 subsequent diversion of prescription opioids throughout Nevada and within Clark County, in
14 particular.

15 202. Upon information and belief, the practice of negotiating certain rebate
16 percentages, maintaining opioids on a certain tier, lowering co-pays, and preventing prior
17 authorizations was prevalent for all PBM Defendants and Manufacturer Defendants. This
18 practice was consistent nationwide: manufacturers provide financial incentives and, in return,
19 the PBM Defendants agreed to make certain prescription opioids available without prior
20 authorization and with low copayments.


21 203. PBMs' complicity in the overall deceptive scheme is knowing and purposeful.
22 Manufacturers compete for PBM formulary placement (preferred placement results in greater
23 utilization and greater profits) and pay PBMs incentives to avoid pre-authorization requirements
24 and other hurdles that would slow down flow. Upon information and belief, the defendant PBM
25 formularies include the majority of the opioids at issue in this case, often in preferred tiers,
26 without quantity limits or prior authorization requirements.

27 204. Moreover, at the same time that PBMs made it easier to obtain prescription
28 opioids, they made it more difficult to receive treatment for addiction.

D. Opioid Addiction in Nevada

205. In Nevada, the opioid epidemic is widespread, not localized to any particular city or county. In 2016, Nevada was ranked as the sixth highest state for the number of milligrams of opioids distributed per adult according to a study by the DEA. From 2009 to 2013, hospitals across the State had patients presenting to emergency rooms for heroin or opioid dependence, abuse, or poisoning. Of those visits, 71% occurred in Clark County.

Heroin or Opioid Dependence, Abuse, or Poisoning
Among Hospital Emergency Department Visitors for
Nevada Residents in 2009-2013 by Region




206. According to data from the Nevada Division of Public and Behavioral Health, the total number of opioid-related hospitalizations in Nevada nearly doubled from 2010 to 2015. In 2010, the number of opioid-related emergency room hospitalizations in Nevada totaled about 4,518 patients. By comparison, that number rose steeply to about 8,231 visits in a mere five years. Similarly, in 2010, the number of opioid-related inpatient admissions statewide totaled 3,095 hospitalizations. However, in a span of only five years, that number exponentially increased to 7,035 visits in 2015. From 2010 to 2015, over 26% of opioid-related emergency room hospitalizations in Nevada were among patients aged 55 years and older. Over 36% of opioid-related inpatient admissions in the State were among that same age group.

207. Opioid-induced hospitalizations and emergency room visits are a significant area of health expenditure. For instance in 2012, over \$40 million was billed for opioid-induced


1 hospitalizations and over \$7 million for similar emergency room visits in Southern Nevada
2 alone.

3 Opioid-Related Hospitalizations, Nevada Residents,
4 2010-2015



21 208. In addition to hospitalizations, the total number of opioid-related deaths
22 continues to mount. According to the Centers for Disease Control, nearly half of all U.S. opioid
23 overdose deaths involve a prescription opioid. In 2015, more than 15,000 people in the U.S.
24 died from overdoses involving prescription opioids.

25 209. Nevada has the fourth highest drug overdose mortality rate in the United States.
26 From 2010 to 2015, approximately 2,800 deaths in Nevada have been attributed to opioid-
27 related overdose. It is estimated that 55% of those deaths were caused by natural and semi-
28 synthetic opioids.



E. The Consequences of Defendants' Fraudulent Scheme

210. Through direct promotional marketing, in conjunction with third-party Front Groups and KOLs, Defendants accomplished exactly what they set out to do: change the institutional and public perception of the risk-benefit assessments and standard of care for treating patients with chronic pain. As a result, Nevada doctors began prescribing opioids long-term to treat chronic pain - something most would never have considered prior to Defendants' extensive marketing campaign.


211. But for the misleading information disseminated by Defendants, prescribing physicians would not, in most instances, have prescribed opioids as medically necessary or reasonably required to address chronic pain. The impact of Defendants' fraudulent marketing on doctors' prescribing and patients' use of opioids is evidenced by the increase in opioid prescribing nationally in concert with Defendants' marketing, and the consequences of opioid over-prescription - including addiction, overdose, and death.

F. Prescription Opioids Fueling Secondary Market of Illegal Drugs

212. Defendants' successful efforts in expanding the market for opioids to new patients and chronic conditions has created an abundance of drugs available for criminal use and fueled a new wave of addiction and abuse. Defendants' behavior supplies both ends of the secondary market for opioids - producing both the inventory of narcotics to sell and the addicts to buy them. It has been estimated that the majority of the opioids that are abused come, directly or indirectly, through doctors' prescriptions. Because heroin is cheaper than prescription painkillers, many prescription opioid addicts migrate to heroin. Thus, prescription drug abuse is fueling the rise of heroin usage in Nevada.

213. As a result, self-reported heroin use nearly doubled in the U.S. between 2007 and 2012, from 373,000 to 669,000 individuals and, in 2010, more than 3,000 people in the U.S.

died from heroin overdoses, also nearly double the rate in 2006; nearly 80% of those who used heroin in the past year previously abused prescription opioids.



214. While the use of opioids continues to take an enormous toll on Clark County and its residents, pharmaceutical companies reap blockbuster profits.

215. In 2014 alone, opioids generated \$11 billion in revenue for drug companies, Defendants experienced a material increase in sales, revenue, and profits from their fraudulent advertising and other unlawful and unfair conduct as described above.

216. Defendants should be held accountable for their misrepresentations and the harms caused to Clark County as well as its residents thus giving rise to this lawsuit.

FIRST CAUSE OF ACTION

(Public Nuisance Against All Defendants)

217. Plaintiff repeats and reiterates the allegations previously set forth herein.

218. This action is brought by Clark County for violations of statutory provisions concerning public nuisance under NRS 202 *et seq.* Nevada law provides that a where a controlled substance, including but not limited to opioids, is “unlawfully sold, served, stored, kept, manufactured, used or given away” constitutes a public nuisance.

219. The public nuisance created by Defendants’ actions is substantial and unreasonable. It has caused, and continues to cause, significant harm to the community. The

1 rates of opioid use resulting from Defendants' deceptive marketing efforts have caused harm to
2 the community

3 220. As a result of Defendants' conduct, Plaintiff has incurred substantial costs
4 including but not limited to law enforcement action opioid-related to drug crimes, for addiction
5 treatment, and other services necessary for the treatment of people addicted to prescription
6 opioids.

7 221. Defendants, and each of them, have contributed to, and/or assisted in creating
8 and maintaining a condition that is harmful to the health of Clark County citizens, "renders a
9 considerable number of persons insecure in life" and/or interferes with the comfortable
10 enjoyment of life in violation of Nevada law.

11 222. Defendants knew or should have known that their marketing of opioid use would
12 create a public nuisance.

13 223. Defendants' actions were, and continue to be, a substantial factor in opioids
14 becoming widely available and widely used. Defendants' actions were, and continue to be, a
15 substantial factor in prescribing physicians and prospective patients not accurately assessing
16 and weighing the risks and benefits of opioids for chronic pain. Without Defendants' actions,
17 opioid use would not have become so widespread, and the enormous public health hazard of
18 opioid overuse, abuse, and addiction that now exists would have been averted.

19 224. The health and safety of the citizens of Clark County, including those who use,
20 have used or will use opioids, as well as those affected by users of opioids, is a matter of great
21 public interest and of legitimate concern.

22 225. Defendants' conduct has affected and continues to affect a considerable number
23 of people within the physical boundaries of Clark County and is likely to continue to cause
24 significant harm to people who take opioids, their families, and the community at large.

25 226. Defendants' conduct constitutes a public nuisance and, if unabated, will continue
26 to threaten the health, safety and welfare of the County's residents, creating an atmosphere of
27 fear and addiction that tears at the residents' sense of well-being and security. Clark County has
28 a clearly ascertainable right to abate conduct that perpetuates this nuisance.

1 227. Defendants created an absolute nuisance. Defendants' actions created and
2 expanded the abuse of opioids, which are dangerously addictive, and the ensuing associated
3 plague of prescription opioid and heroin addiction. Defendants knew the dangers to public
4 health and safety that diversion of opioids would create in Clark County, however, Defendants
5 intentionally and/or unlawfully failed to maintain effective controls against diversion through
6 proper monitoring, reporting and refusal to fill suspicious orders of opioids. Defendants
7 intentionally and/or unlawfully distributed opioids without reporting or refusing to fill
8 suspicious orders or taking other measures to maintain effective controls against diversion.
9 Defendants intentionally and/or unlawfully continued to ship and failed to halt suspicious orders
10 of opioids. Such actions were inherently dangerous.

11 228. Defendants knew the prescription opioids have a high likelihood of being
12 diverted. It was foreseeable to Defendants that where Defendants distributed prescription
13 opioids without maintain effective controls against diversion, including monitoring, reporting,
14 and refusing shipment of suspicious orders, that the opioids would be diverted, and create an
15 opioid abuse nuisance in Clark County.

16 229. Defendants' actions also created a qualified nuisance. Defendants acted
17 recklessly, negligently and/or carelessly, in breach of their duties to maintain effective controls
18 against diversion, thereby creating an unreasonable risk of harm.

19 230. Defendants acted with actual malice because Defendants acted with a conscious
20 disregard for the rights and safety of other persons, and said actions have a great probability of
21 causing substantial harm.

22 231. The damages available to the Plaintiff include, inter alia, recoupment of
23 governmental costs, flowing from an "ongoing and persistent" public nuisance which the
24 government seeks to abate.

25 232. Defendants' conduct is ongoing and persistent, and the Plaintiff seeks all
26 damages flowing from Defendants' conduct. Plaintiff further seeks to abate the nuisance and
27 harm created by Defendants' conduct.

28

1 233. As a direct result of Defendants' conduct, the County has suffered actual injury
2 and damages including, but not limited to, significant expenses for police, emergency, health,
3 prosecution, corrections and other services. The County here seeks recovery for its own harm.

4 234. The County has sustained specific and special injuries because its damages
5 include, *inter alia*, health services, law enforcement expenditures, costs related to opioid
6 addiction treatment and overdose prevention, and related costs.

7 235. The County further seeks to abate the nuisance created by the Defendants'
8 unreasonable, unlawful, intentional, ongoing, continuing, and persistent interference with a
9 right common to the public.

10 236. The public nuisance created by Defendants' actions is substantial and
11 unreasonable – it has caused and continues to cause significant harm to the community, and the
12 harm inflicted outweighs any offsetting benefit. The staggering rates of prescription opioid
13 abuse and heroin use resulting from Defendants' abdication of their gate-keeping duties has
14 caused harm to the entire community that includes, but is not limited to:

- 15 a. The high rates of use have led to unnecessary opioid abuse, addiction, overdose,
16 injuries, and deaths.
- 17 b. Nor have children escaped the opioid epidemic unscathed. Easy access to
18 prescription opioids has made opioids a recreational drug of choice among
19 teenagers; opioid use among teenagers is only outpaced by marijuana use. Even
20 infants have been born addicted to opioids due to prenatal exposure, causing
21 severe withdrawal symptoms and lasting developmental impacts.
- 22 c. Even those County residents who have never taken opioids have suffered from
23 the public nuisance arising from Defendants' abdication of their gate-keeper
24 duties. Many have endured both the emotional and financial costs of caring for
25 loved ones addicted to or injured by opioids, and the loss of companionship,
26 wages, or other support from family members who have used, abused, become
27 addicted to, overdosed on, or been killed by opioids.
- 28 d. The opioid epidemic has increased health care costs.
- e. Employers have lost the value of productive and healthy employees.

- 1 f. Defendants' failure to maintain effective controls against diversion of
2 dangerously addictive prescription opioids for non-medical use and abuses has
3 created an abundance of drugs available for criminal use and fueled a new wave
4 of addiction, abuse, and injury.
- 5 g. Defendants' dereliction of duties resulted in a diverted supply of narcotics to
6 sell, and the ensuing demand of addicts to buy them. Increased supply, due to
7 Defendants' conduct, led to more addiction, with many addicts turning from
8 prescription opioids to heroin. People addicted to opioids frequently require
9 increasing levels of opioids, and many turned to heroin as a foreseeable result.
- 10 h. The diversion of opioids into the secondary, criminal market and the increase in
11 the number of individuals who abuse or are addicted to opioids has increased the
12 demands on health care services and law enforcement in the County.
- 13 i. The significant unreasonable interference with the public rights caused by
14 Defendants' conduct has taxed the human, medical, public health, law
15 enforcement, and financial resources of Clark County.
- 16 j. Defendants' interference with the comfortable enjoyment of life in Clark County
17 is unreasonable because there is little social utility to opioid diversion and abuse,
18 and any potential value is outweighed by the gravity of the harm inflicted by
19 Defendants' actions.

20 237. Plaintiff seeks all legal and equitable relief as allowed by law, including *inter*
21 *alia* abatement, compensatory damages, and punitive damages from the Defendant Wholesale
22 Distributors for the creation of a public nuisance, attorney fees and costs, and pre- and post-
23 judgment interest.

24 238. The continued tortious conduct by the Defendants causes a repeated or
25 continuous injury. The damages have not occurred all at once but have increased as time
26 progresses. The tort is not completed nor have all the damages been incurred until the
27 wrongdoing ceases. The wrongdoing has not ceased. The public nuisance remains unabated.

1 250. The public nuisance created, perpetuated, and maintained by Defendants can be
2 abated and further reoccurrence of such harm and inconvenience can be prevented.

3 251. Defendants' conduct has affected and continues to affect a considerable number
4 of people within the State is likely to continue to cause significant harm to chronic pain patients
5 who take opioids, their families, and the community at large.

6 252. That at all times hereinafter mentioned, upon information and belief, the above-
7 described culpable conduct by Defendants was a proximate cause of injuries sustained by
8 Plaintiff.

9 253. That as a result of the aforesaid occurrence, Plaintiff has suffered extensive
10 monetary and pecuniary losses and other compensatory damages were also incurred and paid,
11 including necessary medical, hospital, and concomitant expenses.

12 254. Defendants' conduct constitutes a public nuisance and, if unabated, will continue
13 to threaten the health, safety and welfare of the County's residents, creating an atmosphere of
14 fear and addiction that tears at the residents' sense of well-being and security. The County has
15 a clearly ascertainable right to abate conduct that perpetuates this nuisance.

16 255. Defendants created an absolute nuisance. Defendants' actions created and
17 expanded the abuse of opioids, which are dangerously addictive, and the ensuing associated
18 plague of prescription opioid and heroin addiction. Defendants knew the dangers to public
19 health and safety that diversion of opioids would create in Clark County, however, Defendants
20 intentionally and/or unlawfully failed to maintain effective controls against diversion through
21 proper monitoring, reporting and refusal to fill suspicious orders of opioids. Defendants
22 intentionally and/or unlawfully distributed opioids without reporting or refusing to fill
23 suspicious orders or taking other measures to maintain effective controls against diversion.
24 Defendants intentionally and/or unlawfully continued to ship and failed to halt suspicious orders
25 of opioids. Such actions were inherently dangerous.

26 256. Defendants knew the prescription opioids have a high likelihood of being
27 diverted. It was foreseeable to Defendants that where Defendants distributed prescription
28 opioids without maintain effective controls against diversion, including monitoring, reporting,

1 and refusing shipment of suspicious orders, that the opioids would be diverted, and create an
2 opioid abuse nuisance in Clark County.

3 257. Defendants' actions also created a qualified nuisance. Defendants acted
4 recklessly, negligently and/or carelessly, in breach of their duties to maintain effective controls
5 against diversion, thereby creating an unreasonable risk of harm.

6 258. Defendants acted with actual malice because Defendants acted with a conscious
7 disregard for the rights and safety of other persons, and said actions have a great probability of
8 causing substantial harm.

9 259. The damages available to the Plaintiff include, *inter alia*, recoupment of
10 governmental costs, flowing from an "ongoing and persistent" public nuisance which the
11 government seeks to abate. Defendants' conduct is ongoing and persistent, and the Plaintiff
12 seeks all damages flowing from Defendants' conduct. Plaintiff further seeks to abate the
13 nuisance and harm created by Defendants' conduct.

14 260. As a direct result of Defendants' conduct, the County has suffered actual injury
15 and damages including, but not limited to, significant expenses for police, emergency, health,
16 prosecution, corrections and other services. The County here seeks recovery for its own harm.

17 261. The County has sustained specific and special injuries because its damages
18 include, *inter alia*, health services, law enforcement expenditures, costs related to opioid
19 addiction treatment and overdose prevention, and related costs.

20 262. The County further seeks to abate the nuisance created by the Defendants'
21 unreasonable, unlawful, intentional, ongoing, continuing, and persistent interference with a
22 right common to the public.

23 263. The public nuisance created by Defendants' actions is substantial and
24 unreasonable – it has caused and continues to cause significant harm to the community, and the
25 harm inflicted outweighs any offsetting benefit. The staggering rates of prescription opioid
26 abuse and heroin use resulting from Defendants' abdication of their gate-keeping duties has
27 caused harm to the entire community that includes, but is not limited to:

- 28 a. The high rates of use have led to unnecessary opioid abuse, addiction, overdose,
injuries, and deaths.

- b. Nor have children escaped the opioid epidemic unscathed. Easy access to prescription opioids has made opioids a recreational drug of choice among Clark County teenagers; opioid use among teenagers is only outpaced by marijuana use. Even infants have been born addicted to opioids due to prenatal exposure, causing severe withdrawal symptoms and lasting developmental impacts.
- c. Even those County residents who have never taken opioids have suffered from the public nuisance arising from Defendants' abdication of their gate-keeper duties. Many have endured both the emotional and financial costs of caring for loved ones addicted to or injured by opioids, and the loss of companionship, wages, or other support from family members who have used, abused, become addicted to, overdosed on, or been killed by opioids.
- d. The opioid epidemic has increased health care costs.
- e. Employers have lost the value of productive and healthy employees.
- f. Defendants' failure to maintain effective controls against diversion of dangerously ^[1]~~SEP~~ addictive prescription opioids for non-medical use and abuses has created an abundance of drugs available for criminal use and fueled a new wave of addiction, abuse, and injury.
- g. Defendants' dereliction of duties resulted in a diverted supply of narcotics to sell, and the ensuing demand of addicts to buy them. Increased supply, due to Defendants' conduct, led to more addiction, with many addicts turning from prescription opioids to heroin. People addicted to opioids frequently require increasing levels of opioids, and many turned to heroin as a foreseeable result.
- h. The diversion of opioids into the secondary, criminal market and the increase in the number of individuals who abuse or are addicted to opioids has increased the demands on health care services and law enforcement in the County.
- i. The significant unreasonable interference with the public rights caused by Defendants' conduct has taxed the human, medical, public health, law enforcement, and financial resources of Clark County.

1 j. Defendants' interference with the comfortable enjoyment of life in Clark County
2 is unreasonable because there is little social utility to opioid diversion and abuse,
3 and any potential value is outweighed by the gravity of the harm inflicted by
4 Defendants' actions.

5 264. Plaintiff seeks all legal and equitable relief as allowed by law, including *inter*
6 *alia* abatement, compensatory damages, and punitive damages from the Defendant Wholesale
7 Distributors for the creation of a public nuisance, attorney fees and costs, and pre- and post-
8 judgment interest.

9 265. The continued tortious conduct by the Defendants causes a repeated or
10 continuous injury. The damages have not occurred all at once but have increased as time
11 progresses. The tort is not completed nor have all the damages been incurred until the
12 wrongdoing ceases. The wrongdoing has not ceased. The public nuisance remains unabated.

13 266. Therefore, Plaintiff's claims are subject to equitable tolling, stemming from
14 Defendants' wrongful concealment and from Plaintiff's inability to obtain vital information
15 underlying its claims.

16 267. That Plaintiff has been required to prosecute this action and is entitled to
17 attorneys' fees and costs as provided by Nevada statute.

18 268. That Plaintiff's general, special and punitive damages are in amounts in excess
19 of \$15,000.00.

20 **THIRD CAUSE OF ACTION**

21 *(Negligent Misrepresentation against all Defendants)*

22 269. Plaintiff repeats and reiterates the allegations previously set forth herein.

23 270. Defendants had a duty to exercise reasonable care in the marketing of opioids.

24 271. Defendants were aware of the potentially dangerous situation involving opioids.

25 272. Defendants marketed opioids in an improper manner by:

- 26 a. overstating the benefits of chronic opioid therapy, promising improvement in
27 patients' function and quality of life, and failing to disclose the lack of evidence
28 supporting long-term use;

- b. trivializing or obscuring opioids' serious risks and adverse outcomes, including the risk of addiction, overdose, and death;
- c. overstating opioids' superiority compared with other treatments, such as other non-opioid analgesics, physical therapy, and other alternatives;
- d. mischaracterizing the difficulty of withdrawal from opioids and the prevalence of withdrawal symptoms; and
- e. marketing opioids for indications and benefits that were outside of the opioids' labels and not supported by substantial evidence.

273. It was Defendants' marketing — and not any medical breakthrough— that rationalized prescribing opioids for chronic pain and opened the floodgates of opioid use and abuse. The result has been catastrophic.

274. Defendants disseminated many of their false, misleading, imbalanced, and unsupported statements indirectly, through KOLs and Front Groups, and in unbranded marketing materials. These KOLs and Front Groups were important elements of Defendants' marketing plans, which specifically contemplated their use, because they seemed independent and therefore outside FDA oversight. Through unbranded materials, Defendants, with their own knowledge of the risks, benefits and advantages of opioids, presented information and instructions concerning opioids generally that were contrary to, or at best, inconsistent with information and instructions listed on Defendants' branded marketing materials and drug labels. Defendants did so knowing that unbranded materials typically are not submitted to or reviewed by the FDA.

275. Defendants also marketed opioids through the following vehicles: (a) KOLs, who could be counted upon to write favorable journal articles and deliver supportive CMEs; (b) a body of biased and unsupported scientific literature; (c) treatment guidelines; (d) CMEs; (e) unbranded patient education materials; and (f) Front Group patient-advocacy and professional organizations, which exercised their influence both directly and through Defendant-controlled KOLs who served in leadership roles in those organizations.

276. Defendants knew or should have known that opioids were unreasonably dangerous and could cause addiction.

277. Defendants' marketing was a factor in physicians, patients, and others to prescribe or purchase opioids.

278. As a direct and proximate result of Defendants' negligence, Plaintiff has suffered and continues to suffer injury, including but not limited to incurring excessive costs related to diagnosis, treatment, and cure of addiction to opioids, bearing the massive costs of these illnesses and conditions by having to provide necessary resources for care, treatment facilities, and law enforcement services for its residents and using County resources in relation to opioid use and abuse.

279. However, Defendants continued to design manufacture, market, distribute and sell opioids so as to maximize sales and profits at the expense of the health and safety of the public, in conscious disregard of the foreseeable harm caused by the opioid drug.

280. Defendants' conduct exhibits such an entire want of care as to establish that their actions were a result of fraud, ill will, recklessness, or willful and intentional disregard of Plaintiff's rights, and, therefore, Plaintiff is entitled to punitive damages.

281. The continued tortious conduct by the Defendants causes a repeated or continuous injury. The damages have not occurred all at once but have increased as time progresses. The tort is not completed nor have all the damages been incurred until the wrongdoing ceases. The wrongdoing has not ceased. The public nuisance remains unabated.

282. Therefore, Plaintiff's claims are subject to equitable tolling, stemming from Defendants' wrongful concealment and from Plaintiff's inability to obtain vital information underlying its claims.

283. That Plaintiff has been required to prosecute this action and is entitled to attorneys' fees and costs as provided by Nevada statute.

284. That Plaintiff's general, special and punitive damages are in amounts in excess of \$15,000.00.

FOURTH CAUSE OF ACTION

(Negligence against Defendant Distributors, Defendant Pharmacies, & Defendant Providers)

285. Plaintiff incorporates the allegations within all prior paragraphs within this Complaint as if they were fully set forth herein.

1 286. Defendant Distributors and Pharmacies owed a non-delegable duty to exercise
2 reasonable care in the distribution and/or sale of opioids.

3 287. Defendants Distributors and Pharmacies further owe a non-delegable duty to
4 Plaintiff to conform their behavior to the legal standard of reasonable conduct under the
5 circumstances, in the light of the apparent risks.

6 288. Defendant Distributors and Pharmacies breached this duty by failing to take any
7 action to prevent or reduce the distribution of the opioids.

8 289. Defendant Providers owed a duty to exercise reasonable care in the prescription
9 of opioids.

10 290. Defendant Providers further owe a duty to Plaintiff to conform their behavior to
11 the legal standard of reasonable conduct under the circumstances, in light of the apparent risks,
12 and in light of Defendant Providers' knowledge as it relates to the inherent dangers in the use
13 of opioids.

14 291. Defendant Providers breached this duty by, not only failing to recognize the risk
15 of writing increased numbers of prescriptions for opioids, but by actively disregarding the
16 dangers associated with opioid use, particularly for off-label purposes and in dosages far
17 exceeding those recommended.

18 292. Defendant Providers further breached their duty by providing false information
19 to health insurance providers in order to obtain authorization and coverage for the opioid
20 prescriptions.

21 293. As a proximate result, Defendant Distributors and Pharmacies, as well as
22 Defendant Providers, and their agents have caused Plaintiff to incur significant damages,
23 including but not limited to costs related to diagnosis, treatment, and cure of addiction or risk
24 of addiction to opioids. Clark County has borne the massive costs of these illnesses and
25 conditions by having to provide necessary medical care, facilities, and services for treatment of
26 County residents.

27 294. Defendant Distributors and Pharmacies and Defendant Providers were negligent
28 in failing to monitor and guard against third-party misconduct and participated and enabled such
misconduct.

1 295. Defendant Distributors and Pharmacies were negligent in disclosing to Plaintiff
2 suspicious orders for opioids.

3 296. Defendant Providers were negligent in writing improper prescriptions for
4 opioids.

5 297. Defendant Distributors and Pharmacies' and Defendant Providers' acts and
6 omissions imposed an unreasonable risk of harm to others separately and/or combined with
7 other Defendants.

8 298. A negligent violation of this trust poses distinctive and significant dangers to the
9 County and its residents from the diversion of opioids for non-legitimate medical purposes and
10 addiction to the same by consumers.

11 299. Defendant Distributors and Pharmacies and Defendant Providers were negligent
12 in not acquiring and utilizing special knowledge and special skills that relate to the dangerous
13 activity in order to prevent and/or ameliorate such distinctive and significant dangers.

14 300. Defendant Distributors and Pharmacies are required to exercise a high degree of
15 care and diligence to prevent injury to the public from the diversion of opioids during
16 distribution.

17 301. Defendant Providers are required to exercise a high degree of care to prescribe
18 appropriate medications in appropriate dosages to avoid harm to patients and their communities.

19 302. Defendant Distributors and Pharmacies breached their duty to exercise the
20 degree of care, prudence, watchfulness, and vigilance commensurate to the dangers involved in
21 the transaction of its business.

22 303. Defendant Providers breached their duty to exercise the degree of care required
23 to protect their patients and their communities.

24 304. Defendant Distributors and Pharmacies are in exclusive control of the
25 distribution management of opioids that it distributed and/or sold in Clark County.

26 305. Defendant Providers were active in providing patients within Clark County with
27 the prescriptions for opioids that were supplied by the Defendant Distributors and Pharmacies
28

3 317. Defendants have been unjustly enriched by their negligent, malicious,
4 oppressive, illegal and unethical acts, omissions, and wrongdoing.

5 318. It would be inequitable to allow Defendants to retain benefit or financial
6 advantage.

7 319. Plaintiff demands judgment against each Defendant for restitution,
8 disgorgement, and any other relief allowed in law or equity.

320. Plaintiff is without fault and the injuries to the County and its residents would not have occurred in the ordinary course of events had Defendants used due care commensurate to the dangers involved in the distribution of opioids.

321. The continued tortious conduct by the Defendants causes a repeated or continuous injury. The damages have not occurred all at once but have increased as time progresses. The tort is not completed nor have all the damages been incurred until the wrongdoing ceases. The wrongdoing has not ceased. The public nuisance remains unabated.

322. Therefore, Plaintiff's claims are subject to equitable tolling, stemming from Defendants' wrongful concealment and from Plaintiff's inability to obtain vital information underlying its claims.

323. That Plaintiff has been required to prosecute this action and is entitled to attorneys' fees and costs as provided by Nevada statute.

21 324. That Plaintiff's general, special and punitive damages are in amounts in excess
22 of \$15,000.00.

SIXTH CAUSE OF ACTION

(Violation of the Nevada Racketeering Act against Defendants Purdue and the Sackler Defendants, Endo, Par Pharmaceutical, Mallinckrodt, SpecGx, Actavis, Teva, McKesson, Cardinal, Amerisourcebergen, and Express Scripts)

325. Clark County, both as a “person” who has sustained injury brings this claim for civil remedies under the Racketeering Act, NRS §§ 207.350 to 207.520, against the following Defendants, as defined above: Purdue and the Sackler Defendants, Endo, Par Pharmaceutical,

1 Mallinckrodt, SpecGX, Actavis, Teva, McKesson, Cardinal, AmerisourceBergen, and Express
2 Scripts (collectively, for purposes of this Count, the “Racketeering Defendants”).

3 326. The Racketeering Defendants conducted and continue to conduct their business
4 through legitimate and illegitimate means in the form of a criminal syndicate or enterprise as
5 defined by NRS §§ 207.370 and 207.380. At all relevant times, the Racketeering Defendants
6 were “persons” under NRS § 0.039 and are included in the definition stating that a person is
7 “any form of business or social organization...including, but not limited to, a corporation,
8 partnership, association, trust or unincorporated organization.”

9 327. Section 207.400 of the Racketeering Act makes it unlawful “for a
10 person....employed by or associated with any enterprise to conduct or participate, directly or
11 indirectly, in: (1) The affairs of the enterprise through racketeering activity; or (2) Racketeering
12 activity through the affairs of the enterprise.” NRS § 207.400(1)(c).

13 328. The term “enterprise” is defined as including a “sole proprietorship, partnership,
14 corporation, business trust or other legal entity” as well as a “union, association or other group
15 of persons associated in fact although not a legal entity.” The definition includes “illicit as well
16 as licit enterprises and governmental as well as other entities.” NRS § 207.380.

17 329. For over a decade, the Racketeering Defendants aggressively sought to bolster
18 their revenue, increase profit, and grow their share of the prescription painkiller market by
19 unlawfully and surreptitiously increasing the volume of opioids they sold. However, the
20 Racketeering Defendants are not permitted to engage in a limitless expansion of their market
21 through the unlawful sales of regulated painkillers. As “registrants,” the Racketeering
22 Defendants operated and continue to operate within the nationwide “closed-system” created
23 under the Controlled Substances Act, 21 USC § 821, *et seq.* (the “CSA”) and the Nevada
24 Controlled Substances Act, §§ 453.005 to 453.730. Together, the CSA and Nevada Controlled
25 Substances Act restrict the Racketeering Defendants’ ability to manufacture or distribute
26 Schedule II substances like opioids nationally and in Nevada by requiring them to: (1) register
27 to manufacture or distribute opioids; (2) maintain effective controls against diversion of the
28 controlled substances that they manufacturer or distribute; (3) design and operate a system to
identify suspicious orders of controlled substances, halt such unlawful sales, and report them

1 to the DEA, the Nevada Pharmacy Board, and the FDA; and (4) make sales within a limited
2 quota set by the DEA for the overall production of Schedule II substances like opioids.

3 330. The nationwide closed-system, including the establishment of quotas, was
4 specifically intended to reduce or eliminate the diversion of Schedule II substances like opioids
5 from “legitimate channels of trade” to the illicit market by controlling the quantities of the basic
6 ingredients needed for the manufacture of [controlled substances].”⁴

7 331. Finding it impossible to legally achieve their ever increasing sales ambitions,
8 members of the Opioid Diversion Enterprise (as defined below) systematically and fraudulently
9 violated their duty under Nevada law to maintain effective controls against diversion of their
10 drugs, to design and operate a system to identify suspicious orders of their drugs, to halt
11 unlawful sales of suspicious orders, and to notify the DEA, the Nevada Board of Pharmacy,
12 and the FDA of suspicious orders.⁵ As discussed in detail below, through the Racketeering
13 Defendants’ scheme, members of the Opioid Diversion Enterprise repeatedly engaged in
14 unlawful sales of painkillers which, in turn, artificially and illegally increased the annual
15 production quotas throughout the United States for opioids allowed by the DEA.²⁸² In doing
16 so, the Racketeering Defendants allowed hundreds of millions of pills to enter the illicit market
17 which allowed them to generate obscene profits.

18 332. Defendants’ illegal scheme was hatched by an association-in-fact enterprise
19 between the Manufacturer Defendants and the Distributor Defendants, and executed in perfect
20 harmony by each of them. In particular, each of the Racketeering Defendants were associated
21 with, and conducted or participated in, the affairs of the racketeering enterprise (defined below
22 and referred to collectively as the “Opioid Diversion Enterprise”), whose purpose was to engage
23 in the unlawful sales of opioids, and to deceive the public, and federal and state regulators into
24 believing that the Racketeering Defendants were faithfully fulfilling their statutory obligations.
25 The Racketeering Defendants’ scheme allowed them to make billions in unlawful sales of
26 opioids and, in turn, increase and/or maintain high production quotas with the purpose of
27

28 ⁴ 1970 U.S.C.C.A.N. 4566 at 5490; *see also* Testimony of Joseph T. Rannazzisi before the Caucus on International
Narcotics Control, United States Senate, May 5, 2015 (available at
https://www.drugcaucus.senate.gov/sites/default/files/Rannazzisi%20Testimony_0.pdf).

⁵ 21 USC § 823(a)(1), (b)(1); 21 CFR § 1301.74(b)-(c).

1 ensuring unlawfully increasing revenues, profits, and market share. As a direct result of the
 2 Racketeering Defendants' deceptive scheme, course of conduct, and pattern of racketeering
 3 activity, they were able to extract billions of dollars of revenue from the addicted American
 4 public, while entities like Clark County, Nevada experienced tens of millions of dollars of injury
 5 caused by the reasonably foreseeable consequences of the prescription opioid addiction
 6 epidemic. As explained in detail below, the Racketeering Defendants' misconduct violated §
 7 207.400 of the Racketeering Act and Plaintiff is entitled to treble damages for its injuries under
 8 NRS § 207.410.

9 333. Alternatively, the Racketeering Defendants were members of a legal entity
 10 enterprise within the meaning of NRS § 207.380 through which the Racketeering
 11 Defendants conducted their pattern of racketeering activity in Nevada and throughout the
 12 United States. Specifically, the Healthcare Distribution Alliance (the "HDA")⁶ is a distinct legal
 13 entity that satisfies the definition of a racketeering enterprise. The HDA is a non-profit
 14 corporation formed under the laws of the District of Columbia and doing business in Virginia.
 15 As a non-profit corporation, HDA qualifies as an "enterprise" within the definition set out in §
 16 207.380 because it is a corporation and a legal entity.

17 334. On information and belief, each of the Racketeering Defendants is a member,
 18 participant, and/or sponsor of the HDA and utilized the HDA to conduct the Opioid Diversion
 19 Enterprise and to engage in the pattern of racketeering activity that gives rise to the Count.

20 335. Each of the Racketeering Defendants is a legal entity separate and distinct from
 21 the HDA. And, the HDA serves the interests of distributors and manufacturers beyond the
 22 Racketeering Defendants. Therefore, the HDA exists separately from the Opioid Diversion
 23 Enterprise, and each of the Racketeering Defendants exists separately from the HDA.
 24 Therefore, the HDA may serve as a racketeering enterprise.

25 336. The legal and association-in-fact enterprises alleged in the previous and
 26 subsequent paragraphs were each used by the Racketeering Defendants to conduct the Opioid
 27 Diversion Enterprise by engaging in a pattern of racketeering activity. Therefore, the legal and
 28

⁶ Health Distribution Alliance, History, Health Distribution Alliance, (last accessed on September 15, 2017),
<https://www.healthcaredistribution.org/about/hda-history>.

1 association- in-fact enterprises alleged in the previous and subsequent paragraphs are pleaded
2 in the alternative and are collectively referred to as the “Opioid Diversion Enterprise.”

3 **A. THE OPIOID DIVERSION ENTERPRISE**

4 337. Throughout the United States—and within the Clark County, Nevada—the
5 Racketeering Defendants have operated at all relevant times under a “closed distribution
6 system” of quotas that governs the production and distribution of prescription opioid drugs.
7 The Opioids Diversion Enterprise is an ongoing and continuing business organization that
8 created and maintained systemic links for a common purpose: To protect and maximize their
9 profitability under this quota system through the unlawful sale of opioids. The Racketeering
10 Defendants participated in the Opioids Diversion Enterprise through a pattern of racketeering
11 activity, which includes multiple violations of Nevada state criminal law.

12 338. Recognizing that there is a need for greater scrutiny over controlled substances
13 due to their potential for abuse and danger to public health and safety, the United States
14 Congress enacted the Controlled Substances Act in 1970.⁷ The CSA and its implementing
15 regulations created a closed-system of distribution for all controlled substances and listed
16 chemicals.⁸ Congress specifically designed the closed chain of distribution to prevent the
17 diversion of legally produced controlled substances into the illicit market.⁹ As reflected in
18 comments from United States Senators during deliberation on the CSA, the “[CSA] is designed
19 to crack down hard on the narcotics pusher and the illegal diverters of pep pills and goof
20 balls.”¹⁰ Congress was concerned with the diversion of drugs out of legitimate channels of
21 distribution when it enacted the CSA and acted to halt the “widespread diversion of [controlled
22 substances] out of legitimate channels into the illegal market.”¹¹ Moreover, the closed-system
23 was specifically designed to ensure that there are multiple ways of identifying and preventing
24

25 ⁷ Joseph T. Rannazzisi Decl. ¶4, *Cardinal Health, Inc. v. Eric Holder, Jr., Attorney General*,
D.D.C. Case No. 12-cv-185 (Document 14-2 February 10, 2012).

26 ⁸ See H.R. Rep. No. 91-1444, 1970 U.S.C.C.A.N. at 4566.

27 ⁹ *Gonzalez v. Raich*, 545 U.S. 1, 12-14 (2005); 21 USC § 801(20); 21 USC §§ 821-824, 827,
880; H.R. Rep. No. 91-1444, 1970 U.S.C.C.A.N. 4566, 4572 (Sept. 10, 1970).

28 ¹⁰ See H.R. Rep. No. 91-1444, 1970 U.S.C.C.A.N. at 4566; 116 Cong. Rec. 977-78 (Comments
of Sen. Dodd, Jan 23, 1970).

¹¹ See Testimony of Joseph T. Rannazzisi before the Caucus on International Narcotics Control, United State Senate,
May 5, 2015 (available at https://www.drugcaucus.senate.gov/sites/default/files/Rannazzisi%20Testimony_0.pdf).

diversion through active participation by registrants within the drug delivery chain.¹² All registrants – manufacturers and distributors alike – must adhere to the specific security, recordkeeping, monitoring and reporting requirements that are designed to identify or prevent diversion.¹³ When registrants at any level fail to fulfill their obligations, the necessary checks and balances collapse.¹⁴ The result is the scourge of addiction that has occurred.

339. Central to the closed-system created by the CSA was the directive that the DEA determine quotas of each basic class of Schedule I and II controlled substances each year. The quota system was intended to reduce or eliminate diversion from “legitimate channels of trade” by controlling the “quantities of the basic ingredients needed for the manufacture of [controlled substances], and the requirement of order forms for all transfers of these drugs.”¹⁵ When evaluating production quotas, the DEA was instructed to consider the following information:

- a. Information provided by the United States Department of Health and Human Services;
- b. Total net disposal of the basic class by all manufacturers;
- c. Trends in the national rate of disposal of the basic class;
- d. An applicant’s production cycle and current inventory position;
- e. Total actual or estimated inventories of the class and of all substances manufactured from the class and trends in inventory accumulation; and
- f. Other factors such as: changes in the currently accepted medical use of substances manufactured for a basic class; the economic and physical

¹² See Statement of Joseph T. Rannazzisi before the Caucus on International Narcotics Control United States Senate, July 18, 2012 (available at <https://www.justice.gov/sites/default/files/testimonies/witnesses/attachments/07/18/12/07-18-12-dea-rannazzisi.pdf>).

¹³ *Id.*; 16.19.8.13(F) NMAC (requiring anyone licensed to distribute Schedule II controlled substances in Nevada to “report any theft, suspected theft, diversion or other significant loss of any prescription drug or device to the board and where applicable, to the DEA.”); 16.19.20.48(A) NMSA (“All applicants and registrants shall provide effective controls and procedures to guard against theft and diversion of controlled substances.”).

¹⁴ Joseph T. Rannazzisi Decl. ¶ 10, *Cardinal Health, Inc. v. Eric Holder, Jr., Attorney General*, Case No. 12-cv-185 (Document 14-2 February 10, 2012).

¹⁵ 1970 U.S.C.C.A.N. 4566 at 5490; *see also* Testimony of Joseph T. Rannazzisi before the Caucus on International Narcotics Control, United States Senate, May 5, 2015 (available at https://www.drugcaucus.senate.gov/sites/default/files/Rannazzisi%20Testimony_0.pdf).

1 availability of raw materials; yield and sustainability issues; potential
2 disruptions to production; and unforeseen emergencies.¹⁶

3 340. Under the CSA, as incorporated into Nevada law, it is unlawful for a registrant to
4 manufacture a controlled substance in Schedule II, like prescription opioids, that is (1) not
5 expressly authorized by its registration and by a quota assigned to it by DEA, or (2) in excess
6 of a quota assigned to it by the DEA.¹⁷

7 341. At all relevant times, the Racketeering Defendants operated as an enterprise
8 formed for the purpose of unlawfully increasing sales, revenues and profits by disregarding
9 their duty under Nevada law to identify, investigate, halt or report suspicious orders of opioids
10 and diversion of their drugs into the illicit market, *see generally* IV.E.1 *supra*, in order to
11 unlawfully increase the quotas set by the DEA and allow them to collectively benefit from the
12 unlawful formation of a greater pool of prescription opioids from which to profit. The
13 Racketeering Defendants conducted their pattern of racketeering activity in Clark County,
14 Nevada and throughout the United States through this enterprise.

15 342. The Racketeering Defendants hid from the general public and suppressed and/or
16 ignored warnings from third parties, whistleblowers and governmental entities, about the
17 reality of the suspicious orders that the Racketeering Defendants were filling on a daily basis -
18 - leading to the diversion of a tens of millions of doses of prescriptions opioids into the illicit
19 market.

20 343. The Racketeering Defendants, with knowledge and intent, agreed to the overall
21 objective of their fraudulent scheme and participated in the common course of conduct to
22 commit acts of fraud and illegal trafficking in and distribution of prescription opioids, in
23 violation of Nevada law.

24 344. Indeed, for the Defendants' fraudulent scheme to work, each of the Defendants

25
26 ¹⁶ See Testimony of Joseph T. Rannazzisi before the Caucus on International Narcotics Control, United State
27 Senate, May 5, 2015 (available at
28 https://www.drugcaucus.senate.gov/sites/default/files/Rannazzisi%20Testimony_0.pdf).

¹⁷ *Id.* (citing 21 USC 842(b)); NRS § 453.385 (regulations must ensure “compliance with, but may be more
stringent than required by, applicable federal law governing controlled substances and the rules, regulations and
orders of any federal agency administering such law.”); NRS § 453.146 (the Nevada Board of Pharmacy may
consider findings of “the federal Food and Drug Administration or the Drug Enforcement Administration as prima
facie evidence relating to one or more of the determinative factors.”).

1 had to agree to implement similar tactics regarding reports and representations about their
2 systems for controlling against diversion, and refusal to report suspicious orders.

3 345. The opioid epidemic has its origins in the mid-1990s when, between 1997 and
4 2007, nationwide per capita purchases of methadone, hydrocodone, and oxycodone increased
5 13-fold, 4-fold, and 9-fold, respectively. By 2010, enough prescription opioids were sold in the
6 United States to medicate every adult in the country with a dose of 5 milligrams of hydrocodone
7 every 4 hours for 1 month.¹⁸ On information and belief, the Opioid Diversion Enterprise has
8 been ongoing nationally and in Clark County, Nevada for at least the last decade.¹⁹

9 346. The Opioid Diversion Enterprise was and is a shockingly successful endeavor.
10 The Opioid Diversion Enterprise has been conducting business uninterrupted since its genesis.
11 But, it was not until recently that State and federal regulators finally began to unravel the extent
12 of the enterprise and the toll that it exacted on the American public and Clark County, Nevada
13 and its citizens.

14 347. At all relevant times, the Opioid Diversion Enterprise: (a) had an existence
15 separate and distinct from each Racketeering Defendant; (b) was separate and distinct from the
16 pattern of racketeering in which the Racketeering Defendants engaged; (c) was an ongoing and
17 continuing organization consisting of legal entities, including each of the Racketeering
18 Defendants; (d) characterized by interpersonal relationships among the Racketeering
19 Defendants; (e) had sufficient longevity for the enterprise to pursue its purpose; and (f)
20 functioned as a continuing unit. Each member of the Opioid Diversion Enterprise participated
21 in the conduct of the enterprise, including patterns of racketeering activity, and shared in the
22 astounding growth of profits supplied by fraudulently inflating opioid sales generated as a
23 result of the Opioid Diversion Enterprise's disregard for their duty to prevent diversion of their
24 drugs into the illicit market and then requesting the DEA increase production quotas, all so that
25 the Racketeering Defendants would have a larger pool of prescription opioids from which to
26

27 ¹⁸ Keyes KM, Cerdá M, Brady JE, Havens JR, Galea S. *Understanding the rural-urban differences in nonmedical*
28 *prescription opioid use and abuse in the United States*. Am J Public Health. 2014;104(2):e52-9.

¹⁹ Matthew Perrone, *Pro-Painkiller echo chamber shaped policy amid drug epidemic*, The Center for Public Integrity (September 19, 2017, 12:01 a.m.), <https://www.publicintegrity.org/2016/09/19/20201/pro-painkiller-echo-chamber-shaped-policy-amid-drug-epidemic>.

1 profit.

2 348. The Opioid Diversion Enterprise functioned by selling prescription opioids.
3 While there may be some legitimate uses and/or needs for prescription opioids, the
4 Racketeering Defendants, through their illegal enterprise, engaged in a pattern of racketeering
5 activity that involves a fraudulent scheme to increase revenue by violating State and Federal
6 laws requiring the maintenance of effective controls against diversion of prescription opioids,
7 and the identification, investigation, and reporting of suspicious orders of prescription opioids
8 destined for the illicit drug market. The goal of Defendants' scheme was to increase profits
9 from opioid sales. But, Defendants' profits were limited by the production quotas set by the
10 DEA, so the Defendants refused to identify, investigate and/or report suspicious orders of their
11 prescription opioids being diverted into the illicit drug market. The end result of this strategy
12 was to increase and maintain artificially high production quotas of opioids so that there was a
13 larger pool of opioids for Defendants to manufacture and distribute for public consumption.

14 349. Within the Opioid Diversion Enterprise, there were interpersonal relationships
15 and common communication by which the Racketeering Defendants shared information on a
16 regular basis. These interpersonal relationships also formed the organization of the Opioid
17 Diversion Enterprise. The Opioid Diversion Enterprise used their interpersonal relationships
18 and communication network for the purpose of conducting the enterprise through a pattern of
19 racketeering activity.

20 350. Each of the Racketeering Defendants had a systematic link to each other through
21 joint participation in lobbying groups, trade industry organizations, contractual relationships
22 and continuing coordination of activities. The Racketeering Defendants participated in the
23 operation and management of the Opioid Diversion Enterprise by directing its affairs, as
24 described herein. While the Racketeering Defendants participated in, and are members of, the
25 enterprise, they each have a separate existence from the enterprise, including distinct legal
26 statuses, different offices and roles, bank accounts, officers, directors, employees, individual
27 personhood, reporting requirements, and financial statements.

28 351. The Racketeering Defendants exerted substantial control over the Opioid

1 Diversion Enterprise by their membership in the Pain Care Forum (“PCF”), the HDA, and
2 through their contractual relationships.

3 352. PCF has been described as a coalition of drugmakers, trade groups and dozens
4 of non-profit organizations supported by industry funding. The PCF recently became a national
5 news story when it was discovered that lobbyists for members of the PCF quietly shaped federal
6 and state policies regarding the use of prescription opioids for more than a decade.

7 353. The Center for Public Integrity and The Associated Press obtained “internal
8 documents shed[ding] new light on how drugmakers and their allies shaped the national
9 response to the ongoing wave of prescription opioid abuse.”²⁰ Specifically, PCF members spent
10 over \$740 million lobbying in the nation’s capital and in all 50 statehouses on an array of issues,
11 including opioid-related measures.²¹

12 354. Not surprisingly, each of the Racketeering Defendants who stood to profit from
13 lobbying in favor of prescription opioid use is a member of and/or participant in the PCF.²² In
14 2012, membership and participating organizations included the HDA (of which all
15 Racketeering Defendants are members), Purdue, Actavis, and Teva.²³ Each of the Manufacturer
16 Defendants worked together through the PCF to advance the interests of the enterprise. But,
17 the Manufacturer Defendants were not alone. The Distributor Defendants actively participated,
18 and continue to participate in the PCF, at a minimum, through their trade organization, the
19 HDA.²⁴ Plaintiff is informed and believes that the Distributor Defendants participated directly
20 in the PCF as well.

21 355. The 2012 Meeting Schedule for the Pain Care Forum is particularly revealing
22 on the subject of the Defendants’ interpersonal relationships. The meeting schedule indicates
23 that meetings were held in the D.C. office of Powers Pyles Sutter & Verville on a monthly basis,
24

25 ²⁰ Matthew Perrone, *Pro-Painkiller echo chamber shaped policy amid drug epidemic*, The Center for Public
26 Integrity (September 19, 2017, 12:01 a.m.), <https://www.publicintegrity.org/2016/09/19/20201/pro-painkiller-echo-chamber-shaped-policy-amid-drug-epidemic> (emphasis added).

27 ²¹ *Id.*

28 ²² PAIN CARE FORUM 2012 Meetings Schedule, (last updated December 2011),
<https://assets.documentcloud.org/documents/3108982/PAIN-CARE-FORUM-Meetings-Schedule-amp.pdf>.

²³ *Id.* Plaintiff is informed and believes that Mallinckrodt became an active member of the PCF sometime after 2012.

²⁴ *Id.*

1 unless otherwise noted. Local members were “encouraged to attend in person” at the monthly
 2 meetings. And, the meeting schedule indicates that the quarterly and year-end meetings
 3 included a “Guest Speaker.”

4 356. The 2012 Pain Care Forum Meeting Schedule demonstrates that each of the
 5 Defendants participated in meetings on a monthly basis, either directly or through their trade
 6 organization, in a coalition of drugmakers and their allies whose sole purpose was to shape
 7 the national response to the ongoing prescription opioid epidemic, including the concerted
 8 lobbying efforts that the PCF undertook on behalf of its members.

9 357. Second, the HDA – or Healthcare Distribution Alliance – led to the formation
 10 of interpersonal relationships and an organization between the Racketeering Defendants.
 11 Although the entire HDA membership directory is private, the HDA website confirms that each
 12 of the Distributor Defendants and the Manufacturer Defendants named in the Complaint,
 13 including Actavis, Purdue, and Mallinckrodt, were members of the HDA.²⁵ The HDA and each
 14 of the Distributor Defendants eagerly sought the active membership and participation of the
 15 Manufacturer Defendants by advocating that one of the benefits of membership included the
 16 ability to develop direct relationships between Manufacturers and Distributors at high executive
 17 levels.

18 358. In fact, the HDA touted the benefits of membership to the Manufacturer
 19 Defendants, advocating that membership included the ability to, among other things, “network
 20 one on one with manufacturer executives at HDA’s members-only Business and Leadership
 21 Conference,” “networking with HDA wholesale distributor members,” “opportunities to host
 22 and sponsor HDA Board of Directors events,” “participate on HDA committees, task forces
 23 and working groups with peers and trading partners,” and “make connections.”²⁶ Clearly, the
 24 HDA and the Distributor Defendants believed that membership in the HDA was an opportunity
 25 to create interpersonal and ongoing organizational relationships between the Manufacturers and
 26 Distributors.

27
 28 ²⁵ Manufacturer Membership, Healthcare Distribution Alliance, (accessed on September 14, 2017),
<https://www.healthcaredistribution.org/about/membership/manufacturer>.

²⁶ Manufacturer Membership Benefits, Healthcare Distribution Alliance, (accessed on September 14, 2017),
<https://www.healthcaredistribution.org/~media/pdfs/membership/manufacturer-membership-benefits.ashx?la=en>.

1 359. The application for manufacturer membership in the HDA further indicates the
 2 level of connection that existed between the Racketeering Defendants.²⁷ The manufacturer
 3 membership application must be signed by a “senior company executive,” and it requests that
 4 the manufacturer applicant identify a key contact and any additional contacts from within its
 5 company. The HDA application also requests that the manufacturer identify its current
 6 distribution information and its most recent year end net sales through any HDA distributors,
 7 including but not limited to, Defendants AmerisourceBergen, Cardinal Health, and
 8 McKesson.²⁸

9 360. After becoming members, the Distributors and Manufacturers were eligible to
 10 participate on councils, committees, task forces and working groups, including:

- 11 a. Industry Relations Council: “This council, composed of distributor and
 12 manufacturer members, provides leadership on pharmaceutical distribution and
 supply chain issues.”²⁹
- 13 b. Business Technology Committee: “This committee provides guidance to HDA
 14 and its members through the development of collaborative e-commerce
 15 business solutions. The committee’s major areas of focus within pharmaceutical
 16 distribution include information systems, operational integration and the impact
 of e- commerce.” Participation in this committee includes distributors and
 17 manufacturer members.³⁰
- 18 c. Health, Beauty and Wellness Committee: “This committee conducts research,
 19 as well as creates and exchanges industry knowledge to help shape the future of
 the distribution for health, beauty and wellness/consumer products in the
 20 healthcare supply chain.” Participation in this committee includes distributors
 and manufacturer members.³¹
- 21 d. Logistics Operation Committee: “This committee initiates projects designed to
 22 help members enhance the productivity, efficiency and customer satisfaction
 23 within the healthcare supply chain. Its major areas of focus include process
 24 automation, information systems, operational integration, resource management
 and quality improvement.” Participation in this committee includes distributors

25
 26 ²⁷ Manufacturer Membership Application, Healthcare Distribution Alliance, (accessed on September 14, 2017),
[https://www.healthcaredistribution.org/~media/pdfs/membership/manufacturer-membership-](https://www.healthcaredistribution.org/~media/pdfs/membership/manufacturer-membership-application.ashx?la=en)
 27 [application.ashx?la=en](https://www.healthcaredistribution.org/~media/pdfs/membership/manufacturer-membership-application.ashx?la=en).

28 ²⁸ *Id.*

²⁹ Councils and Committees, Healthcare Distribution Alliance, (accessed on September 14, 2017),
<https://www.healthcaredistribution.org/about/councils-and-committees>.

³⁰ *Id.*

³¹ *Id.*

and manufacturer members.³²

- e. Manufacturer Government Affairs Advisory Committee: “This committee provides a forum for briefing HDA’s manufacturer members on federal and state legislative and regulatory activity affecting the pharmaceutical distribution channel. Topics discussed include such issues as prescription drug traceability, distributor licensing, FDA and DEA regulation of distribution, importation and Medicaid/Medicare reimbursement.” Participation in this committee includes manufacturer members.³³
- f. Bar Code Task Force: Participation includes Distributor, Manufacturer and Service Provider Members.³⁴
- g. eCommerce Task Force: Participation includes Distributor, Manufacturer and Service Provider Members.³⁵
- h. ASN Working Group: Participation includes Distributor, Manufacturer and Service Provider Members.³⁶
- i. Contracts and Chargebacks Working Group: “This working group explores how the contract administration process can be streamlined through process improvements or technical efficiencies. It also creates and exchanges industry knowledge of interest to contract and chargeback professionals.” Participation includes Distributor and Manufacturer Members.³⁷

361. The councils, committees, task forces and working groups provided the Manufacturer and Distributor Defendants with the opportunity to work closely together in shaping their common goals and forming the enterprise’s organization.

362. The HDA also offers a multitude of conferences, including annual business and leadership conferences. The HDA and the Distributor Defendants advertise these conferences to the Manufacturer Defendants as an opportunity to “bring together high-level executives, thought leaders and influential managers . . . to hold strategic business discussions on the most pressing industry issues.”³⁸ The conferences also gave the Manufacturer and Distributor

³² *Id.*

³³ *Id.*

³⁴ *Id.*

³⁵ *Id.*

³⁶ *Id.*

³⁷ *Id.*

³⁸ Business and Leadership Conference – Information for Manufacturers, Healthcare Distribution Alliance, (accessed on September 14, 2017), <https://www.healthcaredistribution.org/events/2015-business-and-leadership-conference/blc-for-manufacturers>.

1 Defendants “unmatched opportunities to network with [their] peers and trading partners at all
 2 levels of the healthcare distribution industry.”³⁹ The HDA and its conferences were significant
 3 opportunities for the Manufacturer and Distributor Defendants to interact at a high-level of
 4 leadership. And, it is clear that the Manufacturer Defendants embraced this opportunity by
 5 attending and sponsoring these events.⁴⁰

6 363. Third, the Racketeering Defendants maintained their interpersonal relationships
 7 by working together and exchanging information and driving the unlawful sales of their opioids
 8 through their contractual relationships, including chargebacks and vault security programs.

9 364. The Manufacturer Defendants engaged in an industry-wide practice of paying
 10 rebates and/or chargebacks to the Distributor Defendants for sales of prescription opioids.⁴¹ As
 11 reported in the Washington Post, identified by Senator McCaskill, and acknowledged by the
 12 HDA, there is an industry-wide practice whereby the Manufacturers paid the Distributors
 13 rebates and/or chargebacks on their prescription opioid sales.⁴² On information and belief, these
 14 contracts were negotiated at the highest levels, demonstrating ongoing relationships between
 15 the Manufacturer and Distributor Defendants. In return for the rebates and chargebacks, the
 16 Distributor Defendants provided the Manufacturer Defendants with detailed information
 17 regarding their prescription opioid sales, including purchase orders, acknowledgements, ship
 18 notices, and invoices.⁴³ The Manufacturer Defendants used this information to gather high-
 19 level data regarding overall distribution and direct the Distributor Defendants on how to most
 20 effectively sell the prescription opioids.

21 365. The contractual relationships among the Racketeering Defendants also include

22 ³⁹ *Id.*

23 ⁴⁰ 2015 Distribution Management Conference and Expo, Healthcare Distribution Alliance, (accessed on September
 24 14, 2017), <https://www.healthcaredistribution.org/events/2015-distribution-management-conference>.

25 ⁴¹ Lenny Bernstein & Scott Higham, *The government's struggle to hold opioid manufacturers accountable*, The
 26 Washington Post, (April 2, 2017), [https://www.washingtonpost.com/graphics/investigations/dea-](https://www.washingtonpost.com/graphics/investigations/dea-mallinckrodt/?utm_term=.b24cc81cc356)
 27 [mallinckrodt/?utm_term=.b24cc81cc356](https://www.washingtonpost.com/graphics/investigations/dea-mallinckrodt/?utm_term=.b24cc81cc356); *see also*, Letter from Sen. Claire McCaskill, (July 27, 2017),
 28 [https://www.mccaskill.senate.gov/imo/media/image/july-opioid-investigation-letter-](https://www.mccaskill.senate.gov/imo/media/image/july-opioid-investigation-letter-manufacturers.png)
[manufacturers.png](https://www.mccaskill.senate.gov/imo/media/image/july-opioid-investigation-letter-manufacturers.png); Letter from Sen. Claire McCaskill, (July 27, 2017), [https://www.mccaskill.senate.gov/imo/media/image/july-opioid-](https://www.mccaskill.senate.gov/imo/media/image/july-opioid-investigation-letter-manufacturers.png)
[investigation-letter-manufacturers.png](https://www.mccaskill.senate.gov/imo/media/image/july-opioid-investigation-letter-manufacturers.png); Letters From Sen. Claire McCaskill, (March 28, 2017),
<https://www.mccaskill.senate.gov/opioid-investigation>; Purdue Managed Markets, Purdue Pharma, (accessed on
 September 14, 2017), [http://www.purduepharma.com/payers/managed-](http://www.purduepharma.com/payers/managed-markets/)
[markets/](http://www.purduepharma.com/payers/managed-markets/).

⁴² *Id.*

⁴³ Webinars, Healthcare Distribution Alliance, (accessed on September 14, 2017),
<https://www.healthcaredistribution.org/resources/webinar-leveraging-edi>.

1 vault security programs. The Racketeering Defendants are required to maintain certain
 2 security protocols and storage facilities for the manufacture and distribution of their opiates.
 3 Plaintiff is informed and believes that manufacturers negotiated agreements whereby the
 4 Manufacturers installed security vaults for Distributors in exchange for agreements to maintain
 5 minimum sales performance thresholds. Plaintiff is informed and believes that these
 6 agreements were used by the Racketeering Defendants as a tool to violate their reporting and
 7 diversion duties under Nevada law,⁴⁴ in order to reach the required sales requirements.

8 366. Taken together, the interaction and length of the relationships between and
 9 among the Manufacturer and Distributor Defendants reflects a deep level of interaction and
 10 cooperation between two groups in a tightly knit industry. The Manufacturer and Distributor
 11 Defendants were not two separate groups operating in isolation or two groups forced to work
 12 together in a closed system. The Racketeering Defendants operated together as a united entity,
 13 working together on multiple fronts, to engage in the unlawful sale of prescription opioids. The
 14 HDA and the Pain Care Forum are but two examples of the overlapping relationships and
 15 concerted joint efforts to accomplish common goals and demonstrate that the leaders of each
 16 of the Racketeering Defendants were in communication and cooperation.

17 367. According to articles published by the Center for Public Integrity and The
 18 Associated Press, the Pain Care Forum – whose members include the Manufacturers and the
 19 Distributors’ trade association – has been lobbying on behalf of the Manufacturers and
 20 Distributors for “more than a decade.”⁴⁵ From 2006 to 2016 the Distributors and
 21 Manufacturers worked together through the Pain Care Forum to spend over \$740 million
 22 lobbying in the nation’s capital and in all 50 statehouses on issues including opioid-related
 23 measures.⁴⁶ Similarly, the HDA has continued its work on behalf of Distributors and
 24 Manufacturers, without interruption, since at least 2000, if not longer.⁴⁷

25
 26 ⁴⁴ See, e.g., NRS § 453.231(a).

27 ⁴⁵ Matthew Perrone & Ben Wieder, *Pro-Painkiller Echo Chamber Shaped Policy Amid Drug Epidemic*, The Ctr.
 for Pub. Integrity, [https://www.publicintegrity.org/2016/09/19/20201/pro-painkiller-echo-chamber-shaped-policy-](https://www.publicintegrity.org/2016/09/19/20201/pro-painkiller-echo-chamber-shaped-policy-amid-drug-epidemic)
 28 amid-drug-epidemic (last updated Dec. 15, 2016, 9:09 AM).

⁴⁶ *Id.*

⁴⁷ HDA History, Healthcare Distribution Alliance, (accessed on September 14, 2017),
<https://www.healthcaredistribution.org/about/hda-history>.

368. Defendants, individually and collectively through trade groups in the industry, pressured the U.S. Department of Justice to “halt” prosecutions and lobbied Congress to strip the DEA of its ability to immediately suspend distributor registrations. The result was a “sharp drop in enforcement actions” and the passage of the “Ensuring Patient Access and Effective Drug Enforcement Act” which, ironically, raised the burden for the DEA to revoke a distributor’s license from “imminent harm” to “immediate harm” and provided the industry the right to “cure” any violations of law before a suspension order can be issued.⁴⁸

369. As described above, the Racketeering Defendants began working together as early as 2006 through the Pain Care Forum and/or the HDA to further the common purpose of their enterprise. Plaintiff is informed and believes that the Racketeering Defendants worked together as an ongoing and continuous organization throughout the existence of their enterprise.

CONDUCT OF THE OPIOID DIVERSION ENTERPRISE

370. The Racketeering Defendants conducted the Opioids Diversion Enterprise, and participated in the enterprise, by engaging in a pattern of racketeering activity, as prohibited by NRS § 207.400.

371. During the time period alleged in this Complaint, the Racketeering Defendants exerted control over, conducted and/or participated in the Opioid Diversion Enterprise by fraudulently failing to comply with their obligations under Nevada law (and federal law, as incorporated into Nevada law) to identify, investigate and report suspicious orders of opioids in order to prevent diversion of those highly addictive substances into the illicit market, to halt such unlawful sales as set forth below. In doing so, the Racketeering Defendants increased production quotas and generated unlawful profits.

372. The Racketeering Defendants disseminated statements that were false and misleading – either affirmatively or through half-truths and omissions – to the general public, Clark County, Clark County consumers, and the Nevada Board of Pharmacy, claiming that they were complying with their obligations to maintain effective controls against diversion of

⁴⁸ See Bernstein & Higham, *Investigation: The DEA Slowed Enforcement While the Opioid Epidemic Grew Out of Control*, *supra*; Bernstein & Higham, *Investigation: U.S. Senator Calls for Investigation of DEA Enforcement Slowdown Amid Opioid Crisis*, *supra*; Eyre, *supra*.

1 their prescription opioids.

2 373. The Racketeering Defendants disseminated statements that were false and
3 misleading – either affirmatively or through half-truths and omissions – to the general public
4 Clark County, Clark County consumers, and the Nevada Board of Pharmacy, claiming that
5 they were complying with their obligations to design and operate a system to disclose to the
6 registrant suspicious orders of their prescription opioids.

7 374. The Racketeering Defendants disseminated statements that were false and
8 misleading – either affirmatively or through half-truths and omissions – to the general public,
9 Clark County, Clark County consumers, and the Nevada Board of Pharmacy claiming that
10 they were complying with their obligation to notify the DEA of any suspicious orders or
11 diversion of their prescription opioids.

12 375. The Opioid Diversion Enterprise worked to scale back regulatory oversight by
13 the DEA that could interfere with the Racketeering Defendants' ability to distribute their opioid
14 drugs in Clark County, Nevada. To distribute controlled substances in Nevada, the Racketeering
15 Defendants had to be able to demonstrate possession of a current Nevada registration. *See* NRS
16 § 453.226. Even if they held a current registration, the Racketeering Defendants' ability to
17 obtain a Nevada registration could be jeopardized by past suspension or revocation of their DEA
18 registration. NRS § 453.231(1)(g).

19 376. The Racketeering Defendants paid nearly \$800 million dollars to influence
20 local, state and federal governments throughout the United States and in Nevada, through joint
21 lobbying efforts as part of the Pain Care Forum. The Racketeering Defendants were all
22 members of the Pain Care Forum either directly or indirectly through the HDA. The lobbying
23 efforts of the Pain Care Forum and its members included efforts to pass legislation making it
24 more difficult for the DEA to suspend and/or revoke the Manufacturers' and Distributors'
25 registrations for failure to report suspicious orders of opioids—protecting the Racketeering
26 Defendants' ability to distribute prescription opioids in Nevada.

27 377. The Racketeering Defendants exercised control and influence over the
28 distribution industry by participating and maintaining membership in the HDA.

1 378. The Racketeering Defendants applied political and other pressure on the DOJ
2 and DEA to halt prosecutions for failure to report suspicious orders of prescription opioids and
3 lobbied Congress to strip the DEA of its ability to immediately suspend registrations pending
4 investigation by passing the “Ensuring Patient Access and Effective Drug Enforcement Act.”⁴⁹

5 379. The Racketeering Defendants engaged in an industry-wide practice of paying
6 rebates and chargebacks to incentivize unlawful opioid prescription sales. Plaintiff is informed
7 and believes that the Manufacturer Defendants used the chargeback program to acquire detailed
8 high-level data regarding sales of the opioids they manufactured. And, Plaintiff is informed
9 and believes that the Manufacturer Defendants used this high-level information to direct the
10 Distributor Defendants’ sales efforts to regions where prescription opioids were selling in
11 larger volumes.

12 380. The Manufacturer Defendants lobbied the DEA to increase Aggregate
13 Production Quotas, year after year by submitting net disposal information that the
14 Manufacturer Defendants knew included sales that were suspicious and involved the diversion
15 of opioids that had not been properly investigated or reported by the Racketeering Defendants.

16 381. The Distributor Defendants developed “know your customer” questionnaires
17 and files. This information, compiled pursuant to comments from the DEA in 2006 and 2007,
18 was intended to help the Racketeering Defendants identify suspicious orders or customers who
19 were likely to divert prescription opioids.⁵⁰ On information and belief, the “know your
20 customer” questionnaires informed the Racketeering Defendants of the number of pills that the
21 pharmacies sold, how many non-controlled substances are sold compared to controlled
22 substances, whether the pharmacy buys from other distributors, the types of medical providers
23 in the area, including pain clinics, general practitioners, hospice facilities, cancer treatment
24

25 ⁴⁹ See HDMA is now the Healthcare Distribution Alliance, Pharmaceutical Commerce, (June 13, 2016, updated
26 July 6, 2016), [http://pharmaceuticalcommerce.com/business-and-finance/hdma-now-healthcare-distribution-](http://pharmaceuticalcommerce.com/business-and-finance/hdma-now-healthcare-distribution-alliance/)
27 [alliance/](http://pharmaceuticalcommerce.com/business-and-finance/hdma-now-healthcare-distribution-alliance/); Bernstein & Higham, *Investigation: The DEA Slowed Enforcement While the Opioid Epidemic Grew Out*
28 *of Control*, *supra*; Bernstein & Higham, *Investigation: U.S. Senator Calls for Investigation of DEA Enforcement*
Slowdown Amid Opioid Crisis, *supra*; Eyre, *supra*.

⁵⁰ Suggested Questions a Distributor should ask prior to shipping controlled substances, Drug Enforcement
Administration (available at [https://www.deadiversion.usdoj.gov/mtgs/pharm_industry/14th_pharm/](https://www.deadiversion.usdoj.gov/mtgs/pharm_industry/14th_pharm/levinl_ques.pdf)
[levinl_ques.pdf](https://www.deadiversion.usdoj.gov/mtgs/pharm_industry/14th_pharm/levinl_ques.pdf)); Richard Widup, Jr., Kathleen H. Dooley, Esq. Pharmaceutical Production Diversion: Beyond the
PDMA, Purdue Pharma and McQuite Woods LLC, (available at [https://www.mcguirewoods.com/news-](https://www.mcguirewoods.com/news-resources/publications/lifesciences/product_diversion_beyond_pdma.pdf)
[resources/publications/lifesciences/product_diversion_beyond_pdma.pdf](https://www.mcguirewoods.com/news-resources/publications/lifesciences/product_diversion_beyond_pdma.pdf)).

1 facilities, among others, and these questionnaires put the recipients on notice of suspicious
2 orders.

3 382. The Racketeering Defendants refused to identify, investigate and report
4 suspicious orders to the DEA, the Nevada Board of Pharmacy, and the FDA when they became
5 aware of the same despite their actual knowledge of drug diversion rings. The Racketeering
6 Defendants refused to identify suspicious orders and diverted drugs despite the DEA issuing
7 final decisions against the Distributor Defendants in 178 registrant actions between 2008 and
8 2012⁵¹ and 117 recommended decisions in registrant actions from The Office of Administrative
9 Law Judges. These numbers include 76 actions involving orders to show cause and 41 actions
10 involving immediate suspension orders – all for failure to report suspicious orders.⁵²

11 383. Defendants' scheme had decision-making structure that was driven by the
12 Manufacturer Defendants and corroborated by the Distributor Defendants. The Manufacturer
13 Defendants worked together to control the State and Federal Government's response to the
14 manufacture and distribution of prescription opioids by increasing production quotas through
15 a systematic refusal to maintain effective controls against diversion and to identify suspicious
16 orders and report them to the DEA and State governments, including the State of Nevada.

17 384. The Racketeering Defendants also worked together to ensure that the Aggregate
18 Production Quotas, Individual Quotas and Procurement Quotas allowed by the DEA stayed
19 high and to ensure that suspicious orders were not reported to the DEA. By not reporting
20 suspicious orders or diversion of prescription opioids, the Racketeering Defendants ensured
21 that the DEA had no basis for refusing to increase, or to decrease, the production quotas for
22 prescription opioids due to diversion of suspicious orders. The Racketeering Defendants
23 influenced the DEA production quotas in the following ways:

- 24 a. The Distributor Defendants assisted the enterprise and the Manufacturer
25 Defendants in their lobbying efforts through the Pain Care Forum;
- 26 b. The Distributor Defendants invited the participation, oversight and control of
27 the Manufacturer Defendants by including them in the HDA, including on the

28 ⁵¹ Evaluation and Inspections Div., Office of the Inspector Gen., U.S. Dep't of Justice, *The Drug Enforcement Administration's Adjudication of Registrant Actions* 6 (2014), <https://oig.justice.gov/reports/2014/e1403.pdf>.

⁵² *Id.*

councils, committees, task forces, and working groups;

- c. The Distributor Defendants provided sales information to the Manufacturer Defendants regarding their prescription opioids, including reports of all opioid prescriptions filled by the Distributor Defendants;
- d. The Manufacturer Defendants used a chargeback program to ensure delivery of the Distributor Defendants' sales information;
- e. The Manufacturer Defendants obtained sales information from QuintilesIMS (formerly IMS Health) that gave them a "stream of data showing how individual doctors across the nation were prescribing opioids."⁵³
- f. The Distributor Defendants accepted rebates and chargebacks for orders of prescription opioids;
- g. The Manufacturer Defendants used the Distributor Defendants' sales information and the data from QuintilesIMS to instruct the Distributor Defendants to focus their distribution efforts to specific areas where the purchase of prescription opioids was most frequent;
- h. The Racketeering Defendants identified suspicious orders of prescription opioids and then continued filling those unlawful orders, without reporting them, knowing that they were suspicious and/or being diverted into the illicit drug market;
- i. The Racketeering Defendants refused to report suspicious orders of prescription opioids despite repeated investigation and punishment of the Distributor Defendants by the DEA for failure to report suspicious orders; and
- j. The Racketeering Defendants withheld information regarding suspicious orders and illicit diversion from the DEA because it would have revealed that the "medical need" for and the net disposal of their drugs did not justify the production quotas set by the DEA.

385. The scheme devised and implemented by the Racketeering Defendants amounted to a common course of conduct characterized by a refusal to maintain effective controls against diversion, in intentional violation of Nevada law, and all designed and operated to ensure the continued unlawful sale of controlled substances.

⁵³ Harriet Ryan, et al., *More than 1 million OxyContin pills ended up in the hands of criminals and addicts. What the drugmaker knew*, Los Angeles Times, (July 10, 2016), <http://www.latimes.com/projects/la-me-oxycotin-part2/>.

PATTERN OF RACKETEERING ACTIVITY

386. The Racketeering Defendants conducted and participated in the conduct of the Opioid Diversion Enterprise through a pattern of racketeering activity as defined in NRS § 207.390, by at least two crimes related to racketeering (NRS § 207.360), trafficking in controlled substances (NRS §§ 207.360(22); 453.3395), multiple transactions involving deceit in the course of an enterprise (NRS §§ 207.360(35); 205.377) and distribution of controlled substances or controlled substance analogues (NRS § 453.331), and punishable by imprisonment of at least one year, with the intent of accomplishing activities prohibited by § 207.400 of the Racketeering Act.

387. The Racketeering Defendants committed, conspired to commit, and/or aided and abetted in the commission of at least two predicate acts of racketeering activity (i.e. violations of NRS §§ 207.360), within a five-year period. The multiple acts of racketeering activity that the Racketeering Defendants committed, or aided and abetted in the commission of, were related to each other, posed a threat of continued racketeering activity, and therefore constitute a “pattern of racketeering activity.” The racketeering activity was made possible by the Racketeering Defendants’ regular use of the facilities, services, distribution channels, and employees of the Opioid Diversion Enterprise.

388. The Racketeering Defendants committed these predicate acts, which number in the thousands, intentionally and knowingly with the specific intent to advance the Opioids Diversion Enterprise by conducting activities prohibited by NRS §§ 207.360, 207.390, 207.400.

389. The predicate acts all had the purpose of generating significant revenue and profits for the Racketeering Defendants while Clark County was left with substantial injury to its business through the damage that the prescription opioid epidemic caused. The predicate acts were committed or caused to be committed by the Racketeering Defendants through their participation in the Opioid Diversion Enterprise and in furtherance of its fraudulent scheme. The predicate acts were related and not isolated events.

390. The pattern of racketeering activity alleged herein and the Opioid Diversion Enterprise are separate and distinct from each other. Likewise, the Racketeering Defendants

1 are distinct from the enterprise.

2 391. The pattern of racketeering activity alleged herein is continuing as of the date
3 of this Third Amended Complaint and, upon information and belief, will continue into the
4 future unless enjoined by this Court.

5 392. Many of the precise dates of the Racketeering Defendants' criminal actions at
6 issue here have been hidden and cannot be alleged without access to Defendants' books and
7 records. Indeed, an essential part of the successful operation of the Opioid Diversion Enterprise
8 alleged herein depended upon secrecy.

9 393. Each instance of racketeering activity alleged herein was related, had similar
10 purposes, involved the same or similar participants and methods of commission, and had
11 similar results affecting similar victims, including consumers in the Clark County, Nevada.
12 Defendants calculated and intentionally crafted the Opioid Diversion Enterprise and their
13 scheme to increase and maintain their increased profits, without regard to the effect such
14 behavior would have on Clark County, Nevada, Clark County, Nevada consumers, or other
15 Clark County, Nevada citizens. In designing and implementing the scheme, at all times
16 Defendants were cognizant of the fact that those in the manufacturing and distribution chain
17 rely on the integrity of the pharmaceutical companies and ostensibly neutral third parties to
18 provide objective and reliable information regarding Defendants' products and their
19 manufacture and distribution of those products. The Racketeering Defendants were also aware
20 that Clark County and the citizens of this jurisdiction rely on the Racketeering Defendants to
21 maintain a closed system and to protect against the non-medical diversion and use of their
22 dangerously addictive opioid drugs.

23 394. By intentionally refusing to report and halt suspicious orders of their
24 prescription opioids, the Racketeering Defendants engaged in a deceptive scheme and unlawful
25 course of conduct constituting a pattern of racketeering activity.

26 395. It was foreseeable to Defendants that refusing to report and halt suspicious
27 orders would harm Clark County by allowing the flow of prescription opioids from appropriate
28 medical channels into the illicit drug market.

1 396. The Racketeering Defendants did not undertake the predicate acts described
 2 herein in isolation, but as part of a common scheme. Various other persons, firms, and
 3 corporations, including third-party entities and individuals not named as defendants in this Third
 4 Amended Complaint, may have contributed to and/or participated in the scheme with the
 5 Racketeering Defendants in these offenses and have performed acts in furtherance of the
 6 scheme to increase revenues, increase market share, and /or minimize the losses for the
 7 Racketeering Defendants.

8 397. The Racketeering Defendants aided and abetted others in the violations of NRS
 9 §§ 207.360, 207.390, and 207.400, while sharing the same criminal intent as the principals who
 10 committed those violations, thereby rendering them indictable as principals in the offenses.

11 398. The last racketeering incident occurred within five years of the commission of
 12 a prior incident of racketeering.

13 **1. The Racketeering Defendants Conducted the Opioid Diversion Enterprise**
 14 **through Acts of Fraud.**

15 399. Fraud consists of the intentional misappropriation or taking of anything of value
 16 that belongs to another by means of fraudulent conduct, practices or representations.

17 400. The Racketeering Defendants' fraudulent conduct, practices, and
 18 representations include, but are not limited to:

- 19 a. Misrepresentations to facilitate Defendants' DEA registrations, which could be a bar
 20 to their registrations with the Nevada Board of Pharmacy;
- 21 b. Requests for higher aggregate production quotas, individual production quotas, and
 22 procurement quotas to support Defendants' manufacture and distribution of
 23 controlled substances they knew were being or would be unlawfully diverted;
- 24 c. Misrepresentations and misleading omissions in Defendants' records and reports
 25 that were required to be submitted to the DEA and the Nevada Board of Pharmacy
 pursuant to Nevada Administrative Code provisions;
- 26 d. Misrepresentations and misleading omissions in documents and communications
 27 related to the Defendants' mandatory DEA reports that would affect Nevada
 28 registrant status; and
- e. Rebate and chargeback arrangements between the Manufacturers and the

1 Distributors that Defendants used to facilitate the manufacture and sale of controlled
 2 substances they knew were being or would be unlawfully diverted into and from
 Nevada.

3
 4 401. Specifically, the Racketeering Defendants made misrepresentations about their
 5 compliance with Federal and State laws requiring them to identify, investigate and report
 6 suspicious orders of prescription opioids and/or diversion of the same into the illicit market, all
 7 while Defendants were knowingly allowing millions of doses of prescription opioids to divert
 8 into the illicit drug market. The Racketeering Defendants' scheme and common course of
 9 conduct was intended to increase or maintain high production quotas for their prescription
 10 opioids from which they could profit.

11 402. At the same time, the Racketeering Defendants misrepresented the superior
 12 safety features of their order monitoring programs, their ability to detect suspicious orders,
 13 their commitment to preventing diversion of prescription opioids, and that they complied with
 14 all state and federal regulations regarding the identification and reporting of suspicious orders
 15 of prescription opioids.

16 403. The Racketeering Defendants intended to and did, through the above-described
 17 fraudulent conduct, practices, and representations, intentionally misappropriate funds from
 18 Clark County and from private insurers, in excess of \$500, including, for example:

- 19 a. Costs incurred by and resources diverted from Clark County infrastructure and health
 20 care providers;
- 21 b. Any and all cost or payments related to benefits of Clark County employees;

22 404. Many of the precise dates of the fraudulent acts and practices have been
 23 deliberately hidden and cannot be alleged without access to Defendants' books and records.
 24 But, Plaintiff has described the types of, and in some instances, occasions on which the
 25 predicate acts of fraud occurred.

26 **The Racketeering Defendants Unlawfully Trafficked in and Distributed Controlled
 Substances.**

27 405. Defendants' racketeering activities also included violations of the Nevada
 28 Controlled Substances Act, § 453.3395, and each act is chargeable or indictable under the laws
 of Nevada and punishable by imprisonment for more than one year. *See* NRS § 207.360(22).

1 406. Under Nevada law (NRS § 453.3395), it is unlawful to “knowingly or
2 intentionally sell[], manufacture[], deliver[] or bring[] into this state”— prescription opioids,
3 which are Schedule II controlled substances that are narcotic drugs, except as authorized by the
4 Nevada Controlled Substances Act.

5 407. The Racketeering Defendants intentionally trafficked in prescription opioid
6 drugs, in violation of Nevada law, by manufacturing, selling, and/or distributing those drugs in
7 Nevada in a manner not authorized by the Nevada Controlled Substances Act. The
8 Racketeering Defendants failed to act in accordance with the Nevada Controlled Substances
9 Act because they did not act in accordance with registration requirements as provided in that
10 Act.

11 408. Among other infractions, the Racketeering Defendants did not comply with 21
12 USC § 823 and its attendant regulations (*e.g.*, 21 CFR § 1301.74)⁵⁴ which are incorporated into
13 Nevada state law, or the Nevada Pharmacy Board regulations. The Racketeering Defendants
14 failed to furnish notifications and omitted required reports to the Nevada Board.

15 409. Plaintiff is informed and believes that the Racketeering Defendants failed to
16 furnish required notifications and make reports as part of a pattern and practice of willfully and
17 intentionally omitting information from their mandatory reports to the DEA, as required by 21
18 CFR § 1301.74, throughout the United States.

19 410. For example, the DEA and DOJ began investigating McKesson in 2013
20 regarding its monitoring and reporting of suspicious controlled substances orders. On April 23,
21 2015, McKesson filed a Form-8-K announcing a settlement with the DEA and DOJ wherein it
22 admitted to violating the CSA and agreed to pay \$150 million and have some of its DEA
23 registrations suspended on a staggered basis. The settlement was finalized on January 17,
24 2017.⁵⁵

25
26 ⁵⁴ Once again, throughout this Count and in this Complaint Plaintiff cites federal statutes and federal regulations to
27 state the duty owed under Nevada tort law, *not* to allege an independent federal cause of action or substantial
28 federal question. *See, e.g., Herrera*, 2003-NMSC-018, ¶7.

⁵⁵ McKesson, McKesson Finalizes Settlement with U.S. Department of Justice and U.S. Drug Enforcement Administration to Resolve Past Claims, About McKesson / Newsroom / Press Releases, (January 17, 2017), <http://www.mckesson.com/about-mckesson/newsroom/press-releases/2017/mckesson-finalizes-settlement-with-doj-and-dea-to-resolve-past-claims/>.

411. Purdue's experience in Los Angeles is another striking example of Defendants' willful violation of their duty to report suspicious orders of prescription opioids. In 2016, the Los Angeles Times reported that Purdue was aware of a pill mill operating out of Los Angeles yet failed to alert the DEA.⁵⁶ The LA Times uncovered that Purdue began tracking a surge in prescriptions in Los Angeles, including one prescriber in particular. A Purdue sales manager spoke with company officials in 2009 about the prescriber, asking "Shouldn't the DEA be contacted about this?" and adding that she felt "very certain this is an organized drug ring."⁵⁷ Despite knowledge of the staggering amount of pills being issued in Los Angeles, and internal discussion of the problem, "Purdue did not shut off the supply of highly addictive OxyContin and did not tell authorities what it knew about Lake Medical until several years later when the clinic was out of business and its leaders indicted. By that time, 1.1 million pills had spilled into the hands of Armenian mobsters, the Crips gang and other criminals."⁵⁸

412. Finally, Mallinckrodt was recently the subject of a DEA and Senate investigation for its opioid practices. Specifically, in 2011, the DEA targeted Mallinckrodt, arguing that it ignored its responsibility to report suspicious orders as 500 million of its pills ended up in Florida between 2008 and 2012.⁵⁹ After six years of DEA investigation, Mallinckrodt agreed to a settlement involving a \$35 million fine. Federal prosecutors summarized the case by saying that Mallinckrodt's response was that everyone knew what was going on in Florida, but they had no duty to report it.⁶⁰

413. The Racketeering Defendants' pattern and practice of willfully and intentionally omitting information from their mandatory reports is evident in the sheer volume of enforcement actions available in the public record against the Distributor Defendants.⁶¹ For example:

⁵⁶ Harriet Ryan, et al., *More than 1 million OxyContin pills ended up in the hands of criminals and addicts. What the drugmaker knew*, Los Angeles Times, (July 10, 2016), <http://www.latimes.com/projects/la-me-oxycontin-part2/>.

⁵⁷ *Id.*

⁵⁸ *Id.*

⁵⁹ Bernstein & Higham, *The government's struggle to hold opioid manufacturers accountable*, *supra*. This number accounted for 66% of all oxycodone sold in the state of Florida during that time.

⁶⁰ *Id.*

⁶¹ Evaluation and Inspections Div., Office of the Inspector Gen., U.S. Dep't of Justice, *The Drug Enforcement Administration's Adjudication of Registrant Actions* 6 (2014), <https://oig.justice.gov/reports/2014/e1403.pdf>.

- a. On April 24, 2007, the DEA issued an *Order to Show Cause and Immediate Suspension Order* against the AmerisourceBergen Orlando, Florida distribution center (“Orlando Facility”) alleging failure to maintain effective controls against diversion of controlled substances. On June 22, 2007, AmerisourceBergen entered into a settlement that resulted in the suspension of its DEA registration;
- b. On November 28, 2007, the DEA issued an *Order to Show Cause and Immediate Suspension Order* against the Cardinal Health Auburn, Washington Distribution Center (“Auburn Facility”) for failure to maintain effective controls against diversion of hydrocodone;
- c. On December 5, 2007, the DEA issued an *Order to Show Cause and Immediate Suspension Order* against the Cardinal Health Lakeland, Florida Distribution Center (“Lakeland Facility”) for failure to maintain effective controls against diversion of hydrocodone;
- d. On December 7, 2007, the DEA issued an *Order to Show Cause and Immediate Suspension Order* against the Cardinal Health Swedesboro, New Jersey Distribution Center (“Swedesboro Facility”) for failure to maintain effective controls against diversion of hydrocodone;
- e. On January 30, 2008, the DEA issued an *Order to Show Cause and Immediate Suspension Order* against the Cardinal Health Stafford, Texas Distribution Center (“Stafford Facility”) for failure to maintain effective controls against diversion of hydrocodone;
- f. On May 2, 2008, McKesson Corporation entered into an *Administrative Memorandum of Agreement* (“2008 MOA”) with the DEA which provided that McKesson would “maintain a compliance program designed to detect and prevent the diversion of controlled substances, inform DEA of suspicious orders required by 21 CFR § 1301.74(b), and follow the procedures established by its Controlled Substance Monitoring Program”;
- g. On September 30, 2008, Cardinal Health entered into a *Settlement and Release Agreement and Administrative Memorandum of Agreement* with the DEA related to its Auburn Facility, Lakeland Facility, Swedesboro Facility and Stafford Facility. The document also referenced allegations by the DEA that Cardinal failed to maintain effective controls against the diversion of controlled substances at its distribution facilities located in McDonough, Georgia (“McDonough Facility”), Valencia, California (“Valencia Facility”) and Denver, Colorado (“Denver Facility”);

- h. On February 2, 2012, the DEA issued an *Order to Show Cause and Immediate Suspension Order* against the Cardinal Health Lakeland, Florida Distribution Center (“Lakeland Facility”) for failure to maintain effective controls against diversion of oxycodone;
- i. On December 23, 2016, Cardinal Health agreed to pay a \$44 million fine to the DEA to resolve the civil penalty portion of the administrative action taken against its Lakeland, Florida Distribution Center; and
- j. On January 5, 2017, McKesson Corporation entered into an *Administrative Memorandum Agreement* with the DEA wherein it agreed to pay a \$150,000,000 civil penalty for violation of the 2008 MOA as well as failure to identify and report suspicious orders at its facilities in Aurora CO, Aurora IL, Delran NJ, LaCrosse WI, Lakeland FL, Landover MD, La Vista NE, Livonia MI, Methuen MA, Santa Fe Springs CA, Washington Courthouse OH and West Sacramento CA.

414. These actions against the Distributor Defendants confirm that the Distributors knew they had a duty to maintain effective controls against diversion, design and operate a system to disclose suspicious orders, and to report suspicious orders to the DEA. These actions also demonstrate, on information and belief, that the Manufacturer Defendants were aware of the enforcement against their Distributors and the diversion of the prescription opioids and a corresponding duty to report suspicious orders.

415. Many of the precise dates of Defendants’ criminal actions at issue herein were hidden and cannot be alleged without access to Defendants’ books and records. Indeed, an essential part of the successful operation of the Opioid Diversion Enterprise depended upon the secrecy of the participants in that enterprise.

SEVENTH CAUSE OF ACTION

(Violation of the Nevada Racketeering Act against the Insys Executives)

416. Clark County, as a “person” who has sustained injury brings this claim for civil remedies under the Racketeering Act, NRS §§207.350 to 207.520, against the Insys Executives.

417. The Insys Executives conducted business through legitimate and illegitimate means in the form of a criminal syndicate defined by NRS §207.370.

1 418. Section 207.400 of the Racketeering Act makes it unlawful “for a person . . .
2 employed by or associated with any enterprise to conduct or participate, directly or indirectly,
3 in: (1) The affairs of the enterprise through racketeering activity; or (2) Racketeering activity
4 through the affairs of the enterprise.” NRS § 207.400(1)(c).

5 419. Section 207.400 of the Racketeering Act also makes it unlawful “for a person . . .
6 to conspire to violate any of the provisions” of the Racketeering Act. NRS §207.400(1)(j).

7 420. The term “criminal syndicate” is defined as “any combination of persons, so
8 structured that the organization will continue its operation even if individual members enter or
9 leave the organization, which engages in or has the purpose of engaging in racketeering
10 activity.”

11 421. Over a period years, the Insys Executives developed a scheme to bribe
12 physicians around the country, including in Clark County, to prescribe the Insys product,
13 Subsys, which is a Fentanyl product delivered by an oral spray. Subsys was developed and
14 approved solely for use by cancer patients with breakthrough pain. The Insys Executives
15 bribed doctors using Insys money, kickbacks, and other “speaker fees,” to encourage increased
16 Subsys prescriptions. If a doctor did not prescribe sufficient quantities of Subsys, as
17 determined by the Insys Executives, the Insys Executives would threaten the doctors that they
18 would withhold bribe money previously promised.

19 422. The Insys Executives falsely informed doctors and other healthcare professionals
20 that Subsys was not addictive and could be used for off-label purposes, such as long-term
21 management of moderate pain.

22 423. The Insys Executive’s scheme violated NRS§ 205.377(1), which prohibits any
23 person from, “in the course of an enterprise or occupation, knowingly and with the intent to
24 defraud, engage in an act, practice or course of business or employ a . . . scheme which
25 operates or would operate as a fraud or deceit upon a person by means of a false representation
26 or omission of a material fact” on two (2), or more, occasions, utilizing the same or similar
27 pattern, intents, or results, with an aggregate loss or intended loss of over \$650. The Insys
28 Executives knew that their representations or omissions of material facts related to the
approved uses and dangers of Subsys were false or omitted. NRS § 205.377(1)(a). The Insys

1 Executives intended doctors, patients, and communities, to rely upon those false
2 representations or omissions. NRS § 205.377(1)(b). The Insys Executives' deceptive scheme
3 resulted in a loss to the County who relied upon the false representations or omissions. NRS §
4 205.377(1)(c).

5 424. Each individual act of deception by the Insys Executives constitutes a separate
6 violation of NRS §205.377. NRS § 205.377(2).

7 425. The bribes provided by the Insys Executives to prescribing doctors took many
8 forms, including, but not limited to, paying for speaking engagements that did not actually
9 occur; paying for the salaries of the doctor's office staff; and providing doctors with exotic
10 dances performed by Insys employees, including Sunrise Lee.

11 426. The Insys Executives pushed sales representatives to get at least one prescription
12 per day from doctors in their sales areas and to be sure that prescriptions were for high dosages.

13 427. If there was ever an issue with prescription approval through insurance, the Insys
14 Executives developed a scheme involving a call-center where the sales representatives would
15 call insurance companies to lie in whatever way was necessary to convince the insurance
16 companies to authorize payment for the prescriptions.

17 428. The Insys Executives instructed their sales representatives to not include
18 "cancer" in their sales pitches when discussing the appropriate use of the medication.
19 Defendant, Michael Babich, led training seminars in which sales representatives were told to
20 encourage pain management physicians to prescribe Subsys for off-label purposes in any way
21 they wanted and, thus, the representatives should not discuss the Subsys use for "cancer pain."

22 429. Upon reports of "pill-mills" from concerned sales representatives, the Insys
23 Executives directed the sales representatives to increase their visits with the doctors operating
24 the "pill-mills," to offer them additional kickbacks and bribes, and to provide additional
25 benefits related to the increased number of Subsys prescriptions.

26 430. The Insys Executives arranged speaking engagements for doctors who would be
27 paid for their appearance. The doctors invited to speak were those with high Subsys
28 prescription levels. Oftentimes, the speaking engagement was nothing more than a lunch or
dinner with Insys Executives.

431. The Insys Executives' actions were regular and ongoing over a period of years. Many of the precise dates of the Insys Executives' actions at issue herein were hidden and cannot be alleged without access to the Insys Executives' books and records. The full extent of the Insys Executives' fraudulent and deceptive behavior cannot be known without the benefit of discovery and is information within the Insys Executives' possession.

432. Each violation of NRS § 205.377 was a violation of Nevada's Racketeering Act.
NRS § 207.360(35).

433. The Insys Executives' scheme in which they bribed doctors to prescribe Subsys, provided false information as to the dangerous and addictive nature of Subsys, and concealed Subsys' actual, approved purpose, caused harm to the citizens of Clark County who relied upon the representations that the drug they were prescribe was safe and appropriate for use, and harmed the County through the increase costs of law enforcement, public health, and health care services.

PRAYER FOR RELIEF

WHEREFORE, the Plaintiff prays for judgment against the Defendants as follows:

1. General damages in an amount in excess of \$15,000.00;
2. Special damages in an amount in excess of \$15,000.00;
3. For punitive damages in such amount as will sufficiently punish Defendants for their wrongful conduct in Nevada as well as serve as an example to prevent a repetition of such conduct in Nevada in the future;
4. For a fund establishing a medical monitoring program due to the increased susceptibility to injuries and irreparable threat to the health of opioid users resulting from their exposure to opioids, which can only be mitigated or addressed by the creation of a Court-supervised fund, financed by Defendants, and which will:
 - a. Notify individuals who use or used opioids of the potential harm from opioids;
 - b. Aid in the early diagnosis and treatment of resulting injuries through ongoing testing and monitoring of opioid use;

- 1 c. Fund studies and research of the short and long term effects of opioids and
- 2 the possible cures and treatments for the detrimental effects of using
- 3 opioids;
- 4 d. Accumulate and analyze relevant medical and demographic information
- 5 from opioid users, including but not limited to the results of testing
- 6 performed on them;
- 7 e. Gather and forward to treating physicians information related to the
- 8 diagnosis and treatment of injuries which may result from using opioids.
- 9 5. For restitution and reimbursement sufficient to cover all prescription costs the
- 10 County has incurred related to opioids due to Defendants' wrongful conduct, with
- 11 said amount to be determined at trial;
- 12 6. For restitution and reimbursement sufficient to cover all costs expended for health
- 13 care services and programs associated with the diagnosis and treatment of adverse
- 14 health consequences of opioids use, including but not limited to addiction due to
- 15 Defendants ' wrongful conduct, with said amount to be determined at trial;
- 16 7. For restitution and reimbursement for all prescription costs incurred by consumers
- 17 related to opioids;
- 18 8. For such other and further extraordinary equitable, declaratory and/or injunctive
- 19 relief as permitted by law as necessary to assure that the Plaintiffs have an effective
- 20 remedy and to stop Defendants' promotion and marketing of opioids for
- 21 inappropriate uses in Nevada, currently and in the future;

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

9. For disgorgement;
10. Costs of suit, reasonable attorney fees, interest incurred herein; and
11. For such other and further relief as is just and proper.

DATED this 11th day of September, 2019.


EGLET ADAMS

ROBERT T. EGLET, ESQ.

Nevada Bar No. 3402

ROBERT M. ADAMS, ESQ.

Nevada Bar No. 6551

RICHARD K. HY, ESQ.

Nevada Bar No. 12406

400 S. 7th Street, 4th Floor

Las Vegas, NV 89101

Tel.: (702) 450-5400

Fax: (702) 450-5451

E-Mail eservice@egletlaw.com

-and-

STEVEN B. WOLFSON, ESQ.

Nevada Bar No. 1565

Clark County District Attorney

200 E. Lewis Ave

Las Vegas, NV 89101

Tel.: 702-671-2700

Email: steven.wolfson@clarkcountynyda.com

Attorneys for Plaintiff, Clark County

DEMAND FOR JURY TRIAL

Plaintiff, by and through its attorneys of record, hereby demands a jury trial of all of the issues in the above matter.

DATED this 11th day of September, 2019

EGLET ADAMS

ROBERT T. EGLET, ESQ.

Nevada Bar No. 3402

ROBERT M. ADAMS, ESQ.

Nevada Bar No. 6551

RICHARD K. HY, ESQ.

Nevada Bar No. 12406

400 S. 7th Street, 4th Floor

Las Vegas, NV 89101

Tel.: (702) 450-5400

Fax: (702) 450-5451

E-Mail eservice@egletlaw.com

-and-

STEVEN B. WOLFSON, ESQ.

Nevada Bar No. 1565

Clark County District Attorney

200 E. Lewis Ave

Las Vegas, NV 89101

Tel.: 702-671-2700

Email: steven.wolfson@clarkcountynvda.com

Attorneys for Plaintiff, Clark County

CERTIFICATE OF SERVICE

Pursuant to NRCP 5(b), I certify that I am an employee of EGLET ADAMS, and that on September 12th, 2019, I caused the foregoing document entitled **THIRD AMENDED COMPLAINT AND DEMAND FOR JURY TRIAL** to be served upon those persons designated by the parties in the E-Service Master List for the above-referenced matter in the Eighth Judicial District Court eFiling System in accordance with the mandatory electronic service requirements of Administrative Order 14-2 and the Nevada Electronic Filing and Conversion Rules.


An Employee of EGLET ADAMS

Case Information

A-17-765828-C | Clark County, Plaintiff(s) vs. Purdue Pharma, L.P., Defendant(s)

Case Number
A-17-765828-C
File Date
12/07/2017

Court
Department 22
Case Type
Other Tort

Judicial Officer
Johnson, Susan
Case Status
Open

Party

Special Master (Participant)
Cherry, Justice Michael

Plaintiff
Clark County

Active Attorneys ▼
Attorney
Eglet, Robert T.
Retained

Lead Attorney
Adams, Robert M
Retained

Attorney
Wolfson, Steven B
Retained

Attorney
HY, RICHARD K
Retained

Attorney
Cummings,
Cassandra

Attorney

Nicole
Retained

Active Attorneys ▼
Lead Attorney
Evans, Kelly A.
Retained

Attorney
Gutke, David W.
Retained

Attorney
Cheffo, Mark Steven
Retained

Attorney
Cusker Gonzalez,
Mara C
Retained

Attorney
Murphy, Matthew T.
Retained

Attorney
Coleman, Hayden
Adam
Retained

Attorney
Zanello, Lindsay
Nicole
Retained

Defendant

Purdue Frederick Company, Inc.

Aliases

DBA Purdue Frederick Company Inc

Active Attorneys ▼

Lead Attorney

Evans, Kelly A.

Retained

Attorney

Fears, Chad R.

Retained

Attorney

Gutke, David W.

Retained

Attorney

Cheffo, Mark Steven

Retained

Attorney

Cusker Gonzalez,

Mara C

Retained

Attorney

Murphy, Matthew T.

Retained

Attorney

Coleman, Hayden

Adam

Retained

Attorney

Zanello, Lindsay

Nicole

Retained

Defendant

Purdue Pharmaceuticals, L.P.

Active Attorneys ▼

Lead Attorney

Evans, Kelly A.

Retained

Attorney

Fears, Chad R.

Attorney
Gutke, David W.
Retained

Attorney
Cheffo, Mark Steven
Retained

Attorney
Cusker Gonzalez,
Mara C
Retained

Attorney
Murphy, Matthew T.
Retained

Attorney
Coleman, Hayden
Adam
Retained

Attorney
Zanello, Lindsay
Nicole
Retained

Defendant
Teva Pharmaceuticals Usa, Inc.

Active Attorneys ▼
Lead Attorney
Hymanson, Philip M.
Retained

Attorney
Reed, Steven A.
Retained

Attorney
James, Collie, IV
Retained

Defendant
Cephalon, Inc.;

Active Attorneys ▼
Lead Attorney
Hymanson, Philip M.
Retained

Attorney
Fears, Chad R.
Retained

Attorney
Gutke, David W.
Retained

Attorney
Evans, Kelly A.
Retained

Attorney
Reed, Steven A.
Retained

Attorney
James, Collie, IV
Retained

Defendant
Johnson & Johnson

Active Attorneys ▼
Lead Attorney
Bendavid, Jeffrey A.
Retained

Attorney
Smith, Stephanie J.
Retained

Attorney
Murphy, Matthew T.
Retained

Attorney
Brody, Stephen D
Retained

Janssen Pharmaceuticals, Inc.

Lead Attorney

Bendavid, Jeffrey A.
Retained

Gutke, David W.

Retained

Smith, Stephanie J.

Retained

Brody, Stephen D

Retained

Murphy, Matthew T.

Retained

Endo Health Solutions Inc

Lead Attorney

Lundvall, Patricia K.

Retained

Yen, Amanda C.

Retained

Lombardo, John

David

Retained

Miller, Jake

Retained

Endo Pharmaceuticals, Inc

Lead Attorney
Lundvall, Patricia K.
Retained

Attorney
Yen, Amanda C.
Retained

Attorney
Lombardo, John
David
Retained

Attorney
Miller, Jake
Retained

Actavis, Inc

FKA Watson Pharmaceuticals Inc

Lead Attorney
Corrick, Max E
Retained

Attorney
Levy, Jennifer G.,
ESQ
Retained

Attorney
Roth, Martin Louis
Retained

Attorney
Welch, Donna Marie
Retained

Attorney
Knapp, Timothy
William
Retained

Attorney

Attorney
Zolner, Erica B.
Retained

Attorney
Fears, Chad R.
Retained

Attorney
Evans, Kelly A.
Retained

Attorney
Gutke, David W.
Retained

Attorney
Reed, Steven A.
Retained

Attorney
James, Collie, IV
Retained

Active Attorneys ▼
Lead Attorney
Hymanson, Philip M.
Retained

Attorney
Fears, Chad R.
Retained

Attorney
Evans, Kelly A.
Retained

Attorney
Gutke, David W.
Retained

Attorney
Roth, Martin Louis
Retained

Attorney
Reed, Steven A.
Retained

Attorney
James, Collie, IV
Retained

Defendant
Actavis Pharma, Inc

Aliases
FKA Watson Pharma Inc

Active Attorneys ▼
Lead Attorney
Hymanson, Philip M.
Retained

Attorney
Fears, Chad R.
Retained

Attorney
Evans, Kelly A.
Retained

Attorney
Gutke, David W.
Retained

Roth, Martin Louis
Retained

Attorney
Reed, Steven A.
Retained

Attorney
James, Collie, IV
Retained

Defendant
Amerisourcebergen Drug Corporation

Active Attorneys ▼
Attorney
Semenza, Lawrence
J., III
Retained

Attorney
Kircher, Christopher
D.
Retained

Lead Attorney
Rickard, Jarrod L.
Retained

Attorney
Boranian, Steven J.
Retained

Attorney
Johansen, Sarah B.
Retained

Defendant
Cardinal Health, Inc

Active Attorneys ▼
Attorney
Jorgensen, J.
Christopher
Retained

Attorney
Shafroth, Nathan
Retained

Defendant

Masters Pharmaceutical, LLC

Aliases

FKA Masters Pharmaceutical Inc

Active Attorneys ▼

Lead Attorney

Terry, Brian K.

Retained

Attorney

Smith, John Andrew

Retained

Defendant

C & R Pharmacy

Aliases

DBA Ken's Pharmacy

FKA Lam's Pharmacy Inc

Active Attorneys ▼

Lead Attorney

Daehnke, Patricia

Egan

Retained

Attorney

Rosenthal, Amanda

E.

Retained

Attorney

Lucero, Laura S.

Retained

Defendant

Teva Pharmaceuticals Industries LTD

Active Attorneys ▼

Lead Attorney

Evans, Kelly A.

Retained

Attorney

Fears, Chad R.

Retained

Attorney

Gutke, David W.

Retained

Defendant

Insys Therapeutics Inc

Active Attorneys ▼

Lead Attorney

Vigil, Abran E.

Retained

Attorney

Donohue, John

Matthew

Retained

Attorney

Franco, Joseph Lee

Retained

Attorney

Rubin, Stacy H,

Retained

Attorney

Nadel, Heidi

Retained

Defendant

Mallinckrodt LLC

Active Attorneys ▼

Lead Attorney

Guinn, Steven E

Retained

Attorney

Leary, Ryan William

Retained

Attorney

Tsai, Rocky Chiu-

Feng

Retained

Attorney

Davison, William

Thomas

Retained

Maxsam, Aida B

Lead Attorney
Barr, Jeffrey F.
Retained

Attorney
Cohen, Joseph D.
Retained

Attorney
Summers, Jonna
Retained

Holper, Steven A, M.D.

Lead Attorney
Bohn, Michael F
Retained

Attorney
Trippiedi, Adam R.
Retained

Holper Out-Patients Medical Center LTD

Lead Attorney
Bohn, Michael F
Retained

Attorney
Trippiedi, Adam R.
Retained

Steven A. Holper, M.D., Professional Corporation

Lead Attorney
Bohn, Michael F
Retained

Attorney
Trippiedi, Adam R.
Retained

Active Attorneys ▼
Attorney
Jorgensen, J.
Christopher
Retained

Attorney
Polsenberg, Daniel
F.
Retained

Lead Attorney
Smith, Abraham G.
Retained

Attorney
Henriod, Joel D.
Retained

Attorney
Hardin, Ashley W.
Retained

Attorney
Pyser, Steven M.
Retained

Active Attorneys ▼
Attorney
Jorgensen, J.
Christopher
Retained

Attorney
Polsenberg, Daniel
F.
Retained

Lead Attorney
Smith, Abraham G.
Retained

Attorney
Pyser, Steven M.
Retained

Attorney
Pyser, Steven M.
Retained

Cardinal Health 200 LLC

Attorney
Jorgensen, J.
Christopher
Retained

Attorney
Polenberg, Daniel
F.
Retained

Lead Attorney
Smith, Abraham G.
Retained

Attorney
Henriod, Joel D.
Retained

Attorney
Hardin, Ashley W.
Retained

Attorney
Pyser, Steven M.
Retained

Defendant
Allergan Inc

Lead Attorney
Ciullo, Zachary A.
Retained

Attorney
Zolner, Erica B.
Retained

Defendant
Allergan USA Inc

Lead Attorney
Corrick, Max E
Retained

Attorney
Knapp, Timothy
William
Retained

Attorney
Levy, Jennifer G.,
ESQ
Retained

Attorney
Welch, Donna Marie
Retained

Attorney
Roth, Martin Louis
Retained

Attorney
Ciullo, Zachary A.
Retained

Attorney
Zolner, Erica B.
Retained

Defendant
Allergan Finance, LLC

Active Attorneys ▼
Lead Attorney
Corrick, Max E
Retained

Attorney
Knapp, Timothy
William
Retained

Attorney
Levy, Jennifer G.,
ESQ
Retained

Attorney
Welch, Donna Marie

Retained

Attorney
Roth, Martin Louis
Retained

Attorney
Ciullo, Zachary A.
Retained

Attorney
Zolner, Erica B.
Retained

Defendant
SpecGX LLC

Defendant
Sackler, Richard S.

Defendant
Sackler, Jonathan D

Defendant
Sackler, Mortimer D.A.

Defendant
Sackler, Kathe A.

Defendant
Sackler Lefcourt, Ilene

Sackler, David

Sackler, Beverly

Sackler, Theresa

PLP Associates Holdings L.P.

Rosebay Medical Company L.P

Beacon Company

Par Pharmaceutical Inc

Par Pharmaceutical Companies Inc

Kapoor, John

Simon, Richard M

Defendant
CVS Health Corporation

Monetary Judgment

Debtors: Adare Pharmaceuticals Inc (Defendant)

Creditors: Clark County (Plaintiff)

Judgment: 06/25/2018 Docketed: 07/02/2018

07/06/2018 Judgment ▼

Judicial Officer
Williams, Timothy C.

Judgment Type
Voluntary Dismissal

Monetary Judgment

Debtors: Mallinckrodt PLC (Defendant)

Creditors: Clark County (Plaintiff)

Judgment: 07/06/2018 Docketed: 07/13/2018

08/01/2018 Judgment ▼

Judicial Officer
Williams, Timothy C.

Judgment Type
Voluntary Dismissal

Monetary Judgment

Debtors: Mylan Pharmaceuticals Inc (Defendant)

Creditors: Clark County (Plaintiff)

Judgment: 08/01/2018 Docketed: 08/02/2018

08/01/2018 Judgment ▼

Judgment Type
Voluntary Dismissal

Judgment: 08/01/2018 Docketed: 08/02/2018

Judgment Type
Voluntary Dismissal

Judgment: 10/22/2018 Docketed: 10/23/2018

Judgment Type
Voluntary Dismissal

Judgment: 10/24/2018 Docketed: 10/24/2018

07/01/2019 Judgment ▼

Judicial Officer
Williams, Timothy C.

Judgment Type
Order of Dismissal Without Prejudice

Monetary Judgment

Debtors: Clark County (Plaintiff)

Creditors: Depomed Inc (Defendant)

Judgment: 07/01/2019 Docketed: 07/01/2019

07/01/2019 Judgment ▼

Judicial Officer
Williams, Timothy C.

Judgment Type
Order of Dismissal Without Prejudice

Monetary Judgment

Debtors: Clark County (Plaintiff)

Creditors: Johnson & Johnson (Defendant), Janssen Pharmaceuticals, Inc. (Defendant), Janssen Pharmaceutica, Inc. (Defendant), Ortho-Mcneil-Janssen Pharmaceuticals, Inc. (Defendant)

Judgment: 07/01/2019 Docketed: 07/02/2019

07/08/2019 Judgment ▼

Judicial Officer
Williams, Timothy C.

Judgment Type
Order of Dismissal Without Prejudice

Monetary Judgment

Debtors: James Kumle (Defendant)

Creditors: Clark County (Plaintiff)

Judgment: 07/08/2019 Docketed: 07/09/2019

Events and Hearings

12/07/2017 Complaint With Jury Demand ▼

Comment

Complaint and Demand for Jury Trial

03/21/2018 Ex Parte Application to Extend Time for Service ▼

Comment

Ex-Parte Application for Enlargement of Time to Serve Summons and Complaint

03/22/2018 Order ▼

Comment

Order Granting Plaintiff's Ex Parte Application for Enlargement of Time to Serve Summons and Complaint

03/23/2018 Notice of Entry of Order ▼

Comment

Notice of Entry of Order Granting Plaintiff's Ex Parte Application for Enlargement of Time to Serve Summons and Complaint

05/16/2018 Amended Complaint ▼

Comment

First Amended Complaint and Demand for Jury Trial

05/17/2018 Summons Electronically Issued - Service Pending ▼

Comment

Summons

Pharmacy f/k/a Lam's Pharmacy, Inc.

06/11/2018 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure (NRS Chapter 19)

06/11/2018 Opposition ▼

Comment

Specially Appearing Defendant C&R Pharmacy d/b/a Ken's Pharmacy f/k/a Lam's Pharmacy, Inc.'s Opposition to Motion to Preserve Evidence as to Defendants C&R Pharmacy d/b/a Ken's Pharmacy f/k/a Lam's Pharmacy, Inc. on an Order Shortening Time

06/11/2018 Notice of Entry ▼

Comment

Notice of Entry of Stipulation and Order to Continue the Hearing on
Plaintiff's Motion to Preserve Evidence as to Defendant C&R
Pharmacy d/b/a Ken's Pharmacy f/k/a Lam's Pharmacy, Inc.

06/11/2018 Summons Electronically Issued - Service Pending ▼

Comment

Summons_Watson Laboratories Inc.

06/11/2018 Summons Electronically Issued - Service Pending ▼

Comment

Summons

06/11/2018 Summons Electronically Issued - Service Pending ▼

Comment

Summons

06/11/2018 Reply ▼

Comment

Reply in Support of Motion to Preserve Evidence as to Defendants
C&R Pharmacy d/b/a Kens Pharmacy f/k/a LAM's Pharmacy, Inc. on
an Order Shortening Time

06/12/2018 Summons Electronically Issued - Service Pending ▼

Comment

Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Comment

Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Comment
Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Comment
Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Comment
Summons_Mylan Pharmaceuticals Inc.

06/12/2018 Summons Electronically Issued - Service Pending ▼

Comment
Summons_McKesson Corporation

06/12/2018 Summons Electronically Issued - Service Pending ▼

Comment
Summons_Masters Pharmaceutical, LLC. f/k/a Masters
Pharmaceutical, Inc.

06/12/2018 Summons Electronically Issued - Service Pending ▼

Comment
Summons_Cardinal Health 414, LLC

06/12/2018 Summons Electronically Issued - Service Pending ▼

Comment
Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Comment
Summons_Actavis, Inc. f/k/a Watson Pharmaceuticals, Inc.

06/12/2018 Summons Electronically Issued - Service Pending ▼

Comment
Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Comment
Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons Holper Out-Patients Medical Center, Ltd.

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons Mallinckrodt LLC

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons Johnson & Johnson

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons Janssen Pharmaceuticals, Inc.

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons_Janssen Pharmaceutica, Inc. n/k/a Janssen
Pharmaceuticals, Inc.

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons

06/12/2018 Summons Electronically Issued - Service Pending ▼

Summons James Kumle

06/15/2018 Summons Electronically Issued - Service Pending ▼

Summons_Allergan PLC f/k/a Actavis PLC

06/15/2018 Summons Electronically Issued - Service Pending ▼

Summons_Allison Foster

06/15/2018 Summons Electronically Issued - Service Pending ▼

Summons_Ortho-McNeil-Janssen Pharmaceuticals Inc. n/k/a
Janssen Pharmaceuticals Inc.

06/22/2018 Summons ▼

Summons - Purdue Pharam LP

06/22/2018 Summons ▼

Summons - Teva Pharmaceuticals USA

06/22/2018 Summons ▼

Summons - Cephalon, Inc.

06/22/2018 Summons ▼

Summons - Actavis, LLC

06/22/2018 Summons ▼

Comment

Summons - Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.

06/22/2018 Summons ▼

Comment

Summons - The Purdue Frederick Company, Inc. d/b/a The Purdue Frederick Co.

06/22/2018 Summons ▼

Comment

Summons - Purdue Pharmaceuticals, LP

06/22/2018 Summons ▼

Comment

Summons - Ends Health Solutions, Inc.

06/22/2018 Summons ▼

Comment

Summons - Adare Pharmaceuticals, Inc.

06/22/2018 Summons ▼

Comment

Summons - Cardinal Health 200, LLC

06/22/2018 Summons ▼

Comment

Summons - Abbvie US, LLC

06/22/2018 Summons ▼

Comment

Summons - Daiichi Sankyo, Inc.

06/22/2018 Summons ▼

Comment

Summons - Cardinal Health Technologies, LLC

06/22/2018 Summons ▼

Comment

Summons - Cardinal Health 414 LLC

06/22/2018 Summons ▼

Comment

Summons - Cardinal Health 6 Inc.

06/22/2018 Summons ▼

Comment

Summons - Purdue Pharma, Inc.

06/22/2018 Summons ▼

Comment

Summons - Endo Pharmaceuticals, Inc.

06/22/2018 Summons ▼

Comment

Summons - Mallinckrodt, LLC

06/22/2018 Summons ▼

Comment

Summons - Amerisourcebergen Drug Corporation

06/22/2018 Summons ▼

Comment

Summons - Allergan, PLC f/k/a Actavis, PLC

06/22/2018 Summons ▼

Comment

Summons - Masters Pharmaceutical, LLC f/k/a Masters
Pharmaceutical Inc

06/22/2018 Summons ▼

Comment

Summons - Janssen Pharmaceutica, Inc. n/k/a Janssen
Pharmaceuticals, Inc.

06/22/2018 Summons ▼

Comment

Summons - Ortho-McNeil-Janssen Pharmaceuticals, Inc n/k/a
Janssen Pharmaceuticals, Inc.

06/22/2018 Summons ▼

Comment

Summons - Cardinal Health, Inc.

06/22/2018 Summons ▼

Comment

Summons - Abbvie, Inc.

06/22/2018 Summons ▼

Comment

Summons - Janssen Pharmaceuticals Inc

06/25/2018 Notice of Voluntary Dismissal Without Prejudice ▼

Comment

Notice of Voluntary Dismissal of All Claims Against Defendant Adare Pharmaceuticals Inc. Without Prejudice

06/27/2018 Summons ▼

Comment

Summons - Watson Laboratories Inc

06/27/2018 Summons ▼

Comment

Summons - Steven A. Holper, M.D.

06/27/2018 Summons ▼

Comment

Summons - Steven A. Holper, M.D., Professional Corporation

06/27/2018 Summons ▼

Comment

Summons - Mylan Technologies, Inc.

06/27/2018 Summons ▼

Comment

Summons - Mylan Pharmaceuticals, Inc.

06/27/2018 Summons ▼

Comment

Summons - McKesson Corporation

06/27/2018 Summons ▼

Comment

Summons - Holper Out-Patients Medical Center, Ltd.

06/27/2018 Summons ▼

Comment

Summons - Aida B. Maxsam

06/27/2018 Summons ▼

Comment

Summons - James Kumle

07/02/2018 Answer to Amended Complaint ▼

Comment

Answer to First Amended Complaint

07/02/2018 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure

07/06/2018 Request for Exemption From Arbitration ▼

Comment

Plaintiff's Petition for Exemption from Arbitration

07/06/2018 Summons ▼

Comment

Summons - Depomed, Inc.

07/06/2018 Summons ▼

Comment

Summons - JohnsonJohnson

07/06/2018 Summons ▼

Comment

Summons - Insys Therapeutics, Inc.

07/06/2018 Summons ▼

Comment

Summons - Actavis Inc f/k/a Watson Pharmaceuticals Inc

07/06/2018 Notice of Voluntary Dismissal Without Prejudice ▼

Comment

Notice of Voluntary Dismissal of all Claims Against Defendant
Mallinckrodt, PLC without Prejudice

07/06/2018 Summons ▼

Comment

Summons - Allison Foster

07/16/2018 Order ▼

Comment

Order Granting Plaintiff's Motion to Preserve Evidence as to Defendants C&R Pharmacy d/b/a Kens Pharmacy f/k/a Lam's Pharmacy, Inc. on an Order Shortening Time

07/19/2018 Notice of Entry of Order ▼

Comment

Notice of Entry of Order Granting Plaintiff's Motion to Preserve Evidence as to Defendants C&R Pharmacy d/b/a Kens Pharmacy f/k/a Lam's Pharmacy, Inc. on an Order Shortening Time

07/23/2018 Commissioners Decision on Request for Exemption - Granted ▼

Comment

Commissioner's Decision on Request For Exemption - GRANTED

07/27/2018 Demand for Jury Trial ▼

Comment

Defendant C&R Pharmacy d/b/a Ken's Pharmacy f/k/a Lam's Pharmacy, Inc.'s Demand for Jury Trial

08/01/2018 Notice of Voluntary Dismissal With Prejudice ▼

Comment

Notice of Voluntary Dismissal of All Claims Against Defendant Mylan Pharmaceuticals, Inc. With Prejudice

08/01/2018 Notice of Voluntary Dismissal With Prejudice ▼

Comment

Notice of Voluntary Dismissal of All Claims Against Defendant Mylan Technologies, Inc. With Prejudice

08/08/2018 Notice of Change of Address ▼

Comment

Notice of Change of Address

08/10/2018 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure

08/12/2018 Motion ▼

Motion to Strike Peremptory Challenge

Notice of Department Reassignment

Plaintiff's Motion for Reassignment on an Order Shortening Time

NRCP 7.1 Disclosure

Notice of Appearance

Initial Appearance Fee Disclosure

Initial Appearance Fee Disclosure

Notice of Appearance

Manufacturer Defendants' Opposition to Plaintiff Clark County's
Motion for Reassignment on Order Shortening Time

Exhibits to Manufacturer Defendants' Opposition to Plaintiff Clark
County's Motion for Reassignment on Order Shortening Time

08/27/2018 Reply in Support ▼

Comment

Reply In Support of Motion for Reassignment on an Order Shortening Time

08/27/2018 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure

08/27/2018 Opposition to Motion ▼

Comment

Manufacturer Defendants' Opposition To Plaintiff Clark County's Motion To Strike Peremptory Challenge

08/27/2018 Appendix ▼

Comment

Exhibits To Manufacturer Defendants' Opposition To Plaintiff Clark County's Motion To Strike Peremptory Challenge

08/27/2018 Receipt of Copy ▼

Comment

Receipt of Copy of Manufacturer Defendants' Opposition and Exhibits to Plaintiff Clark County's Motion for Reassignment on an Order Shortening Time

08/28/2018 Motion ▼

Judicial Officer

Bell, Linda Marie

Hearing Time

9:00 AM

Result

Denied

Comment

Plaintiff's Motion for Reassignment on an Order Shortening Time

Parties Present ▲

Plaintiff

Attorney: Eglet, Robert T.

Attorney: Adams, Robert M

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Daehnke, Patricia Egan

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Trippiedi, Adam R.

Defendant

Attorney: Trippiedi, Adam R.

Defendant

Attorney: Trippiedi, Adam R.

08/30/2018 Reporters Transcript ▼

Comment

Reporters Transcript of Plaintiffs Motion for Reassignment on An
Order Shortening Time Heard On 8-28-18

08/31/2018 Decision and Order ▼

Comment

Decision and Order

09/07/2018 Motion to Dismiss ▼

Comment

Defendant Aida Maxsam's Motion to Dismiss

09/07/2018 Initial Appearance Fee Disclosure ▼

Comment

Defendant Aida Maxsam's Initial Appearance Fee Disclosure

09/07/2018 Initial Appearance Fee Disclosure ▼

Initial Appearance Fee Disclosure

Notice Of Appearance

Notice of Entry of Decision and Order

Stipulation and Order to Continue the Hearing on Plaintiff's Motion to Strike Peremptory Challenge

Notice of Entry of Stipulation and Order to Continue the Hearing on
Plaintiff's Motion to Strike Peremptory Challenge

Plaintiff's Reply in Support of Motion to Strike Peremptory Challenge

NRCP Rule 7.1 Disclosure Statement

Initial Appearance Fee Disclosure

Motion to Associate Counsel (Joseph L. Franco)

Motion to Associate Counsel (Heidi A. Nadel)

09/26/2018 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel (J. Matthew Donohue)

09/26/2018 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure

09/26/2018 Brief ▼

Comment

Hearing Brief Regarding Peremptory Challenge

09/28/2018 Motion ▼

Comment

Plaintiff Clark County's Motion To Strike Defendant Cardinal Health, Inc's Hearing Brief Regarding Peremptory Challenge

10/01/2018 Disclosure Statement ▼

Comment

Defendants Purdue Pharma L.P., Purdue Pharma Inc., The Purdue Frederick Company Inc., and Purdue Pharmaceuticals L.P.'s Disclosure Statement (NRCP 7.1)

10/02/2018 Motion to Strike ▼

Judicial Officer

Crockett, Jim

Hearing Time

9:00 AM

Result

Granted

Comment

Plaintiff's Motion to Strike Peremptory Challenge

Parties Present ▲

Plaintiff

Attorney: Eglet, Robert T.

Attorney: Adams, Robert M

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Hymanson, Philip M.

Attorney: Fears, Chad R.

Defendant

Attorney: Hymanson, Philip M.

Attorney: Fears, Chad R.

Defendant

Attorney: Hymanson, Philip M.

Attorney: Fears, Chad R.

Defendant

Attorney: Hymanson, Philip M.

Attorney: Fears, Chad R.

Defendant

Attorney: Polsenberg, Daniel F.

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Daehnke, Patricia Egan

Attorney: Lucero, Laura S.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

10/02/2018 Opposition ▼

Comment

Plaintiff's Opposition to Defendant Aida Maxam's Motion to Dismiss

10/08/2018 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel - Joseph D Cohen

10/08/2018 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure

10/08/2018 Motion to Associate Counsel ▼

Comment

(10/9/18 Please see Errata)Motion to Associate Counsel - Steven A Reed

10/09/2018 Errata ▼

Comment

Errata to Motion to Associate Counsel - Steve A Reed

10/16/2018 Notice of Department Reassignment ▼

Comment

Notice of Department Reassignment

10/19/2018 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure

10/19/2018 Notice of Appearance ▼

Comment

Notice of Appearance

10/19/2018 Motion to Dismiss ▼

Comment

Defendant James Kumle's Motion to Dismiss the First Amended Complaint and Demand for Jury Trial

10/19/2018 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure

10/19/2018 Motion to Dismiss ▼

Comment

Allergan Finance, LLC and Allergan PLC's Motion to Dismiss the Amended Complaint

10/19/2018 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure

10/19/2018 Motion to Dismiss ▼

Comment

Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.'s Motion to Dismiss First Amended Complaint

10/19/2018 Motion to Dismiss ▼

Comment

Manufacturer Defendants' Joint Motion to Dismiss

10/19/2018 Disclosure Statement ▼

Comment

Defendant Mallinckrodt LLC's NRCP 7.1 Disclosure

10/19/2018 Disclosure Statement ▼

Comment

Disclosure Statement Pursuant to NRCP 7.1

10/19/2018 Motion to Dismiss ▼

Comment

Defendant Assertio Therapeutics, Inc. f/k/a Depomed, Inc.'s Motion to Dismiss

10/19/2018 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel - Mara Caitlin Cusker Gonzalez, Esq.

10/19/2018 Motion to Dismiss ▼

Comment

Defendant Insys Therapeutics, Inc.'s Motion to Dismiss Plaintiff's First Amended Complaint (and Joinder)

10/19/2018 Motion to Dismiss ▼

Comment

Motion to Dismiss of Defendants Watson Laboratories, Inc., Actavis LLC and Actavis Pharma Inc.

10/19/2018 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel - Mark Steven Cheffo, Esq.

10/19/2018 Motion to Dismiss ▼

Comment

Motion to Dismiss of Defendants Cephalon, Inc. and Teva Pharmaceuticals USA Inc.

10/19/2018 Notice of Appearance ▼

Comment

Notice of Appearance - McKesson Corporation

10/19/2018 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure - McKesson Corporation

10/19/2018 Disclosure Statement ▼

Comment

McKesson Corporation's NRCP 7.1 Disclosure Statement

10/19/2018 Joinder To Motion ▼

Comment

Defendant Mallinckrodt LLC's Joinder to Manufacturer Defendants' Joint Motion to Dismiss

10/19/2018 Motion to Dismiss ▼

Comment

Janssen Pharmaceuticals, Inc. and Johnson and Johnson's Joint Motion to Dismiss

10/19/2018 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure

10/19/2018 Motion to Dismiss ▼

Comment

Distributors' Joint Motion to Dismiss First Amended Complaint

10/22/2018 Findings of Fact, Conclusions of Law and Order ▼

Comment

Findings of Fact, Conclusions of Law, and Order Granting Plaintiff's Motion to Strike Peremptory Challenge

10/22/2018 Notice of Motion ▼

Notice of Motion to Dismiss of Defendants Cephalon, Inc. and Teva
Pharmaceuticals USA Inc

Notice of Motion to Dismiss of Defendants Watson Laboratories, Inc.,
Actavis LLC and Actavis Pharma Inc

Notice of Voluntary Dismissal of All Claims Against Defendants
Abbvie US, LLC and Abbvie, Inc Without Prejudice

Plaintiff and Manufacturer Defendants' Joint Stipulation and Order

Notice of Voluntary Dismissal of all Claims Against Defendants
Daiichi Sankyo, Inc. and Allison Foster Without Prejudice

Notice of Entry of Plaintiff and Manufacturer Defendants' Joint
Stipulation and Order

Motion to Associate Out-of-State Counsel on Order Shortening Time
- Jennifer Levy

Defendant James Kumle's Joinder in the Manufacturer Defendant's Joint Motion to Dismiss

Notice of Entry of Findings of Fact, Conclusions of Law, and Order
Granting Plaintiff's Motion to Strike Peremptory Challenge

Defendant C&R Pharmacy d/b/a Ken's Pharmacy f/k/a Lam's
Pharmacy, Inc.'s Joinder to Distributors' Joint Motion to Dismiss First
Amended Complaint

Defendant C&R Pharmacy d/b/a Ken's Pharmacy f/k/a Lam's
Pharmacy, Inc.'s Joinder to Manufacturer Defendants' Joint Motion to
Dismiss

Defendant C&R Pharmacy d/b/a Ken's Pharmacy f/k/a Lam's Pharmacy, Inc.'s Motion to Dismiss First Amended Complaint

Notice of Non-Opposition to Motion to Associate Counsel (J. Matthew Donohue)

Notice of Non-Opposition to Motion to Associate Counsel (Joseph Franco)

Notice of Non-Opposition to Motion to Associate Counsel (Heidi A. Nadel)

Stipulation and Order Re: Allergan's Motion to Associate Out-of-state Counsel

Notice of Entry of Stipulation and Order Re: Allergan's Motion to Associate Out-of-state Counsel

Stipulation and Order to Extend Briefing Schedules and Continue Hearings on Motions to Dismiss Filed by Manufacturer Defendants

11/09/2018 Stipulation and Order ▼

Comment

Stipulation and Order to Extend Briefing Schedule and Continue the Hearing on Allergan Finance LLC and Allergan PLC's Motion to Dismiss the Amended Complaint

11/09/2018 Stipulation and Order ▼

Comment

Stipulation and Order to Extend Briefing Schedule and Continue the Hearing on the Distributor Defendants' Joint Motion to Dismiss

11/09/2018 Stipulation and Order ▼

Comment

Stipulation and Order to Extend Briefing Schedule and Continue the Hearing on James Kumle's Motion to Dismiss the Amended Complaint

11/09/2018 Stipulation and Order ▼

Comment

Stipulation and Order to Continue Reply Deadline and the Hearing on Aida Maxsam's Motion to Dismiss the Amended Complaint

11/13/2018 Notice of Entry ▼

Comment

Notice of Entry of Stipulation and Order to Extend Briefing Schedule
and Continue the Hearing on James Kumle's Motion to Dismiss the
Amended Complaint

11/13/2018 Notice of Entry ▼

Comment

Notice of Entry of Stipulation and Order to Extend Briefing Schedules
and Continue Hearings on Motions to Dismiss filed by Manufacturer
Defendants

11/13/2018 Notice of Entry ▼

Comment

Notice of Entry of Stipulation and Order to Extend Briefing Schedule
and Continue the Hearing on Allergan Finance, LLC and Allergan
PLC's Motion to Dismiss the Amended Complaint

11/13/2018 Notice of Entry ▼

Comment

Notice of Entry of Stipulation and Order to Extend Briefing Schedule
and Continue the Hearing on the Distributor Defendants' Joint Motion
to Dismiss

11/13/2018 Notice of Entry ▼

Comment

Notice of Entry of Stipulation and Order to Continue Reply Deadline and the Hearing on Aida Maxsam's Motion to Dismiss the Amended Complaint

11/14/2018 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Cancel Reason

Vacated - per Stipulation and Order

Comment

Defendants Actavis' Motion to Associate Out of State Counsel on Order Shortening Time (Jennifer Gardner Levy, Esq., Martin Louis Roth, Esq., Donna Marie Welch, Esq. and Timothy William Knapp, Esq.)

11/15/2018 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel Tiffany Miyumi Ikeda

11/15/2018 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel Jake Redon Miller

11/15/2018 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel John David Lombardo

11/16/2018 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure

11/16/2018 Joinder ▼

Comment

Masters Pharmaeutical's Joinder To Distributors Joint Motion To Dismiss First Amended Complaint

11/19/2018 Stipulation and Order ▼

Stipulation and Order to Extend Briefing Schedule and Continue the Hearing on C&R Pharmacy d/b/a Ken's Pharmacy f/k/a Lam's Pharmacy Inc.'s Motion to Dismiss the Amended Complaint

Motion to Associate Counsel - Rocky Chiu-Feng Tsai and William Davidson

Notice of Entry of Stipulation and Order to Extend Briefing Schedule
and Continue the Hearing on C&R Pharmacy d/b/a Ken's Pharmacy
f/k/a Lam's Pharmacy Inc.'s Motion to Dismiss the Amended
Complaint

Notice of Rescheduling of Hearing on Motion to Associate Counsel
Steven A. Reed

Motion to Associate Counsel Adeyemi O. Adenrele

Motion to Associate Counsel Michael A. Battle

Motion to Associate Counsel Joseph L Franco

Judicial Officer
Williams, Timothy C.

9:00 AM

Motion Granted

Motion to Associate Counsel Heidi A Nadel

11/29/2018 Motion to Associate Counsel ▼

Williams, Timothy C.

9:00 AM

Motion Granted

Motion to Associate Counsel J Matthew Donohue

11/29/2018 Motion to Associate Counsel ▼

Williams, Timothy C.

9:00 AM

Motion Granted

Motion to Associate Counsel Joseph David Cohen

11/29/2018 All Pending Motions ▼

Williams, Timothy C.

9:00 AM

Matter Heard

Plaintiff

Attorney: Adams, Robert M

Attorney: Vigil, Abran E.

Order Admitting to Practice - Joseph David Cohen Esq

Order Admitting to Practice (Heidi A. Nadel)

Order Admitting to Practice (Joseph L. Franco)

Order Admitting to Practice (J. Matthew Donohue)

Notice of Entry of Order (Admitting to Practice)

Motion to Associate Counsel - Collie Fitch James IV

Notice of Entr of Order

Notice of Entry of Order

Notice of Entry of Order

Williams, Timothy C.

9:00 AM

Motion Granted

Motion to Associate Counsel Steven A. Reed

12/04/2018 Motion to Associate Counsel ▼

Williams, Timothy C.

9:00 AM

Motion Granted

Motion to Associate Counsel Mara Catilin Cusker Gonzalez, Esq.

12/04/2018 Motion to Associate Counsel ▼

Williams, Timothy C.

9:00 AM

Motion Granted

Motion to Associate Counsel Mark Steven Cheffo, Esq.

12/04/2018 All Pending Motions ▼

Williams, Timothy C.

9:00 AM

Matter Heard

Plaintiff

Attorney: Eglet, Robert T.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Hymanson, Philip M.

Attorney: Fears, Chad R.

Defendant

Attorney: Hymanson, Philip M.

Attorney: Fears, Chad R.

Defendant

Attorney: Hymanson, Philip M.

Attorney: Fears, Chad R.

Defendant

Attorney: Hymanson, Philip M.

Attorney: Fears, Chad R.

Defendant

Attorney: Fears, Chad R.

12/04/2018 Order Admitting to Practice ▼

Comment

Order Admitting to Practice - Mark Steven Cheffo, Esq.

12/04/2018 Order Admitting to Practice ▼

Comment

Order Admitting to Practice - Mara Caitlin Cusker Gonzalez, Esq.

12/04/2018 Order Admitting to Practice ▼

Comment

Order Admitting to Practice

12/04/2018 Notice of Entry of Order ▼

Comment

NOTICE OF ENTRY OF ORDER ADMITTING TO PRACTICE -
MARA CAITLIN CUSKER GONZALEZ, ESQ.

12/04/2018 Notice of Entry of Order ▼

NOTICE OF ENTRY OF ORDER ADMITTING TO PRACTICE -
MARK STEVEN CHEFFO, ESQ.

Notice of Entry of Order Granting Motion to Associate Counsel
Steven A. Reed

Clark County's Opposition to Defendant Mallinckrodt's Joinder to
Manufacturer Defendants' Joint Motion to Dismiss

Clark County's Opposition to Endo Health Solutions Inc. and Endo
Pharmaceutical Inc.'s Motion to Dismiss First Amended Complaint

Clark County's Opposition to Defendant C&R Pharmacy d/b/a Ken's Pharmacy f/k/a Lam's Pharmacy, Inc.'s Motion to Dismiss First Amended Complaint

Clark County's Opposition to Defendant Assertio Therapeutics, Inc.
f/k/a Deposited, Inc.'s Motion to Dismiss

Clark County's Opposition to Defendant James Kumle's Motion to Dismiss First Amended Complaint

Clark County's Opposition to the Motion to Dismiss of Defendants
Watson Laboratories, Inc., Actaves LLC, and Actaves Pharma, Inc.

Clark County's Opposition to Janssen Pharmaceuticals, Inc. and
Johnson & Johnson's Joint Motion to Dismiss

12/05/2018 Opposition ▼

Comment

Clark County's Opposition to Manufacturer Defendants' Joint Motion
to Dismiss and All Joinders Thereto

12/05/2018 Opposition ▼

Comment

Clark County's Opposition to Defendant Allergan Finance, LLC's
Motion to Dismiss; and Countermotion for Leave to Amend

12/06/2018 Opposition ▼

Comment

Clark County's Opposition to the Motion to Dismiss of Defendants
Cephalon, Inc. and Teva Pharmaceuticals USA, Inc.

12/06/2018 Opposition ▼

Comment

Clark County's Opposition to Defendant Insys Therapeutics, Inc.'s
Motion to Dismiss Plaintiff's First Amended Complaint

12/07/2018 Opposition ▼

Comment

Clark County's Opposition to Distributors' Joint Motion to Dismiss and
all Joinders Thereto

12/11/2018 Stipulation and Order ▼

Comment

Joint Stipulation and Order to Combine and Reschedule Hearings on Motions to Dismiss

12/12/2018 Notice of Entry of Order ▼

Comment

Notice of Entry of Order to Combine and Reschedule Hearings on Motions to Dismiss

12/13/2018 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel, John Andrew Smith

12/19/2018 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Result

Motion Granted

Comment

Motion to Associate Counsel Tiffany Miyumi Ikeda

12/19/2018 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Result

Motion Granted

Comment

Motion to Associate Counsel Jake Redon Miller

12/19/2018 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Result

Motion Granted

Comment

Motion to Associate Counsel John David Lombardo

12/19/2018 All Pending Motions ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Result

Matter Heard

Parties Present ▲

Plaintiff

Attorney: Eglet, Robert T.

12/19/2018 Order Granting Motion ▼

Comment

Order Granting Motion to Associate Counsel Tiffany Miyumi Ikeda

12/19/2018 Order Granting Motion ▼

Comment

Order Granting Motion to Associate Counsel John David Lombardo

12/19/2018 Order ▼

Comment

Order Granting Motion to Associate Counsel Jake Redon Miller

12/19/2018 Notice of Entry of Order ▼

Comment

Notice of Entry of Order Granting Motion to Associate Counsel Jake Redon Miller

12/19/2018 Notice of Entry of Order ▼

Comment

Notice of Entry of Order Granting Motion to Associate Counsel Tiffany Miyumi Ikeda

12/19/2018 Notice of Entry of Order ▼

Comment

Notice of Entry of Order Granting Motion to Associate Counsel John David Lombardo

12/20/2018 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Result

Motion Granted

12/27/2018 Order Granting Motion ▼

Comment

Order granting Motion to Associate Rocky Tsai and William Davison

12/28/2018 Notice of Entry of Order ▼

Comment

Notice of Entry of Order

01/07/2019 Reply in Support ▼

Comment

Defendant Aida Maxsam's Reply in Support of Her Motion to Dismiss

01/08/2019 Motion to Associate Counsel ▼

Judicial Officer
Williams, Timothy C.

Hearing Time
9:00 AM

Result
Motion Granted

Comment
Motion to Associate Counsel Adeyemlo Adenrele

01/08/2019 Motion to Associate Counsel ▼

Judicial Officer
Williams, Timothy C.

Hearing Time
9:00 AM

Result
Motion Granted

Comment
Motion to Associate Counsel Michael A. Battle

01/08/2019 All Pending Motions ▼

Judicial Officer
Williams, Timothy C.

Hearing Time
9:00 AM

Result
Matter Heard

01/08/2019 Order ▼

Comment
Order Admitting to Practice Adeyemi O. Adenrele

01/08/2019 Notice of Entry ▼

Comment
Notice of Entry of Order - Order Admitting to Practice

01/09/2019 Motion to Associate Counsel ▼

Judicial Officer
Williams, Timothy C.

Hearing Time

9:00 AM

Result

Motion Granted

Comment

Motion to Associate Counsel - Collie Fitch James IV

01/10/2019 Order ▼

Comment

Order Admitting to Practice Michael A. Battle

01/11/2019 Notice of Entry ▼

Comment

Notice of Entry of Order - Order Admitting to Practice Michael A. Battle

01/14/2019 Reply in Support ▼

Comment

Reply in Support of Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.'s Motion to Dismiss First Amended Complaint

01/14/2019 Reply in Support ▼

Comment

Insys Therapeutics, Inc.'s Reply in Support of its Motion to Dismiss

01/14/2019 Reply in Support ▼

Comment

Allergan Finance, LLC and Allergan PLC s Reply Memorandum in Support of Motion to Dismiss the Amended Complaint

01/14/2019 Reply in Support ▼

Comment

Defendant Assertio Therapeutics, Inc. F/K/A Depomed, Inc.'s Reply in Support of Motion to Dismiss

01/14/2019 Reply ▼

Comment

James Kumle's Reply to Clark County's Opposition to Motion to Dismiss First Amended Complaint

01/14/2019 Reply in Support ▼

Comment

Reply in Support of Manufacturer Defendants' Joint Motion to Dismiss

01/14/2019 Reply in Support ▼

Comment

Reply in Support of Distributors' Joint Motion to Dismiss First Amended Complaint

01/14/2019 Reply in Support ▼

Comment

Defendant Mallinckrodt LLC's Reply in Support of Its Joinder to Manufacturer Defendants' Joint Motion to Dismiss

01/14/2019 Reply in Support ▼

Comment

Reply Memorandum In Support Of Motion To Dismiss Of Defendants Cephalon, Inc. And Teva Pharmaceuticals USA, Inc.

01/14/2019 Reply in Support ▼

Comment

Reply In Support Of Motion To Dismiss Of Defendants Watson Laboratories, Inc., Actavis LLC, And Actavis Pharma, Inc.

01/14/2019 Reply ▼

Comment

Janssen Pharmaceuticals Inc. and Johnson & Johnson's Reply in support of their Joint Motion to Dismiss

01/14/2019 Reply ▼

Comment

Defendant C&R Pharmacy d/b/a Ken's Pharmacy f/k/a Lam's Pharmacy, Inc.'s Reply to Clark County's Opposition to Motion to Dismiss First Amended Complaint

01/15/2019 Notice of Change of Address ▼

Comment

Notice of Change of Address

01/15/2019 Joinder ▼

Comment

Masters Pharmaceutical, LLC f/k/a Masters Pharmaceutical, Inc.'s Joinder to the Reply in Support of Distributors' Joint Motion to Dismiss First Amended Complaint

01/17/2019 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Result

Motion Granted

Comment

Motion to Associate Counsel, John Andrew Smith

01/17/2019 Order Admitting to Practice ▼

Comment

Order Admitting to Practice, John Andrew Smith

01/22/2019 Notice of Entry of Order ▼

Comment

Notice of Entry of Order

01/22/2019 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel Charles Lifland, Esq.

01/28/2019 Errata ▼

Comment

Errata to Reply in Support of Manufacturer Defendants' Joint Motion to Dismiss

01/29/2019 Notice of Rescheduling ▼

Comment

Notice of Change of Time and Location for Hearings

01/29/2019 Order Admitting to Practice ▼

Comment

Order Admitting to Practice

01/29/2019 Notice of Entry of Order ▼

Comment

Notice of Entry of Order on Motion to Associate Counsel Collie James

01/29/2019 Motion to Associate Counsel ▼

Comment

MOTION TO ASSOCIATE SCOTT D. POWERS AS COUNSEL; EX PARTE APPLICATION FOR ORDER SHORTENING TIME

01/30/2019 Motion to Associate Counsel ▼

Comment

(Jessica Kramer Givens Esq.) Motion to Associate Counsel

02/12/2019 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel Ashley W. Hardin (On Order Shortening Time)

02/13/2019 Motion to Associate Counsel ▼

Comment

Motion to Associate Stephen J. Boranian, Esq. as Counsel on Order Shortening Time

02/15/2019 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel Christian J. Pistilli and Ex-Parte MTC on OST

02/19/2019 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Result

Motion Granted

Comment

Motion to Associate Scott D. Powers as Counsel ; Ex Parte Application for Order Shortening Time

02/19/2019 Order Granting Motion ▼

Comment

ORDER GRANTING MOTION TO ASSOCIATE SCOTT D. POWERS AS COUNSEL

02/19/2019 Notice of Entry of Order ▼

Comment

NOTICE OF ENTRY OF ORDER

02/21/2019 Motion to Associate Counsel ▼

Comment

Motion to Associate Hayden Adam Coleman, Esq. as Counsel; Ex Parte Application for Order Shortening Time

Motion to Associate Counsel Matthew T. Murphy, Esq. on Order
Shortening Time

Manufacturer Defendants' Joint Motion to Dismiss

Defendant Mallinckrodt LLC Joinder to Manufacturer Defendants' Joint Motion to Dismiss

Distributors' Joint Motion to Dismiss First Amended Complaint

Williams, Timothy C.

Hearing Time

9:15 AM

Result

Matter Continued

Comment

Defendant James Kumle's Joinder in the Manufacturer Defendant's Joint Motion to Dismiss

02/26/2019 Joinder ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:15 AM

Result

Matter Continued

Comment

Defendant C&R Pharmacy dba Ken's Pharmacy fka Lam's Pharmacy Inc's Joinder to Distributors' Joint Motion to Dismiss First Amended Complaint

02/26/2019 Joinder ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:15 AM

Result

Matter Continued

Comment

Defendant C&R Pharmacy dba Ken's Pharmacy fka Lam's Pharmacy Inc's Joinder to Manufacturer Defendants' Joint Motion to Dismiss

02/26/2019 Joinder ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:15 AM

Result

Matter Continued

Comment

Masters Pharmaeutical's Joinder To Distributors Joint Motion To Dismiss First Amended Complaint

02/26/2019 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:15 AM

Result

Motion Granted

Comment

Motion to Associate Counsel Ashley W. Hardin on Order Shortening Time

02/26/2019 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:15 AM

Result

Motion Granted

Comment

Motion to Associate Stephen J. Boranian, Esq. as Counsel on Order Shortening Time

02/26/2019 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:15 AM

Result

Motion Granted

Comment

Motion to Associate Counsel Christian J Pistilli and Ex Parte Motion to Consider Motion to Associate on Shortened Time

02/26/2019 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:15 AM

Result

Motion Granted

Comment

Motion to Associate Hayden Adam Coleman, Esq. as Counsel; Ex Parte Application for Order Shortening Time

Comment
Motion to Associate Counsel Matthew T. Murphy, Esq. on Order
Shortening Time

Attorney: Smith, Stephanie J.

Defendant

Attorney: Smith, Stephanie J.

Defendant

Attorney: Lundvall, Patricia K.

Attorney: Lombardo, John David

Defendant

Attorney: Lundvall, Patricia K.

Attorney: Lombardo, John David

Defendant

Attorney: Corrick, Max E

Attorney: Levy, Jennifer G., ESQ

Attorney: Welch, Donna Marie

Defendant

Attorney: Hymanson, Philip M.

Attorney: Fears, Chad R.

Attorney: James, Collie, IV

Defendant

Attorney: Hymanson, Philip M.

Attorney: Fears, Chad R.

Attorney: James, Collie, IV

Defendant

Attorney: Hymanson, Philip M.

Attorney: Fears, Chad R.

Attorney: James, Collie, IV

Defendant

Attorney: Rickard, Jarrod L.

Defendant

Attorney: Polsenberg, Daniel F.

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Solis-Rainey, Rosa

Attorney: Pistilli, Christian J.

Defendant

Attorney: Daehnke, Patricia Egan

Defendant

Attorney: Fears, Chad R.

Defendant

Attorney: Vigil, Abrah E.

Defendant

Attorney: Guinn, Steven E

Attorney: Tsai, Rocky Chiu-Feng

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Corrick, Max E

Attorney: Levy, Jennifer G., ESQ

Attorney: Welch, Donna Marie

Defendant

Attorney: Corrick, Max E

Attorney: Levy, Jennifer G., ESQ

Attorney: Welch, Donna Marie

02/26/2019 All Pending Motions ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:15 AM

Cancel Reason

Vacated - On in Error

02/26/2019 Order Granting Motion ▼

Comment

Order Granting Motion to Associate Stephen J. Boranian, Esq. as Counsel

02/26/2019 Order Granting Motion ▼

Comment

Order Granting Motion to Associate Counsel Christian J. Pistilli

02/26/2019 Notice of Entry of Order ▼

Notice of Entry of Order Granting Motion to Associate Counsel
Christian J. Pistilli

Notice of Entry of Order Granting Motion to Associate Stephen J. Boranian, Esq. as Counsel

Comment

Defendant Aida Maxsam's Motion to Dismiss

Comment

Defendant James Kumle's Motion to Dismiss the First Amended Complaint and Demand for Jury Trial

Comment

Allergan Finance, LLC and Allergan PLC's Motion to Dismiss the Amended Complaint

02/27/2019 Motion to Dismiss ▼

Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.'s Motion to Dismiss First Amended Complaint

Defendant Assertio Therapeutics Inc fka Depomed Inc's Motion to Dismiss

Defendant Insys Therapeutics Inc's Motion to Dismiss Plaintiff's First Amended Complaint (and Joinder)

Janssen Pharmaceuticals Inc and Johnson & Johnson's Joint Motion to Dismiss

Judicial Officer
Williams, Timothy C.

Hearing Time
9:15 AM

Result
Motion Denied

Comment

Notice of Motion to Dismiss of Defendants Cephalon, Inc. and Teva Pharmaceuticals USA Inc

02/27/2019 Motion to Dismiss ▼

Judicial Officer
Williams, Timothy C.

Hearing Time
9:15 AM

Result
Motion Denied

Comment

Notice of Motion to Dismiss of Defendants Watson Laboratories, Inc.,
Actavis LLC and Actavis Pharma Inc

02/27/2019 Motion to Dismiss ▼

Judicial Officer
Williams, Timothy C.

Hearing Time
9:15 AM

Result
Motion Denied

Comment

Defendant C&R Pharmacy d/b/a Ken's Pharmacy f/k/a Lam's Pharmacy,
Inc.'s Motion to Dismiss First Amended Complaint

02/27/2019 Opposition and Countermotion ▼

Judicial Officer
Williams, Timothy C.

Hearing Time
9:15 AM

Result
Motion Granted

Clark County's Opposition to Defendant Allergan Finance, LLC's Motion to Dismiss; and Countermotion for Leave to Amend

Comment

Motion to Associate Counsel Charles Lifland, Esq.

Defendant

Attorney: Corrick, Max E

Attorney: Levy, Jennifer G., ESQ

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Rickard, Jarrod L.

Attorney: Boranian, Steven J.

Defendant

Attorney: Polsenberg, Daniel F.

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Solis-Rainey, Rosa

Defendant

Attorney: Terry, Brian K.

Defendant

Attorney: Daehnke, Patricia Egan

Defendant

Attorney: Vigil, Abran E.

Defendant

Attorney: Guinn, Steven E

Attorney: Tsai, Rocky Chiu-Feng

Defendant

Attorney: Barr, Jeffrey F.

Attorney: Cohen, Joseph D.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Corrick, Max E

Attorney: Levy, Jennifer G., ESQ

Defendant

Attorney: Corrick, Max E

Attorney: Levy, Jennifer G., ESQ

02/27/2019 Order ▼

Comment

Order Granting Motion to Associate Counsel Matthew T. Murphy,
Esq. on Order Shortening Time

02/28/2019 Order Admitting to Practice ▼

Comment

Order Granting "Motion to Associate Counsel Ashley W. Hardin (on
Order Shortening Time)

02/28/2019 Media Request and Order ▼

Comment

Media Request And Order Allowing Camera Access To Court
Proceedings

03/01/2019 Order Scheduling Status Check ▼

Comment

Order Scheduling Status Check

03/04/2019 Amended Complaint ▼

Comment

Second Amended Complaint and Demand for Jury Trial

03/04/2019 Order ▼

Comment

Order Granting Motion to Associate Counsel, Charles Lifland, Esq.

03/05/2019 Motion to Associate Counsel ▼

Comment

MOTION TO ASSOCIATE DAVID T. ARLINGTON AS COUNSEL

03/05/2019 Motion to Associate Counsel ▼

Comment

MOTION TO ASSOCIATE KEVIN M. SADLER AS COUNSEL

03/06/2019 Order Admitting to Practice ▼

Comment

ORDER GRANTING MOTION TO ASSOCIATE COUNSEL -
HAYDEN ADAM COLEMAN, ESQ.

03/06/2019 Notice of Entry of Order ▼

Comment

Notice of Entry of Order Admitting to Practice - Hayden Adam
Coleman, Esq.

03/07/2019 Notice of Entry of Order ▼

Comment

Notice of Entry "Order Granting Motion to Associate Counsel Ashley
W. Hardin "(On Order Shortening Time)"

03/11/2019 Clerk's Notice of Hearing ▼

Comment

Notice of Hearing

03/11/2019 Clerk's Notice of Hearing ▼

Comment

Notice of Hearing

03/12/2019 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Result

Motion Granted

Comment

Motion to Associate Counsel Jessica Givens, Esq.

03/13/2019 Notice of Change of Address ▼

Comment

Notice of Change of Address

03/14/2019 Order ▼

Comment

Order Admitting to Practice Jessica Givens

03/15/2019 Notice ▼

Comment

Notice of Topic of Discussion at the March 20, 2019 Status Check

03/15/2019 Notice of Entry ▼

Comment

Notice of Entry of Order Admitting to Practice Charles Lifland, Esq.

03/15/2019 Notice of Entry ▼

Comment

Notice of Entry of Order Admitting to Practice Matthew T. Murphy, Esq.

03/15/2019 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel Nathan E. Shafroth on OST

03/19/2019 Order ▼

Comment

Order Regarding Defendants' Motions to Dismiss

03/19/2019 Notice of Entry ▼

Comment

Notice of Entry of Order Regarding Defendants' Motions to Dismiss

03/19/2019 Notice of Entry ▼

Comment

Notice of Entry of Order Admitting to Practice

03/20/2019 Status Check ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

1:30 PM

Result

Matter Heard

Comment

Status Check re Status of Case

03/20/2019 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

1:30 PM

Motion Granted

Motion To Associate Kevin M. Sadler As Counsel

03/20/2019 Motion to Associate Counsel ▼

Williams, Timothy C.

1:30 PM

Motion Granted

Motion To Associate David T. Arlington As Counsel

03/20/2019 Motion to Associate Counsel ▼

Williams, Timothy C.

1:30 PM

Motion Granted

Motion to Associate Counsel Nathan E. Shafroth and Ex-Parte Motion to Consider Motion to Associate on Shortened Time

03/20/2019 All Pending Motions ▼

Williams, Timothy C.

1:30 PM

Matter Heard

Plaintiff

Attorney: Eglet, Robert T.

Attorney: Adams, Robert M

Defendant

Attorney: Miller, Hayley E.

Defendant

Attorney: Smith, Stephanie J.

Defendant

Attorney: Smith, Stephanie J.

Defendant

Attorney: Lundvall, Patricia K.

Defendant

Attorney: Lundvall, Patricia K.

Defendant

Attorney: Corrick, Max E

Attorney: Levy, Jennifer G., ESQ

Defendant

Attorney: Rickard, Jarrod L.

Attorney: Boranian, Steven J.

Defendant

Attorney: Polsenberg, Daniel F.

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Solis-Rainey, Rosa

Defendant

Attorney: Terry, Brian K.

Defendant

Attorney: Daehnke, Patricia Egan

Defendant

Attorney: Guinn, Steven E

Defendant

Attorney: Barr, Jeffrey F.

Attorney: Cohen, Joseph D.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Corrick, Max E

Attorney: Levy, Jennifer G., ESQ

Defendant

Attorney: Corrick, Max E

Attorney: Levy, Jennifer G., ESQ

03/20/2019 Order Granting Motion ▼

Comment

Order Granting Motion to Associate Counsel Nathan Evans Shafroth

03/20/2019 Notice of Entry of Order ▼

Comment

Notice of Entry of Order Granting Motion to Associate Counsel
Nathan Evans Shafroth

03/25/2019 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel Stephen D. Brody, Esq.

03/28/2019 Motion to Associate Counsel ▼

Comment

Motion to Associate Out-of-State Counsel Erica Zolner, Esq. and Zac
Ciullo, Esq.

03/29/2019 Motion to Reconsider ▼

Comment

Manufacturer Defendants' Motion for Partial Reconsideration of
Order Denying Manufacturer Defendants' Joint Motion to Dismiss
First Amended Complaint

03/29/2019 Appendix ▼

Comment

Appendix of Exhibits in Support of Manufacturer Defendants' Motion
for Partial Reconsideration of Order Denying Manufacturer
Defendants' Joint Motion to Dismiss First Amended Complaint

03/29/2019 Motion ▼

Comment

Distributors' Motion for Partial Reconsideration of Order Denying
Distributors' Joint Motion to Dismiss First Amended Complaint

04/01/2019 Clerk's Notice of Hearing ▼

Comment

Notice of Hearing

04/02/2019 Clerk's Notice of Hearing ▼

Comment

Notice of Hearing

04/02/2019 Errata ▼

Comment

Errata to Motion to Associate Out-Of-State Counsel Erica Zolner,
Esq. and Zac Ciullo, Esq.

04/02/2019 Joinder ▼

Comment

DEFENDANT C&R PHARMACY D/B/A KEN S PHARMACY F/K/A
LAM S PHARMACY, INC. S JOINDER TO MANUFACTURER
DEFENDANTS MOTION FOR PARTIAL RECONSIDERATION OF
ORDERS DENYING MANUFACTURER DEFENDANTS JOINT
MOTION TO DISMISS FIRST AMENDED COMPLAINT

04/02/2019 Joinder ▼

Comment

Defendant James Kumle's Joinder in the Manufacturer Defendants'
Joint Motion for Partial Reconsideration of Orders Denying
Manufacturer Defendant's Joint Motion to Dismiss First Amended
Complaint

04/03/2019 Joinder ▼

Comment

Defendant Masters Pharmaceutical, LLC f/k/a Masters
Pharmaceutical, Inc. s Joinder To Distributors Motion For Partial
Reconsideration Of Order Denying Distributors Joint Motion To
Dismiss First Amended Complaint

04/04/2019 Order Admitting to Practice ▼

Comment

ORDER GRANTING MOTION TO ASSOCIATE KEVIN M. SADLER
AS COUNSEL

04/04/2019 Order Admitting to Practice ▼

Comment

ORDER GRANTING MOTION TO ASSOCIATE DAVID T.
ARLINGTON AS COUNSEL

04/04/2019 Notice of Entry of Order ▼

Comment

NOTICE OF ENTRY OF ORDER - Arlington

04/04/2019 Notice of Entry of Order ▼

Comment

NOTICE OF ENTRY OF ORDER - Sadler

04/09/2019 Opposition ▼

Comment

Clark County's Opposition to Manufacturers' and Distributors'
Motions for Partial Reconsideration of Order Denying Defendants'
Motions to Dismiss First Amended Complaint and All Joinders
Thereeto

04/10/2019 Clerk's Notice of Hearing ▼

Comment

Notice of Hearing

04/18/2019 Answer to Amended Complaint ▼

Comment

Defendants Purdue Pharma L.P., Purdue Pharma Inc., The Purdue
Frederick Company Inc., and Purdue Pharmaceuticals L.P.'s Answer
and Affirmative Defenses to Plaintiff's Second Amended Complaint

04/18/2019 Answer ▼

Comment

Answer to Second Amended Complaint

04/18/2019 Answer ▼

Comment

Defendant Aida Maxsam's Answer to Second Amended Complaint

04/18/2019 Answer ▼

Comment

AmerisourceBergen Drug Corporation's Answer to Plaintiff's Second
Amended Complaint

04/18/2019 Disclosure Statement ▼

Comment

Defendants Johnson & Johnson and Janssen Pharmaceuticals, Inc.'s
NRCP 7.1 Disclosures

04/18/2019 Answer to Amended Complaint ▼

Comment

Janssen Pharmaceuticals, Inc. and Johnson and Johnson's Answer
to Plaintiff's Second Amended Complaint

04/18/2019 Answer ▼

Defendant James Kumle's Answer to Plaintiff's Second Amended
Complaint and Demand for Jury Trial

Defendant Mallinckrodt LLC's Answer to Plaintiff's Second Amended Complaint

Defendant McKesson Corporation's Answer and Affirmative
Defenses to Plaintiff's Second Amended Complaint

Teva Pharmaceuticals Usa, Inc. s Answer To Plaintiff s Second Amended Complaint And Demand For Jury Trial

Cephalon, Inc. s Answer To Plaintiff s Second Amended Complaint
And Demand For Jury Trial

Actavis LLC, Actavis Pharma, Inc., And Watson Laboratories, Inc. s
Answer To Plaintiff s Second Amended Complaint And Demand For
Jury Trial

Answer, Defenses, and Demand for Jury Trial of Defendants
Allergan, Inc., Allergan USA, Inc., and Allergan Finance, LLC f/k/a
Actavis, Inc. f/k/a Watson Pharmaceuticals, Inc. to Plaintiff s Second
Amended Complaint

DEFENDANT ASSERTIO THERAPEUTICS, INC. F/K/A DEPOMED,
INC.'S ANSWER AND AFFIRMATIVE DEFENSES TO PLAINTIFF S
SECOND AMENDED COMPLAINT AND DEMAND FOR JURY
TRIAL

04/18/2019 Motion to Associate Counsel ▼

Motion to Associate Sarah Barr Johansen, Esq. as Counsel on Order
Shortening Time

Answer to Second Amended Complaint

Endo Health Solutions Inc. and Endo Pharmaceuticals Inc.'s Answer
and Affirmative Defenses to Plaintiff's Second Amended Complaint
and Jury Demand

Insys Therapeutics, Inc.'s Corporate Disclosure Statement

Insys Therapeutics, Inc.'s Answer to Plaintiff's Second Amended
Complaint and Demand for Jury Trial

C&R PHARMACY D/B/A KEN S PHARMACY F/KA/ LAM S
PHARMACY, INC. S ANSWER TO PLAINTIFF S SECOND
AMENDED COMPLAINT

Answer to Second Amended Complaint

Answer and Affirmative Defenses of Cardinal Health, Inc., Cardinal Health 6, Inc., Cardinal Technologies, LLC, Cardinal Health 414, LLC and Cardinal Health 200, LLC

Reply in Support of Manufacturer Defendants' Motion for Partial
Reconsideration of Order Denying Manufacturer Defendants' Joint
Motion to Dismiss First Amended Complaint

04/25/2019 Status Check ▼

Judicial Officer
Williams, Timothy C.

Hearing Time
11:00 AM

Result
Matter Heard

Comment
Status Check: Discovery Protocol/Complex Case/Special Master

Parties Present ▲

Plaintiff

Attorney: Eglet, Robert T.

Attorney: Adams, Robert M

Attorney: Cummings, Cassandra

Defendant

Attorney: Gutke, David W.

Defendant

Attorney: Gutke, David W.

Defendant

Attorney: Gutke, David W.

Defendant

Attorney: Gutke, David W.

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Hymanson, Philip M.

Attorney: Gutke, David W.

Defendant

Attorney: Smith, Stephanie J.

Defendant

Attorney: Gutke, David W.

Attorney: Smith, Stephanie J.

Defendant

Attorney: Lundvall, Patricia K.

Attorney: Miller, Jake

Defendant

Attorney: Lundvall, Patricia K.

Attorney: Miller, Jake

Defendant

Attorney: Corrick, Max E

Defendant

Attorney: Hymanson, Philip M.

Attorney: Gutke, David W.

Defendant

Attorney: Hymanson, Philip M.

Attorney: Gutke, David W.

Defendant

Attorney: Hymanson, Philip M.

Attorney: Gutke, David W.

Defendant

Attorney: Rickard, Jarrod L.

Defendant

Attorney: Polsenberg, Daniel F.

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Shafroth, Nathan

Defendant

Attorney: Gutke, David W.

Defendant

Attorney: Barr, Jeffrey F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Corrick, Max E

Defendant

Attorney: Corrick, Max E

Judicial Officer

Williams, Timothy C.

Hearing Time

11:00 AM

Result

Motion Granted

Comment

Motion to Associate Out-of-State Counsel Erica Zolner Esq and Zac Ciullo Esq

04/25/2019 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

11:00 AM

Result

Motion Granted

Comment

Motion to Associate Sarah Barr Johansen, Esq. as Counsel on Order Shortening Time

04/25/2019 Order ▼

Comment

Order Granting Motion to Associate Counsel Stephen D. Brody, Esq.

04/25/2019 Reply to Motion ▼

Comment

Reply in Support of Distributors' Motion for Partial Reconsideration of Order Denying Distributors' Joint Motion to Dismiss First Amended Complaint

05/02/2019 Motion For Reconsideration ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Result

Motion Denied

Comment

Manufacturer Defendants' Motion for Partial Reconsideration of Order Denying Manufacturer Defendants' Joint Motion to Dismiss First Amended Complaint

Judicial Officer
Williams, Timothy C.

Hearing Time
9:00 AM

Result
Motion Denied

Comment

Distributors' Motion for Partial Reconsideration of Order Denying
Distributors' Joint Motion to Dismiss First Amended Complaint

05/02/2019 Joinder ▼

Judicial Officer
Williams, Timothy C.

Hearing Time
9:00 AM

Result
Motion Denied

Comment
Defendant C&R Pharmacy d/b/a Ken's Pharmacy f/k/a Lam's Pharmacy
Inc's Joinder to Manufacturer Defendants Motion for Partial
Reconsideration of Orders Denying Manufacturer Defendants Joint Motion
to Dismiss First Amended Complaint

05/02/2019 Joinder ▼

Judicial Officer
Williams, Timothy C.

Hearing Time
9:00 AM

Result
Motion Denied

Comment

Defendant James Kumle's Joinder in the Manufacturer Defendants' Joint Motion for Partial Reconsideration of Orders Denying Manufacturer Defendant's Joint Motion to Dismiss First Amended Complaint

05/02/2019 Joinder ▼

Judicial Officer
Williams, Timothy C.

Hearing Time
9:00 AM

Result
Motion Denied

Comment

Defendant Masters Pharmaceutical, LLC f/k/a Masters Pharmaceutical,
Inc. s Joinder To Distributors Motion For Partial Reconsideration Of Order
Denying Distributors Joint Motion To Dismiss First Amended Complaint

05/02/2019 All Pending Motions ▼

Judicial Officer
Williams, Timothy C.

Hearing Time
9:00 AM

Result
Matter Heard

Parties Present ▲
Plaintiff

Attorney: Eglet, Robert T.

Attorney: Adams, Robert M

Attorney: HY, RICHARD K

Attorney: Cummings, Cassandra

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Smith, Stephanie J.

Defendant

Attorney: Smith, Stephanie J.

Defendant

Attorney: Lundvall, Patricia K.

Attorney: Miller, Jake

Defendant

Attorney: Lundvall, Patricia K.

Attorney: Miller, Jake

Defendant

Attorney: Corrick, Max E

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Rickard, Jarrod L.

Defendant

Attorney: Polsenberg, Daniel F.

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Guinn, Steven E

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Corrick, Max E

Defendant

Attorney: Corrick, Max E

05/02/2019 Brief ▼

Comment

Brief Regarding Appointment of Special Master

05/03/2019 Notice of Appearance ▼

Comment

Notice of Appearance

05/03/2019 Notice ▼

Comment

Notice of Disassociation

05/03/2019 Reporters Transcript ▼

Comment

Court Reporters transcript of Proceedings (Civil) 5-2-19

05/03/2019 Order Admitting to Practice ▼

Order Admitting to Practice - Zolner & Ciullo

Distributors' Response to Plaintiff's Brief Regarding Appointment of Special Master

Order Granting Motion to Associate Sarah Barr Johansen, Esq. as Counsel

Notice of Entry of Order

Notice of Entry of Order Granting Motion to Associate Sarah Barr
Johansen, Esq., as Counsel

Order Designating Case Complex Pursuant to NRCP 16.1(f)

Notice of Entry of Order Designating Case Complex Pursuant to
NRCP 16.1(f)

Notice of Entry Order Admitting to Practice Stephen D. Brody

Motion to Associate Counsel Steven M. Pyser (On Order Shortening Time)

Order Appointing Special Master

05/22/2019 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel Jonna N. Summers

05/23/2019 Clerk's Notice of Hearing ▼

Comment

Notice of Hearing

05/29/2019 Notice ▼

Comment

Notice of Disassociation of Tiffany Miyumi Ikeda

05/30/2019 Motion to Associate Counsel ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Result

Motion Granted

Comment

Motion to Associate Counsel Steven M. Pyser (On Order Shortening Time)

Parties Present ▲

Plaintiff

Attorney: HY, RICHARD K

Defendant

Attorney: Polsenberg, Daniel F.

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

05/30/2019 Order Granting Motion ▼

Comment

Order Granting "Motion to Associate Steven M. Pyser (On Order Shortening Time)

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Comment

Stipulation And (Proposed) Order Re: Briefing And Hearing Schedule
For Defendants Motion For Stay Pending Resolution Of Writ Petition

06/17/2019 Clerk's Notice of Hearing ▼

Comment
Notice of Hearing

06/17/2019 Joinder ▼

Comment
DEFENDANT C&R PHARMACY D/B/A KEN S PHARMACY F/K/A
LAM S PHARMACY, INC. S JOINDER TO DEFENDANTS MOTION
FOR STAY PENDING RESOLUTION OF WRIT PETITION

06/17/2019 Order Granting ▼

Comment
Order Scheduling Hearing and Accepting Briefing Schedule Re:
Defendants' Motion for Stay Pending Resolution of Writ Petition

06/18/2019 Notice of Entry of Order ▼

Comment

Notice of Entry of Order Scheduling Hearing and Accepting Briefing
Schedule Re: Defendants Motion for Stay Pending Resolution of Writ
Petition

06/21/2019 Opposition ▼

Comment

Clark County's Opposition to Defendants' Motion for Stay Pending Resolution of Writ Petition

06/24/2019 Reply in Support ▼

Comment

Reply in Support of Defendants' Motion for Stay Pending Resolution
of Writ Petition

06/27/2019 Motion to Associate Counsel ▼

Judicial Officer
Williams, Timothy C.

Hearing Time
9:00 AM

Result
Motion Granted

Comment

Motion to Associate Counsel Jonna N. Summers

06/27/2019 Motion to Associate Counsel ▼

Williams, Timothy C.

Result
Motion Granted

Comment

Motion to Associate Lindsay Zanello, Esq. as Counsel

Judicial Officer
Williams, Timothy C.

Result
Motion Denied

Comment

Defendants' Motion For Stay Pending Resolution of Writ Petition and Request for Order Shortening Time Based Upon Stipulation Among Counsel

Judicial Officer
Williams, Timothy C.

Result
Motion Denied

Comment
Defendant C&R Pharmacy D/B/A Ken S Pharmacy F/K/A Lam S
Pharmacy, Inc s Joinder To Defendants Motion For Stay Pending
Resolution Of Writ Petition

Judicial Officer
Williams, Timothy C.

Result	Matter Heard

Attorney: Eglet, Robert T.

07/03/2019 Motion ▼

Comment

Clark County's Motion for Leave to File Third Amended Complaint

07/08/2019 Stipulation and Order ▼

Comment

Stipulation and Order to Dismiss Defendant James Kumle without Prejudice

07/08/2019 Notice of Entry ▼

Comment

Notice of Entry of Order Granting Dismissal Without Prejudice of Johnson & Johnson Pharmaceuticals, Inc.

07/09/2019 Request ▼

Comment

Plaintiff's Request for Hearing of Plaintiff's Motion on Leave to File Third Amended Complaint

07/10/2019 Order Admitting to Practice ▼

Comment

Order Granting Motion to Associate Counsel - Lindsay Zanello, Esq.

07/10/2019 Notice of Entry of Order ▼

Comment

Notice of Entry of Order Admitting to Practice - Lindsay Zanello, Esq.

07/10/2019 Notice of Entry ▼

Comment

Notice of Entry of Stipulation and Order to Dismiss Defendant James Kumle without Prejudice

07/11/2019 Order Admitting to Practice ▼

Comment

Order Admitting to Practice (Jonna N. Summers)

07/11/2019 Notice of Entry of Order ▼

Comment

Notice of Entry of Order Admitting to Practice (Jonna N. Summers)

07/12/2019 Order ▼

Comment

Order Denying Defendants' Motion for Stay Pending Resolution of Writ Petition and all Joinders Thereto

07/15/2019 Notice of Entry of Order ▼

Comment

Notice of Entry of "Order Granting Motion to Associate Steven M. Pyser" (On Order Shortening Time)

07/15/2019 Notice of Stay ▼

Comment

Notice of Stay Order

07/15/2019 Notice of Entry of Order ▼

Comment

Notice of Entry of Order Denying Defendants' Motion for Stay Pending Resolution of Writ Petition and all Joinders Thereto

07/18/2019 Substitution of Attorney ▼

Comment

SUBSTITUTION OF COUNSEL FOR DEFENDANT
AMERISOURCEBERGEN DRUG CORPORATION

07/23/2019 Non Opposition ▼

Comment

Notice of Non-Opposition to Clark County's Motion for Leave to File Third Amended Complaint

07/24/2019 Case Management Order ▼

Comment

Recommendation for Case Management Order

07/26/2019 Notice ▼

Comment

Notice of Filing Joinder in Supreme Court Writ Petition

07/30/2019 Motion to Vacate ▼

Comment

Motion to Vacate and Reconsider Case Management Order Entered, and Objections Thereto

07/31/2019 Clerk's Notice of Hearing ▼

Comment

Notice of Hearing

08/01/2019 Request ▼

Comment

Plaintiff's Request for Hearing of Plaintiff's Motion on Leave to File Third Amended Complaint

08/02/2019 Clerk's Notice of Hearing ▼

Comment

Notice of Hearing

08/02/2019 Notice of Change of Address ▼

Comment

Notice of Change of Address

08/05/2019 Joinder To Motion ▼

Comment

Defendant Aida Maxsam's Joinder to Defendants' Motion to Vacate and Reconsider Case Management Order Entered, and Objections Thereto

08/05/2019 Joinder ▼

Comment

Defendant C&R Pharmacy D/B/A Ken S Pharmacy F/K/A Lam S Pharmacy, Inc. s Joinder To Motion To Vacate And Reconsider Case Management Order Entered, And Objections Thereto

08/07/2019 Report and Recommendations ▼

Comment

Report & Recommendation for Protective Order

08/13/2019 Opposition to Motion ▼

Comment

Clark County's Opposition to Defendants' Motion to Vacate and Reconsider Case Management Order Entered, and Objections Thereto

08/19/2019 Objection ▼

Comment

Defendants' Objection To The Special Master's Report And Recommendation For Protective Order

08/20/2019 Clerk's Notice of Hearing ▼

Comment

Notice of Hearing

08/23/2019 Order ▼

Comment

Order Regarding Document and Electronically Stored Information
Production Protocol

08/23/2019 Objection ▼

Comment

Plaintiff's Objection to the Order Regarding Document and
Electronically Stored Information Production Protocol

08/26/2019 Response ▼

Comment

Clark County's Response to Defendants' Objection to the Special
Master's Report and Recommendation for Protective Order

08/29/2019 Order ▼

Comment

Order Setting Status Check

08/30/2019 Motion ▼

Comment

Clark County's Motion to Advance the Hearing on Defendant's
Objection to Special Master Report and Recommendation for
Protective Order to September 10, 2019 at 10:00 a.m. on an Order
Shortening Time

09/03/2019 Opposition to Motion ▼

Comment

Defendants' Opposition to Plaintiff's Motion to Advance Hearing on
Defendants' Objection to Special Master Report and
Recommendation for Protective Order

09/03/2019 Reply in Support ▼

Comment

Clark County's Reply In Support of the Motion to Advance the
Hearing on Defendants' Objection to Special Master Report and
Recommendation for Protective Order to September 10, 2019 at
10:00 a.m. On Order Shortening Time

09/04/2019 Motion ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Result

Matter Heard

Comment

Clark County's Motion to Advance the Hearing on Defendant's Objection to Special Master Report and Recommendation for Protective Order to September 10, 2019 at 10:00 a.m. on an Order Shortening Time

Parties Present ▲

Plaintiff

Attorney: Eglet, Robert T.

Attorney: Adams, Robert M

Attorney: HY, RICHARD K

Attorney: Cummings, Cassandra

Defendant

Attorney: Miller, Hayley E.

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Lundvall, Patricia K.

Defendant

Attorney: Lundvall, Patricia K.

Defendant

Attorney: Corrick, Max E

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Hymanson, Philip M.

Defendant

Attorney: Rickard, Jarrod L.

Defendant

Attorney: Polsenberg, Daniel F.

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Polsenberg, Daniel F.

Defendant

Attorney: Corrick, Max E

Defendant

Attorney: Corrick, Max E

09/04/2019 Reply ▼

Comment

Defendants Reply to Opposition to Motion to Vacate and Reconsider
Case Management Order

09/04/2019 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel - Alex Edwin Spjute

09/04/2019 Errata ▼

Comment

Errata to Motion to Vacate and Reconsider Case Management Order
Entered, and Objections Thereto

09/04/2019 Clerk's Notice of Hearing ▼

Comment

Notice of Hearing

09/06/2019 Response ▼

Comment

Defendants' Response to Clark County's Objection to the Order
Regarding Electronically Stored Information (ESI) Production
Protocol

09/10/2019 Motion for Leave ▼

Judicial Officer

Williams, Timothy C.

Hearing Time

9:00 AM

Cancel Reason

Vacated - per Judge

Comment

Clark County's Motion for Leave to File Third Amended Complaint

09/10/2019 Notice of Hearing ▼

Comment

Notice of Hearing

09/10/2019 Notice of Change ▼

Comment

Notice of Change of Time for Hearings

09/11/2019 Media Request and Order ▼

Comment

Media Request And Order Allowing Camera Access To Court Proceedings... The Young Turks Network

09/12/2019 Order ▼

Comment

Order Granting Clark County's Motion for Leave to File Third Amended Complaint

09/12/2019 Notice of Entry ▼

Comment

Notice of Entry of Order Granting Clark County's Motion for Leave to File Third Amended Complaint

09/12/2019 Amended Complaint ▼

Comment

Third Amended Complaint and Demand for Jury Trial

09/12/2019 Motion to Associate Counsel ▼

Comment

Motion to Associate Counsel on Order Shortening Time

09/12/2019 Notice of Appearance ▼

Comment

Notice of Appearance

09/12/2019 Initial Appearance Fee Disclosure ▼

Comment

Initial Appearance Fee Disclosure

Comment

Peremptory Challenge of Judge

Comment

Errata to Motion to Associate Counsel on Order Shortening Time

Comment

Notice of Department Reassignment

Comment

Notice of Change of Hearing

Comment

Motion to Strike Peremptory Challenge and Request for Sanctions on an Order Shortening Time

Comment

REPLY IN SUPPORT OF DEFENDANTS' OBJECTION TO THE
SPECIAL MASTER'S REPORT AND RECOMMENDATION FOR
PROTECTIVE ORDER

Comment
Defendants' Motion to Vacate and Reconsider Case Management Order
Entered, and Objections Thereto

Hearing Time
8:30 AM

Defendant Aida Maxsam's Joinder to Defendants' Motion to Vacate and Reconsider Case Management Order Entered, and Objections Thereto

Judicial Officer
Johnson, Susan

Hearing Time
8:30 AM

Defendant C&R Pharmacy D/B/A Ken S Pharmacy F/K/A Lam S
Pharmacy, Inc. s Joinder To Motion To Vacate And Reconsider Case
Management Order Entered, And Objections Thereto

Judicial Officer
Johnson, Susan

Hearing Time
8:30 AM

Defendants' Objection To The Special Master's Report And Recommendation For Protective Order

Judicial Officer
Johnson, Susan

Hearing Time
8:30 AM

Status Check re Scheduling Order/Trial Setting

Judicial Officer
Johnson, Susan

Hearing Time
8:30 AM

Plaintiff's Objection to the Order Regarding Document and Electronically Stored Information Production Protocol

09/24/2019 Motion to Associate Counsel ▼

Judicial Officer

Johnson, Susan

Hearing Time

8:30 AM

Comment

Motion to Associate Counsel on Order Shortening Time

10/24/2019 Motion to Associate Counsel ▼

Judicial Officer

Johnson, Susan

Hearing Time

9:00 AM

Comment

Defendants' Motion to Associate Alex Edwin Spjute, Esq. as Counsel

Financial

Clark County

Total Financial Assessment	\$1,089.50
Total Payments and Credits	\$1,089.50

12/7/2017	Transaction	\$270.00
	Assessment	

12/7/2017	Fee Waiver	(\$270.00)
-----------	------------	------------

3/13/2018	Transaction	\$25.00
	Assessment	

3/13/2018	Payment	Receipt #	Glen	(\$25.00)
	(Window)	2018-17931-	Meek	
		CCCLK		

3/13/2018	Transaction	\$28.00
	Assessment	

3/13/2018	Payment	Receipt #	Robert	(\$28.00)
	(Window)	2018-17936-	Van	
		CCCLK	Ralph	

10/22/2018	Transaction	\$3.50
	Assessment	

10/22/2018	Efile Payment	Receipt # 2018-70180- CCCLK	Clark County	(\$3.50)
9/12/2019	Transaction Assessment			\$763.00
9/12/2019	Efile Payment	Receipt # 2019-55897- CCCLK	Clark County	(\$763.00)
Purdue Pharma, L.P.				
	Total Financial Assessment			\$1,376.00
	Total Payments and Credits			\$1,376.00
8/13/2018	Transaction Assessment			\$703.00
8/13/2018	Efile Payment	Receipt # 2018-53394- CCCLK	Purdue Pharma, L.P.	(\$703.00)
8/13/2018	Transaction Assessment			\$450.00
8/13/2018	Efile Payment	Receipt # 2018-53404- CCCLK	Purdue Pharma, L.P.	(\$450.00)
4/18/2019	Transaction Assessment			\$223.00
4/18/2019	Efile Payment	Receipt # 2019-23964- CCCLK	Purdue Pharma, L.P.	(\$223.00)
Teva Pharmaceuticals Usa, Inc.				
	Total Financial Assessment			\$1,012.00
	Total Payments and Credits			\$1,012.00
10/9/2018	Transaction Assessment			\$343.00
10/9/2018	Efile Payment	Receipt # 2018- 67266- CCCLK	Teva Pharmaceuticals Usa, Inc.	(\$343.00)
4/18/2019	Transaction Assessment			\$669.00
4/18/2019	Efile Payment	Receipt # 2019- 24120- CCCLK	Teva Pharmaceuticals Usa, Inc.	(\$669.00)
Johnson & Johnson				
	Total Financial Assessment			\$223.00
	Total Payments and Credits			\$223.00

5/30/2019	Efile Payment	Receipt # 2019-32818- CCCLK	Cardinal Health, Inc	(\$3.50)
7/15/2019	Transaction Assessment			\$3.50
7/15/2019	Efile Payment	Receipt # 2019-42804- CCCLK	Cardinal Health, Inc	(\$3.50)
7/26/2019	Transaction Assessment			\$3.50
7/26/2019	Efile Payment	Receipt # 2019-45892- CCCLK	Cardinal Health, Inc	(\$3.50)
9/6/2019	Transaction Assessment			\$3.50
9/6/2019	Efile Payment	Receipt # 2019-54840- CCCLK	Cardinal Health, Inc	(\$3.50)
McKesson Corporation				
	Total Financial Assessment			\$223.00
	Total Payments and Credits			\$223.00
10/22/2018	Transaction Assessment			\$223.00
10/22/2018	Efile Payment	Receipt # 2018- 70154- CCCLK	Mckesson Corporation	(\$223.00)
Masters Pharmaceutical, Llc				
	Total Financial Assessment			\$223.00
	Total Payments and Credits			\$223.00
11/19/2018	Transaction Assessment			\$223.00
11/19/2018	Efile Payment	Receipt # 2018- 76847- CCCLK	Masters Pharmaceutical, Llc	(\$223.00)
C & R Pharmacy				
	Total Financial Assessment			\$223.00
	Total Payments and Credits			\$223.00
6/11/2018	Transaction Assessment			\$223.00
6/11/2018	Efile Payment	Receipt # 2018-38881- CCCLK	C & R Pharmacy	(\$223.00)
Depomed Inc				

Depomed Inc

Total Financial Assessment		\$446.00	
Total Payments and Credits		\$446.00	
8/27/2018	Transaction Assessment	\$223.00	
8/27/2018	Efile Payment	Receipt # 2018-56704- CCCLK	Depomed INC (\$223.00)
4/18/2019	Transaction Assessment	\$223.00	
4/18/2019	Efile Payment	Receipt # 2019-24143- CCCLK	Depomed Inc (\$223.00)
Insys Therapeutics Inc			
Total Financial Assessment		\$446.00	
Total Payments and Credits		\$446.00	
9/27/2018	Transaction Assessment	\$223.00	
9/27/2018	Efile Payment	Receipt # 2018-64469- CCCLK	Insys Therapeutics Inc (\$223.00)
4/18/2019	Transaction Assessment	\$223.00	
4/18/2019	Efile Payment	Receipt # 2019-24223- CCCLK	Insys Therapeutics Inc (\$223.00)
Mallinckrodt LLC			
Total Financial Assessment		\$446.00	
Total Payments and Credits		\$446.00	
10/19/2018	Transaction Assessment	\$223.00	
10/19/2018	Efile Payment	Receipt # 2018-69914- CCCLK	Mallinckrodt LLC (\$223.00)
4/18/2019	Transaction Assessment	\$223.00	
4/18/2019	Efile Payment	Receipt # 2019-24044- CCCLK	Mallinckrodt LLC (\$223.00)
Maxsam, Aida B			
Total Financial Assessment		\$223.00	
Total Payments and Credits		\$223.00	

9/10/2018	Transaction			\$223.00
	Assessment			
9/10/2018	Efile Payment	Receipt #	Maxsam,	(\$223.00)
		2018-59719- CCCLK	Aida B	
Foster, Allison				
	Total Financial Assessment			\$223.00
	Total Payments and Credits			\$223.00
8/27/2018	Transaction			\$223.00
	Assessment			
8/27/2018	Efile Payment	Receipt #	Foster,	(\$223.00)
		2018-56989- CCCLK	Allison	
Kumle, James				
	Total Financial Assessment			\$223.00
	Total Payments and Credits			\$223.00
10/19/2018	Transaction			\$223.00
	Assessment			
10/19/2018	Efile Payment	Receipt #	Kumle,	(\$223.00)
		2018-70072- CCCLK	James	
Holper, Steven A, M.D.				
	Total Financial Assessment			\$283.00
	Total Payments and Credits			\$283.00
7/3/2018	Transaction			\$283.00
	Assessment			
7/3/2018	Efile Payment	Receipt #	Holper,	(\$283.00)
		2018-44013- CCCLK	Steven A	
Cardinal Health 6 Inc				
	Total Financial Assessment			\$7.00
	Total Payments and Credits			\$7.00
1/14/2019	Transaction			\$3.50
	Assessment			
1/14/2019	Efile Payment	Receipt #	Cardinal	(\$3.50)
		2019-02706- CCCLK	Health 6 Inc	
2/28/2019	Transaction			\$3.50
	Assessment			
2/28/2019	Efile Payment	Receipt #	Cardinal	(\$3.50)
		2019-12877- CCCLK	Health 6 Inc	
Allergan Inc				
	Total Financial Assessment			\$223.00
	Total Payments and Credits			\$223.00

4/18/2019 Transaction \$223.00

Assessment

4/18/2019 Efile Payment Receipt # Allergan (\$223.00)
2019-24139- Inc
CCCLK

CVS Pharmacy Inc

Total Financial Assessment \$223.00

Total Payments and Credits \$0.00

9/12/2019 Transaction Assessment \$223.00

CVS Indiana L.L.C

Total Financial Assessment \$30.00

Total Payments and Credits \$0.00

9/12/2019 Transaction Assessment \$30.00

CVS RX Services Inc

Total Financial Assessment \$30.00

Total Payments and Credits \$0.00

9/12/2019 Transaction Assessment \$30.00

CVS Tennessee Distrubution L.L.C

Total Financial Assessment \$30.00

Total Payments and Credits \$0.00

9/12/2019 Transaction Assessment \$30.00